

10/019,652

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 14:55:47 ON 09 DEC 2003

=> file reg

=>

Uploading 1.str

L1 STRUCTURE UPLOADED

=>

Uploading 10019652.str


L2 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR

Hy




G1 O,S

Structure attributes must be viewed using STN Express query preparation.

=> d l2

L2 HAS NO ANSWERS

L2 STR



G1 O,S

Structure attributes must be viewed using STN Express query preparation.

=> file ca

=> d ibib abs fhitrn hitrn 1-20

L9 ANSWER 1 OF 20 CA COPYRIGHT 2003 ACS on STN
 ACCESSION NUMBER: 139:358745 CA
 TITLE: Polyamine analogues as therapeutic and diagnostic agents
 INVENTOR(S): Vermeulin, Nicolaas M. J.; O'Day, Christine L.; Webb, Heather K.; Burns, Mark R.; Bergstrom, Donald E.
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S., 78 pp., Cont.-in-part of U.S. Ser. No. 396,523.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6646149	B1	20031111	US 2000-584175	20000531
WO 9903823	A2	19990128	WO 1998-US14896	19980715 <--
WO 9903823	A3	19990408		
W: AL, AM, AU, AZ, BA, BB, BG, BR, CA, CN, CU, CZ, EE, FI, GE, HU, IL, IS, JP, KG, KP, KR, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6172261	B1	20010109	US 1999-341400	19990903
WO 2001092218	A2	20011206	WO 2001-US17795	20010531
WO 2001092218	A3	20030327		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 EP 1317424 A2 20030611 EP 2001-946044 20010531

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

PRIORITY APPLN. INFO.:

US 1997-52586P P 19970715
 US 1997-65728P P 19971114
 US 1998-85538P P 19980515
 WO 1998-US14896 A2 19980715
 US 1999-341400 A2 19990903
 US 1999-396523 A2 19990915
 US 2000-584175 A 20000531
 WO 2001-US17795 W 20010531

AB Novel "bispolyamine" **inhibitor** compds. of polyamine transport are disclosed. These compds. are useful pharmaceutical agents for treating diseases where it is desired to **inhibit** polyamine transport or other polyamine binding proteins, for example cancer and post-angioplasty injury. These compds. display desirable activities both for diagnostic and research assays and therapy.


IT **330163-32-1P**

RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(novel polyamine transport-**inhibiting** polyamine analogs as therapeutic and diagnostic agents)

RN 330163-32-1 CA

CN 1-Naphthalenesulfonamide, N-[4-[[[3-[[4-[(3-aminopropyl)amino]butyl]amino]propyl]amino]carbonyl]amino]phenyl]-5-(dimethylamino)- (9CI) (CA INDEX NAME)



IT **330163-32-1P 330163-34-3P**

RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(novel polyamine transport-**inhibiting** polyamine analogs as therapeutic and diagnostic agents)


IT **220221-10-3**

RL: BSU (Biological study, unclassified); PAC (Pharmacological activity);

THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(novel polyamine transport-**inhibiting** polyamine analogs as
therapeutic and diagnostic agents)

L9 ANSWER 2 OF 20 CA COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 134:95121 CA
TITLE: Carbonic Anhydrase **Inhibitors**: Water-Soluble
4-Sulfamoylphenylthioureas as Topical Intraocular
Pressure-Lowering Agents with Long-Lasting Effects
AUTHOR(S): Casini, Angela; Scozzafava, Andrea; Mincione,
Francesco; Menabuoni, Luca; Ilies, Marc A.; Supuran,
Claudiu T.
CORPORATE SOURCE: Laboratorio di Chimica Inorganica e Bioinorganica,
Universita degli Studi di Firenze, Florence, I-50121,
Italy
SOURCE: Journal of Medicinal Chemistry (2000),
43(25), 4884-4892
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
AB A series of sulfonamides has been obtained by reaction of
4-isothiocyanatobenzenesulfonamide with amines, amino acids, and
oligopeptides. The new thiourea derivs. showed strong affinities toward
isoenzymes I, II, and IV of carbonic anhydrase (CA, EC 4.2.1.1). In vitro
inhibitory power was good (in the low-nanomolar range) for the
derivs. of .beta.-phenylserine and .alpha.-phenylglycine, for those
incorporating hydroxy and mercapto amino acids (Ser, Thr, Cys, Met),
hydrophobic amino acids (Val, Leu, Ile), arom. amino acids (Phe, His, Trp,
Tyr, DOPA), and dicarboxylic amino acids as well as di/tri/tetrapeptides
among others. Such CA **inhibitors** displayed very good water
soly. (in the range of 2-3%) mainly as sodium (carboxylate) salts, with pH
values of the obtained solns. being 6.5-7.0. Some of these prepn. (such
as the derivs. of Ser, .beta.-Ph-Ser, Leu, Asn, etc.) strongly lowered
intraocular pressure (IOP) when applied topically, directly into the
normotensive/glaucomatous rabbit eye, as 2% water solns. It is
interesting to note that not all the powerful CA **inhibitors**
designed in the present study showed topical IOP-lowering effects (such
as, for instance, the Cys and Lys derivs., devoid of such properties)
whereas the Pro, Arg, and oligopeptidyl thiourea derivs. showed reduced
efficacy when administered topically. This may be due to the very
hydrophilic nature of some of these compds., whereas **inhibitors**
with balanced hydro- and liposoly. also showed optimal in vivo effects.
The interesting pharmacol. properties of this new type of CA
inhibitors, correlated with the neutral pH of their solns. used in
ophthalmol. applications, make them attractive candidates for developing
novel antiglaucoma **drugs** devoid of major ocular side effects.
IT 319473-66-0
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)
(prepn. of water-sol. 4-sulfamoylphenylthioureas as carbonic anhydrase
inhibitors and topical intraocular pressure-lowering agents
with long-lasting effects)
RN 319473-66-0 CA
CN L-Lysine, N2-[[[4-(aminosulfonyl)phenyl]amino]thioxomethyl]- (9CI) (CA
INDEX NAME)

Absolute stereochemistry.



IT 319473-66-0 319473-68-2

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(prepn. of water-sol. 4-sulfamoylphenylthioureas as carbonic anhydrase inhibitors and topical intraocular pressure-lowering agents with long-lasting effects)

REFERENCE COUNT: 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 3 OF 20 CA COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 133:187662 CA

TITLE: The influence of cytotoxicity of macromolecules and of VEGF gene modulated vascular permeability on the enhanced permeability and retention effect in resistant solid tumors

AUTHOR(S): Minko, Tamara; Kopeckova, Pavla; Pozharov, Vitaliy; Jensen, Keith D.; Kopecek, Jindrich

CORPORATE SOURCE: Department of Pharmaceutics and Pharmaceutical Chemistry, University of Utah, Salt Lake City, UT, USA

SOURCE: Pharmaceutical Research (2000), 17(5), 505-514

CODEN: PHREEB; ISSN: 0724-8741

PUBLISHER: Kluwer Academic/Plenum Publishers

DOCUMENT TYPE: Journal

LANGUAGE: English

AB To study the influence of cytotoxicity of macromols., VEGF gene expression, and vascular permeability on the enhanced permeability and retention (EPR) effect. Mice bearing xenografts of A2780 multidrug resistant human ovarian carcinoma were treated by free doxorubicin (DOX) and N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-bound DOX (P(GFLG)-DOX), Texas Red (P-TR), and FITC (P-FITC). Antitumor activity, **drug** distribution in tumor, vascular permeability, VEGF gene expression, and DNA fragmentation were studied. The accumulation of free DOX led to the VEGF gene overexpression and increased the vascular permeability, which in turn enhanced the **drug** accumulation in the same location. This pos. feedback loop led to a highly inhomogeneous distribution of the **drug** within the tumor. In contrast, P(GFLG)-DOX down-regulated the VEGF gene and decreased vascular permeability. This neg. feedback seemed to prevent addnl. **drug** accumulation in dead necrotic tissue, resulting in a more uniform **drug** distribution and enhanced the antitumor activity P(GFLG)-DOX. The EPR effect significantly differed for macromols. contg. DOX when compared to macromols. without **drug**. The cytotoxicity of P(GFLG)-DOX amplified the EPR effect, led to a more homogeneous distribution of the **drug**, increased the av. **drug** concn. in tumor and augmented its efficacy.

IT 86742-37-2D, conjugate with HPMA copolymer


RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use);

10/019,652

BIOL (Biological study); PROC (Process); USES (Uses)
(influence of cytotoxicity of macromols. and of VEGF gene modulated
vascular permeability on the enhanced permeability and retention effect
in resistant solid tumors)

RN 86742-37-2 CA

CN 2-Propenamide, N-[3-[[[(3',6'-dihydroxy-3-oxospiro[isobenzofuran-1(3H),9'-
[9H]xanthen]-5-yl)amino]thioxomethyl]amino]propyl]-2-methyl- (9CI) (CA
INDEX NAME)



IT 86742-37-2D, conjugate with HPMa copolymer

RL: BAC (Biological activity or effector, except adverse); BPR (Biological
process); BSU (Biological study, unclassified); THU (Therapeutic use);
BIOL (Biological study); PROC (Process); USES (Uses)
(influence of cytotoxicity of macromols. and of VEGF gene modulated
vascular permeability on the enhanced permeability and retention effect
in resistant solid tumors)

REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 4 OF 20 CA COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 132:151567 CA

TITLE: Preparation of arylamidoalkylcarboxylic acids and
compositions for delivering active agents.

INVENTOR(S): Gschneidner, David; Leone-Bay, Andrea; Wang, Eric;
Errigo, Lynn; Kraft, Kelly; Moye-Sherman, Destardi;
Ho, Koc-Kan; Press, Jeffrey Bruce; Wang, Nai Fang

PATENT ASSIGNEE(S): Emisphere Technologies, Inc., USA

SOURCE: PCT Int. Appl., 53 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000007979	A2	20000217	WO 1999-US17974	19990806 <--
WO 2000007979	A3	20000518		
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2339765	AA	20000217	CA 1999-2339765	19990806 <--
AU 9954711	A1	20000228	AU 1999-54711	19990806 <--

EP 1102742 A2 20010530 EP 1999-940967 19990806
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO
 BR 9912975 A 20010925 BR 1999-12975 19990806
 JP 2002522413 T2 20020723 JP 2000-563614 19990806
 NZ 509410 A 20030829 NZ 1999-509410 19990806
 ZA 2001000470 A 20010820 ZA 2001-470 20010117
 PRIORITY APPLN. INFO.: US 1998-95778P P 19980807
 US 1998-98500P P 19980831
 US 1998-108366P P 19981113
 US 1999-119207P P 19990205
 WO 1999-US17974 W 19990806

AB 135 Title compds. are claimed. Thus, Me azeloyl chloride was added dropwise to 2-amino-p-cresol in aq. NaOH at 0.degree. to give a residue which was stirred with aq. NaOH in THF to give 4-HO-5-MeC6H3NHCO(CH2)7CO2H. Title compds. at 100-300 mg/kg with parathyroid hormone at 25-200 .mu.g orally or intracolonicly in rats gave peak serum parathyroid hormone levels of 5-1459.71 pg/mL.

IT **257952-07-1P**
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of arylamidoalkylcarboxylic acids and compns. for delivering active agents)

RN 257952-07-1 CA
 CN Octanoic acid, 8,8'-[1,6-hexanediylbis(iminocarbonylimino-2,1-phenylenecarbonylimino)]bis- (9CI) (CA INDEX NAME)




IT **257952-07-1P 257952-42-4P**
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of arylamidoalkylcarboxylic acids and compns. for delivering active agents)

L9 ANSWER 5 OF 20 CA COPYRIGHT 2003 ACS on STN
 ACCESSION NUMBER: 131:225540 CA
 TITLE: Synthesis and Characterization of Fluorescent Ligands for the Norepinephrine Transporter: Potential Neuroblastoma Imaging Agents
 AUTHOR(S): Hadrich, Dirk; Berthold, Frank; Steckhan, Eberhard; Boenisch, Heinz
 CORPORATE SOURCE: Kekule-Institut fuer Organische Chemie und Biochemie, Universitaet Bonn, Bonn, D-53121, Germany
 SOURCE: Journal of Medicinal Chemistry (1999), 42(16), 3101-3108
 CODEN: JMCMAR; ISSN: 0022-2623
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB Radiolabeled m-iodobenzylguanidine (MIBG) is a tumor-seeking radioactive **drug** used in the diagnosis and treatment of pheochromocytomas and neuroblastomas. It is transported into the tumor cells by the neuronal norepinephrine (NE) transporter (NET) which is expressed in almost all neuroblastoma cells. Here, we describe the synthesis and some pharmacol. properties of a series of fluorescent compds. structurally related to the NET substrate, MIBG, or to the NET **inhibitors**, (-)-(2R,3S)-cocaine and nisoxetine. Three of 10 synthesized fluorescent compds., 1-(1-naphthylmethyl)guanidinium sulfate, 1-[2-(dibenz[b,f]azepin-5-yl)ethyl]guanidinium sulfate, and (2R,3S)-2.beta.-ethoxycarbonyl-3.beta.-tropanyl 5-(dimethylamino)naphthalene-1-sulfonate, exhibited high affinity (IC50 about 50 nM) for the NET. The nisoxetine derivs. (rac-N-[(3-methylamino-1-phenyl)propyl]-5-(dimethylamino)-1-naphthalenesulfonamide) and (rac-4-[(3-methylamino-1-phenyl)propyl]amino-7-nitro-2,1,3-benzoxadiazole) and esp. the guanidine deriv. (I) (1-[4-(4-phenyl-1,3-butadienyl)benzyl]guanidinium sulfate) which are characterized by intermediate affinity for the NET (IC50 370-850 nM) caused significant and nisoxetine-sensitive cell fluorescence. At least the guanidine deriv. I might represent a potentially useful agent for imaging of neuroblastoma cells.

IT **244059-00-5P**
 RL: BPR (Biological process); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
 (synthesis and characterization of fluorescent ligands for norepinephrine transporter as potential neuroblastoma imaging agents)

RN 244059-00-5 CA
 CN Thiourea, N-[4-[[4-(dimethylamino)phenyl]azo]phenyl]-N'-[3-(methylamino)-1-phenylpropyl]- (9CI) (CA INDEX NAME)



IT **244059-00-5P**
 RL: BPR (Biological process); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
 (synthesis and characterization of fluorescent ligands for norepinephrine transporter as potential neuroblastoma imaging agents)

REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 6 OF 20 CA COPYRIGHT 2003 ACS on STN
 ACCESSION NUMBER: 130:191387 CA
 TITLE: Conjugation of Dipeptide to Fluorescent Dyes Enhances Its Affinity for a Dipeptide Transporter (PEPT1) in Human Intestinal Caco-2 Cells
 AUTHOR(S): Abe, Hiroshi; Satoh, Momoko; Miyauchi, Seiji; Shuto, Satoshi; Matsuda, Akira; Kamo, Naoki
 CORPORATE SOURCE: Laboratory of Biophysical Chemistry and Medicinal Chemistry Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo, 060-0812, Japan
 SOURCE: Bioconjugate Chemistry (1999), 10(1), 24-31
 CODEN: BCCHES; ISSN: 1043-1802
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB Dipeptide transporters in small intestine have a very wide substrate specificity, so that the transporter sometimes serves as a carrier for peptide-like compds. We have synthesized dipeptide analogs conjugated at an .epsilon.-amino group of Lys in Val-Lys or Lys-Sar with fluorescent compds. such as fluorescein isothiocyanate and coumarin-3-carboxylic acid. Uptakes of these peptide analogs were examd. by measuring intracellular accumulations into monolayers of the human intestinal epithelial cell line Caco-2 expressing the dipeptide transporter PEPT1. Kinetic anal. and effects of addn. either of uncoupler (protonophore) or by Gly-Sar, one of the good substrates of PEPT1, revealed that fluorescent dipeptides were taken up by passive diffusion. In contrast, these analogs remarkably **inhibited** the Gly-Sar uptake by Caco-2 cells. Among the fluorescent analogs synthesized in this paper, Val-Lys(Flu) was the most potent competitive **inhibitor** against the Gly-Sar uptake with an **inhibition** const. of 5 .mu.M. This value is the smallest among those ever reported: Val-Lys(Flu) has the highest affinity for PEPT1 among chems. ever reported. The importance of the hydrophobic part of the substrate was pointed out.

IT **220757-58-4P**


RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(Lys-Sar conjugated to FITC; conjugation of dipeptide to fluorescent dyes enhances affinity for a dipeptide transporter (PEPT1) in human intestinal caco-2 cells)

RN 220757-58-4 CA

CN Glycine, N6-[[[(3',6'-dihydroxy-3-oxospiro[isobenzofuran-1(3H),9'-(9H)xanthen]-5-yl)amino]thioxomethyl]-L-lysyl-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

IT **220757-58-4P**

RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(Lys-Sar conjugated to FITC; conjugation of dipeptide to fluorescent dyes enhances affinity for a dipeptide transporter (PEPT1) in human intestinal caco-2 cells)

IT **220757-56-2P**

RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(Val-Lys conjugated to FITC; conjugation of dipeptide to fluorescent

dyes enhances affinity for a dipeptide transporter (PEPT1) in human intestinal caco-2 cells)

IT 220757-61-9P 220757-62-0P

RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(conjugation of dipeptide to fluorescent dyes enhances affinity for a dipeptide transporter (PEPT1) in human intestinal caco-2 cells)

IT 220757-55-1P 220757-57-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(deprotection, Boc and t-Bu; conjugation of dipeptide to fluorescent dyes enhances affinity for a dipeptide transporter (PEPT1) in human intestinal caco-2 cells)

IT 220757-60-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(deprotection, Boc or Me; conjugation of dipeptide to fluorescent dyes enhances affinity for a dipeptide transporter (PEPT1) in human intestinal caco-2 cells)

REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 7 OF 20 CA COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 130:153469 CA

TITLE: Novel polyamine analogs as therapeutic and diagnostic agents

INVENTOR(S): Vermeulin, Nicolaas M. J.; O'Day, Christine L.; Webb, Heather K.; Burns, Mark R.; Bergstrom, Donald E.

PATENT ASSIGNEE(S): Oridigm Corporation, USA

SOURCE: PCT Int. Appl., 143 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9903823	A2	19990128	WO 1998-US14896	19980715 <--
WO 9903823	A3	19990408		
W:	AL, AM, AU, AZ, BA, BB, BG, BR, CA, CN, CU, CZ, EE, FI, GE, HU, IL, IS, JP, KG, KP, KR, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
AU 9884968	A1	19990210	AU 1998-84968	19980715 <--
AU 758570	B2	20030327		
EP 1001927	A2	20000524	EP 1998-935790	19980715 <--
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
JP 2001510181	T2	20010731	JP 2000-503054	19980715
US 6172261	B1	20010109	US 1999-341400	19990903
US 6646149	B1	20031111	US 2000-584175	20000531
PRIORITY APPLN. INFO.:			US 1997-52586P	P 19970715
			US 1997-65728P	P 19971114
			US 1998-85538P	P 19980515
			WO 1998-US14896	W 19980715
			US 1999-341400	A2 19990903

MARPAT 130:153469




I

IT 220221-10-3P

RN 220221-10-3 CA

CN Urea, N-[3-[[4-[(3-aminopropyl)amino]butyl]amino]propyl]-N'-1-anthracenyl-
(9CI) (CA INDEX NAME)



RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. of polyamines as therapeutic and diagnostic agents)

10/019,652

L9 ANSWER 8 OF 20 CA COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 130:89965 CA
TITLE: Molecular diversity; biological activity and common
ground shared by both
AUTHOR(S): Coffen, David L.; Baldino, Carmen M.; Lange, Meinolf;
Tilton, Robert F.; Tu, Cheng
CORPORATE SOURCE: ArQule Inc., Medford, MA, 02155, USA
SOURCE: Medicinal Chemistry Research (1998), 8(4/5),
206-218
CODEN: MCREEB; ISSN: 1054-2523
PUBLISHER: Birkhaeuser Boston
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English


AB A review, with 16 refs. of some of the broad issues assocd. with the
prodn. and screening of combinatorial libraries with a proposal for a
guideline for optimizing the utility of combinatorial chem. in
drug discovery. This guideline is based on the premise that our
knowledge of how diseases, biomol. targets, and biol. active compd.
classes interrelate can be used to define the most productive regions of
mol. diversity space. Compd. classes known to modulate function in
various disease-related biomol. target classes provide rich, validated
pharmacophores and should be given highest priority in the design and
construction of combinatorial libraries. This selection system is
illustrated with .alpha.-ketoamide libraries for the **inhibition**
of serine and cysteine proteases and with oxindole libraries for the
inhibition of protein kinases.

IT 219313-06-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); BIOL (Biological
study); PREP (Preparation)
(designing proteinase **inhibitors**; guidelines for optimizing
the utility of combinatorial chem. in **drug** discovery
considering mol. diversity, biol. activity and common ground shared by
both)

RN 219313-06-1 CA

CN Benzeneacetamide, 2-chloro-N-[4-[[[(4-methyl-3-
nitrophenyl)amino]carbonyl]amino]butyl]-.alpha.-oxo- (9CI) (CA INDEX
NAME)




IT 219313-06-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); BIOL (Biological
study); PREP (Preparation)
(designing proteinase **inhibitors**; guidelines for optimizing
the utility of combinatorial chem. in **drug** discovery
considering mol. diversity, biol. activity and common ground shared by
both)

REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/019,652

L9 ANSWER 9 OF 20 CA COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 130:47424 CA
TITLE: Adrenergic **drug** effects on cyclic AMP in
cultured human trabecular meshwork cells
AUTHOR(S): Friedman, Zvi; Bloom, Ernest; Polansky, Jon R.
CORPORATE SOURCE: Dep. Ophthalmology, Bnai-Zion Med. Center, Haifa,
31048, Israel
SOURCE: Ophthalmic Research (1999), 31(1), 53-58
CODEN: OPRSAQ; ISSN: 0030-3747
PUBLISHER: S. Karger AG
DOCUMENT TYPE: Journal
LANGUAGE: English
AB CAMP prodn. in the presence or absence of adrenergic agonists and
antagonists was examd. in cultured human trabecular cells. Adrenergic
agonists and antagonists showed activation and **inhibition**
const. (Ka and Ki) consistent with the presence of .beta.2-receptors: Ka
of isoproterenol < epinephrine < norepinephrine < phenylephrine; Ki of
timolol < betaxolol < celiprolol < atenolol. Selective ICI antagonists
showed .beta.2-specificity.
IT **53671-71-9**, ICI 89406
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
(Biological study); PROC (Process)
(antagonist; adrenergic agonist and antagonist effects on cAMP in
cultured human trabecular meshwork cells)
RN 53671-71-9 CA
CN Urea, N-[2-[[3-(2-cyanophenoxy)-2-hydroxypropyl]amino]ethyl]-N'-phenyl-
(9CI) (CA INDEX NAME)



IT **53671-71-9**, ICI 89406
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
(Biological study); PROC (Process)
(antagonist; adrenergic agonist and antagonist effects on cAMP in
cultured human trabecular meshwork cells)
REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 10 OF 20 CA COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 129:149097 CA
TITLE: Preparation of boronic acid derivatives and
pharmaceutical compositions useful as angiogenesis
inhibitors
INVENTOR(S): Cordi, Alex; Desos, Patrice; Atassi, Ghanem; Pierre,
Alain
PATENT ASSIGNEE(S): Adir et Cie., Fr.
SOURCE: PCT Int. Appl., 56 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

10/019,652

L9 ANSWER 11 OF 20 CA COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 119:249974 CA

TITLE: Preparation of (2-imidazolin-2-ylamino)quinoxaline derivatives

INVENTOR(S): Gluchowski, Charles; Garst, Michael E.; Burke, James A.; Wheeler, Larry A.

PATENT ASSIGNEE(S): Allergan, Inc., USA

SOURCE: PCT Int. Appl., 42 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9313771	A1	19930722	WO 1993-US264	19930112 <--
W:	AT, AU, BB, BG, BR, CA, CH, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG, MN, MW, NL, NO, NZ, PL, RO, RU, SD, SE			
RW:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG			
US 5231096	A	19930727	US 1992-820329	19920113 <--
AU 9334700	A1	19930803	AU 1993-34700	19930112 <--
AU 670064	B2	19960704		
EP 620732	A1	19941026	EP 1993-903433	19930112 <--
EP 620732	B1	20010404		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE			
JP 07503015	T2	19950330	JP 1993-512627	19930112 <--
AT 200222	E	20010415	AT 1993-903433	19930112
ES 2157216	T3	20010816	ES 1993-903433	19930112
US 5326763	A	19940705	US 1993-10954	19930129 <--
US 5373010	A	19941213	US 1994-195184	19940210 <--
US 5418234	A	19950523	US 1994-298494	19940830 <--

PRIORITY APPLN. INFO.:

US 1992-820329	A	19920113
US 1989-420817	A3	19891012
US 1990-560776	A2	19900731
US 1991-758696	A2	19910912
WO 1993-US264	A	19930112
US 1993-10954	A3	19930129
US 1994-195184	A3	19940210

OTHER SOURCE(S): MARPAT 119:249974

GI



AB Title compds. I (R1, R4 = H, C1-4 alkyl; R2 = H, C1-4 alkyl, (R2)2 = O; R3 = R2, (R3)2 = O; R5, R6, R7 = H, Ba, Cl, C1-3 alkyl) or a salt thereof, useful as **drugs** for redn. of pain, and as anesthetic, antiischemic, antiinflammatory and antidiarrhea agents, are prepd. 4-Nitrophenylenediamine in EtOH was added Pd/C, hydrogenated and HCl added to give 1,2,4-triaminobenzene 2HCl which was treated with glyoxal sodium

bisulfite to give 6-aminoquinoxaline which was converted in 6 step was converted to I (R1-R4, R6 = R7 = H, R5 = 5-bromo). All I showed a therapeutic effect.


IT **134892-47-0P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. and reaction of, in prepn. of **drugs**)

RN 134892-47-0 CA

CN Thiourea, N-(2-aminoethyl)-N'-(5-bromo-6-quinoxaliny)- (9CI) (CA INDEX NAME)



IT **134892-47-0P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. and reaction of, in prepn. of **drugs**)

L9 ANSWER 12 OF 20 CA COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 119:181238 CA

TITLE: Preparation of peptide hydantoin derivatives as **drugs**

INVENTOR(S): Koenig, Wolfgang; Zoller, Gerhard; Just, Melitta; Jablonka, Bernd

PATENT ASSIGNEE(S): Cassella AG, Germany

SOURCE: Ger. Offen., 17 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 4126277	A1	19930211	DE 1991-4126277	19910808 <--
EP 530505	A2	19930310	EP 1992-113086	19920731 <--
EP 530505	A3	19931229		
EP 530505	B1	19951011		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
AT 128985	E	19951015	AT 1992-113086	19920731 <--
ES 2081000	T3	19960216	ES 1992-113086	19920731 <--
US 5389614	A	19950214	US 1992-924745	19920804 <--
CA 2075590	AA	19930209	CA 1992-2075590	19920807 <--
CA 2075590	C	20030107		
HU 61779	A2	19930301	HU 1992-2583	19920807 <--
HU 218922	B	20001228		
ZA 9205934	A	19930428	ZA 1992-5934	19920807 <--
JP 05213895	A2	19930824	JP 1992-211801	19920807 <--
JP 3293885	B2	20020617		
AU 651716	B2	19940728	AU 1992-20892	19920807 <--
AU 9220892	A1	19930311		
IL 102759	A1	19970610	IL 1992-102759	19920807 <--
CZ 289929	B6	20020417	CZ 1992-2459	19920807

10/019,652


PRIORITY APPLN. INFO.:

DE 1991-4126277 A 19910808

OTHER SOURCE(S):

MARPAT 119:181238

GI



AB Title compds. [I; Y = (CH₂)_mCO, C₆H₄CO; m = 1-4; R₁ = (CH₂)_nNHX, CH₂C₆H₄NHX, CH₂C₆H₄C(:NH)NH₂, CH₂C₆H₄CH₂NHX, C₆H₄NHX; R₁CH may also = X₁C₆H₄CH:C; n = 3-5; X = H, alkyl, R₁₀NHC:NR₁₁; X₁ = NHX, C(:NH)NH₂; R₁₀, R₁₁ = H, alkyl; R₂ = H, alkyl; R₃ = H, Ph; R₄ = H, CO₂R₅, CONHR₅; R₅ = H, NHCONH₂, (substituted) alkyl], were prepd. as **inhibitors** of thrombocyte aggregation, metastasis, and of osteoclast binding to bone surfaces (no data). Thus, [5(R,S)-(4-formamidobenzyl)-2,4-dioxoimidazolidin-3-yl]acetylasparylvaline was prepd. in 5 steps starting with 4-formamidino-DL-phenylalanine dihydrochloride.


IT **150376-44-6P**

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as **drug** intermediate)

RN 150376-44-6 CA

CN Benzoic acid, 3-[[[4-[[imino(nitroamino)methyl]amino]-1-(methoxycarbonyl)butyl]amino]carbonyl]amino]-, ethyl ester, (S)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



IT **150376-44-6P**

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as **drug** intermediate)

L9 ANSWER 13 OF 20 CA COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 117:8489 CA

TITLE: Preparation of tetrapeptide cholecystokinin agonists

INVENTOR(S): Shiosaki, Kazumi; Nadzan, Alex M.; Kopecka, Hana;

Shue, Youe Kona; Holladay, Mark W.; Lin, Chun W.;

Nellans, Hugh N.

PATENT ASSIGNEE(S): Abbott Laboratories, USA

10/019,652

SOURCE: PCT Int. Appl., 216 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9119733	A1	19911126	WO 1991-US4458	19910620 <--
W: CA, JP				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
US 5270302	A	19931214	US 1991-713010	19910617 <--
PRIORITY APPLN. INFO.:			US 1990-541230	19900620
			US 1991-713010	19910614
			US 1988-287955	19881221
			WO 1989-US5673	19891218
OTHER SOURCE(S):			MARPAT 117:8489	
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB XYZQ [X = R3(CH2)nCR1R2CR4R5, (indole ring substituted) Q1; R1 = H, OH, halo, alkyl, alkoxy, haloalkyl, alkanoyl, alkoxycarbonyl, aminocarbonyl, cyano, (acyl)amino, etc; R2 = H, alkyl; R3 = bicyclic carbocyclyl, heterocyclyl; R4, R5 = H; or R4R5 = O, n = 1,2; Y = R10HN(CH2)n CH(NR9)CR11R12, R13NCOA(CH2)4CH(NR9)CR11R12; R9 = H, alkyl; R10 = C(:G)NHR13, CO(CH2)pR14, etc.; G = O, S, p = 0, 1, 2; R13 = (cyclo)alkyl, alkenyl, mono- or bicyclic heterocyclyl, etc.; R14 = cycloalkyl, mono- or bicyclic heterocyclyl, (substituted) aryl; R11, R12 = H; or R11R12 = O; A = O, CH2; Z = R17(CH2)rCH(NR16)U; U = CO, CH2, CH2CO; r = 1 when U = CO, CH2; r = 0 when U = CH2CO; R16 = H, alkyl; R17 (prodrug ester of) CO2H; Q = NR23CR24R26(CH2)sR25; s = 1, 2; R23 = H, alkyl; R24 = H, Me; or R23R24 = (CH2)3; R25 = aryl, mono- or bicyclic heterocyclyl, cycloalkyl; R26 = (substituted) carbamoyl] were prepd. Thus, title peptide I, prepd. by soln. phase methods, **inhibited** feeding in rats with ED50 = 1.3 nmole/kg i.p.


IT **141407-97-8P**

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as cholecystokinin agonist)

RN 141407-97-8 CA

CN L-Phenylalaninamide, N6-[(2-methylphenyl)amino]carbonyl]-N2-[3-(2-naphthalenyl)-1-oxopropyl]-L-lysyl-L-.alpha.-aspartyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 141407-97-8P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of, as cholecystokinin agonist)

IT 141408-94-8P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of, as intermediate for cholecystokinin agonist)

IT 131451-15-5P 131451-16-6P 131451-25-7P
 131451-45-1P 131451-49-5P 141408-20-0P
 141408-22-2P 141408-24-4P 141408-34-6P
 141408-36-8P 141408-47-1P 141408-77-7P
 141408-78-8P 141420-98-6P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of, as intermediate for cholecystokinin agonists)

L9 ANSWER 14 OF 20 CA COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 116:59260 CA

TITLE: Bis basic substituted diaminobenzobisthiazoles as potential antiarthritic agents

AUTHOR(S): Cullen, Ernest; Becker, Reinhold; Freter, Kurt; LeClerq, Thelma; Possanza, Genus; Wong, Hin Chor


CORPORATE SOURCE: Dep. Med. Chem., Boehringer Ingelheim Pharm., Inc., Ridgefield, CT, 06877, USA

SOURCE: Journal of Medicinal Chemistry (1992), 35(2), 350-61
 CODEN: JMCMAR; ISSN: 0022-2623


DOCUMENT TYPE: Journal

LANGUAGE: English

GI



- AB A series of benzobisthiazoles, e.g. I [R = NHCOCH₂NEt₂, NHCOCH₂N(CH₂CH₂OEt)₂, NHCOCH₂R₃, R₁ = R₂ = H, R₃ = 1-piperazinyl, etc.; R = NEtCOCH₂NEt₂, R₁ = Br, R₂ = H; NHCOCH₂NEt₂, R₁ = R₂ = Cl, etc.], were prepd. and screened for antiinflammatory activity in the carrageenan paw edema and adjuvant arthritis tests. Thus, amination of I (R = NHCOCH₂Cl, R₁ = R₂ = H) with NEt₂ in dioxane gave I (R = NHCOCH₂NEt₂, R₁ = R₂ = H) (II) in 50% yield as well as a monoacylated product. II was found to **inhibit** the swelling of the injected paw in the prophylactic adjuvant arthritis model with an ED₅₀ of 2.3 mg/kg orally. As with most compds. of this series, II was inactive in the acute model of inflammation, such as paw edema; like steroids, it showed activity in the granuloma pouch assay but did not **inhibit** cyclooxygenase, indicating a mode of action different from the classical nonsteroidal antiinflammatory **drugs**. At doses higher than those producing antiinflammatory activity, II had some immunoregulating properties.
- IT **137697-51-9P**
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (prepn. and oxidative cyclization of)
- RN 137697-51-9 CA
- CN Thiourea, N,N''-1,3-phenylenebis[N'-[2-(diethylamino)ethyl]- (9CI) (CA INDEX NAME)



- IT **137697-51-9P 137697-52-0P**
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (prepn. and oxidative cyclization of)
- L9 ANSWER 15 OF 20 CA COPYRIGHT 2003 ACS on STN
- ACCESSION NUMBER: 114:203058 CA
- TITLE: Affinity labeling of folate transport proteins with the N-hydroxysuccinimide ester of .gamma.-isomer of fluorescein-methotrexate
- AUTHOR(S): Fan, Jianguo; Pope, Laura E.; Vitols, Karin S.; Huennekens, F. M.
- CORPORATE SOURCE: Res. Inst., Scripps Clin., La Jolla, CA, 92037, USA
- SOURCE: Biochemistry (1991), 30(18), 4573-80
 CODEN: BICHAW; ISSN: 0006-2960
- DOCUMENT TYPE: Journal
- LANGUAGE: English
- AB Fluorescein-methotrexate, a deriv. in which the fluorophore is linked via a diaminopentane spacer to either the .alpha.- and .gamma.-carboxyl group of the glutamate moiety in the **drug** (Gapski et al., 1975), has been synthesized by an improved procedure and sepd. by DEAE-Trisacryl chromatog. into the .alpha.- and .gamma.-isomers (.alpha.-F-MTX and .gamma.-F-MTX). Each isomer was characterized by mass spectrometry, elemental anal., absorbance spectrum, TLC, and reversed-phase HPLC. Identity of the isomers was established by the following enzymic criteria: (a) .gamma.-F-MTX (but not the .alpha.-isomer) was hydrolyzed at the pterate-glutamate bond by carboxypeptidase G2 to yield

4-amino-4-deoxy-10-methylpteroate and .gamma.-glutamyl-diaminopentane-fluorescein; and (b) .gamma.-F-MTX was a much better **inhibitor** of human dihydrofolate reductase than the .alpha.-isomer (K_i values of 0.079 and 4.6 nM). .alpha.- And .gamma.-F-MTX were comparable as **inhibitors** (K_i values of 1.6 and 0.6 .mu.M) of the transport system for reduced folates and MTX in L1210 cells, but the transporter in *Lactobacillus casei* was **inhibited** only by the .gamma.-isomer (K_i = 4.3 .mu.M). The .gamma.-isomer, therefore, was selected for covalent labeling of proteins. When *L. casei* folate transport protein (18 kDa) was treated with .gamma.-F-MTX that had been activated with N-hydroxysuccinimide (NHS), the protein was readily visualized as a fluorescent band on SDS-PAGE electrophoretograms. The probe was also able to detect the transporter in membranes. SDS-PAGE anal. of a Triton X 100 ext. of *L. casei* membrane fragments that had been pretreated with activated .gamma.-F-MTX revealed only 2 fluorescent-labeled bands, viz., the 18-kDa transporter and an unidentified 33-kDa protein. The 43-kDa transporter for reduced folate compds. and MTX in L1210 cells was also labeled by this procedure but, because of its relatively low level, visualization required immunopurification, SDS-PAGE, and transfer to nitrocellulose, followed by immunoblotting with rabbit anti-fluorescein antibody/biotinylated goat anti-rabbit IgG/streptavidin-peroxidase conjugate. NHS-activated .gamma.-F-MTX also facilitated visualization, via fluorescence microscopy, of folate transporters on individual L1210 cells. The validity of this procedure was demonstrated by the marked redn. in fluorescence when labeling was conducted in the presence of excess MTX or when a mutant subline (R81) down-regulated for the transporter was used. *L. casei* spheroplasts treated with NHS-activated .gamma.-F-MTX were also fluorescent, and specificity was shown by reduced labeling in the presence of MTX. In this instance, however, the 33-kDa protein rather than the transporter appeared to be the labeled component.


IT **87328-05-0P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. and reaction with methotrexate)

RN 87328-05-0 CA

CN Thiourea, N-(5-aminopentyl)-N'-(3',6'-dihydroxy-3-oxospiro[isobenzofuran-1(3H),9'-[9H]xanthen]-5-yl)- (9CI) (CA INDEX NAME)



IT **87328-05-0P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. and reaction with methotrexate)

IT **132884-73-2P**

RL: PREP (Preparation)

(prepn. of)

L9 ANSWER 16 OF 20 CA COPYRIGHT 2003 ACS on STN


ACCESSION NUMBER: 110:185631 CA

TITLE: Frequency- and voltage-dependent effects of recainam

on the upstroke velocity of action potential in rabbit ventricular muscle

AUTHOR(S): Kamiya, Kaichiro; Takikawa, Reiko; Singh, Bramah N.
 CORPORATE SOURCE: Sch. Med., UCLA, Los Angeles, CA, USA
 SOURCE: Journal of Cardiovascular Pharmacology (1989), 13(4), 630-7
 CODEN: JCPCDT; ISSN: 0160-2446


DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI



AB The effects of recainam (Wy 42,362) (I) on transmembrane action potentials were examd. in isolated rabbit right ventricular papillary muscles. Recainam (3 .times. 10⁻⁵ to 3 .times. 10⁻⁴ M) caused a concn.-dependent decrease in the .ovrhdot.V_{max} of the action potential. At 3 .times. 10⁻⁴ M, there was a slight decrease in the amplitude of the action potential. The resting potential and the action potential duration were not affected. Use-dependent block of .ovrhdot.V_{max} was tested over a wide range of pacing frequencies (0.1-3.0 Hz). At 1.0 Hz, recainam 10⁻⁴ M produced exponential decreases in .ovrhdot.V_{max} with a rate const. of 0.17 per action potential and 3.98% redn. at steady state. This use-dependent block was augmented at the higher stimulation frequencies. The time const. for the recovery of .ovrhdot.V_{max} from use-dependent block (offset) was 17.2 s. In papillary muscles depolarized with 10 mM [K⁺]O, the use-dependent block was augmented but tonic block and the rates of onset and offset of the use-dependent block were similar to those in normally polarized prepns. in 4 mM [K⁺]O. The curves relating membrane potential and .ovrhdot.V_{max} in prepns. stimulated at a low frequency (0.01 Hz) were not shifted by 10⁻⁴ M recainam. These findings suggest that recainam is a specific Na-channel blocker and has kinetically slow but potent affinity for the channel during action potentials. This selective binding during action potential was further augmented by depolarization and is likely to play a significant role in the control of ventricular arrhythmias by the **drug**.

IT **74738-24-2**, Wy 42362
 RL: BIOL (Biological study)
 (ventricular arrhythmia **inhibition** by, mechanism of)

RN 74738-24-2 CA
 CN Urea, N-(2,6-dimethylphenyl)-N'-[3-[(1-methylethyl)amino]propyl]- (9CI)
 (CA INDEX NAME)




IT **74738-24-2**, Wy 42362
 RL: BIOL (Biological study)
 (ventricular arrhythmia **inhibition** by, mechanism of)

L9 ANSWER 17 OF 20 CA COPYRIGHT 2003 ACS on STN
 ACCESSION NUMBER: 103:154758 CA
 TITLE: Coexistence of beta-1 and beta-2 adrenergic receptors
 in the human heart: effects of treatment with
 receptor antagonists or calcium entry blockers
 AUTHOR(S): Hedberg, Anders; Kempf, Francis, Jr.; Josephson, Mark
 E.; Molinoff, Perry B.
 CORPORATE SOURCE: Sch. Med., Univ. Pennsylvania, Philadelphia, PA,
 19104, USA
 SOURCE: Journal of Pharmacology and Experimental Therapeutics
 (1985), 234(3), 561-8
 CODEN: JPETAB; ISSN: 0022-3565
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB The properties of the binding of [125I]iodopindolol (PIN) to
 .beta.-adrenergic receptors on plasma membranes prepd. from right atrial
 tissue removed during cardiac bypass surgery were investigated. Some of
 the patients from whom the tissue was removed were treated before surgery
 with either a .beta.-adrenergic receptor antagonist or a Ca entry blocker
 or both. The specific binding of [125I]PIN to .beta.-adrenergic receptors
 was saturable, stereoselective, and rapidly reversible. Studies of the
inhibition of the specific binding of [125I]PIN by **drugs**
 selective for .beta.1- or .beta.2-adrenergic receptors suggested that both
 .beta.1 and .beta.2-adrenergic receptors are present in the tissue, with
 approx. 55% of the receptors having the properties of .beta.2-adrenergic
 receptors. The d. of receptors in patients not treated with
 .beta.-adrenergic receptor antagonists or Ca entry blockers was approx. 80
 fmol/mg of protein, whereas the d. of .beta.-adrenergic receptors in
 treated patients was increased by approx. 50%. The relative proportion of
 .beta.1 to .beta.2-adrenergic receptors in subjects treated with
 .beta.-adrenergic receptor antagonists and (or) Ca entry blockers was not
 different from that in untreated subjects. Studies were also carried out
 with a limited no. of samples of human ventricular muscle obtained from
 untreated subjects at the time of surgery. The d. of receptors was lower
 than that obsd. in studies with atrial tissue. However, as with atrial
 tissue, approx. half of the receptors appeared to be .beta.2-adrenergic
 receptors.

IT **53671-71-9**
 RL: BIOL (Biological study)
 (.beta.-adrenergic receptors response to, in heart of human)
 RN 53671-71-9 CA
 CN Urea, N-[2-[[3-(2-cyanophenoxy)-2-hydroxypropyl]amino]ethyl]-N'-phenyl-
 (9CI) (CA INDEX NAME)



IT **53671-71-9**

RL: BIOL (Biological study)
(.beta.-adrenergic receptors response to, in heart of human)

L9 ANSWER 18 OF 20 CA COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 84:144584 CA

TITLE: Relationship between antiinflammatory and antiproteolytic properties of substituted oxothiazolylacetic acids

AUTHOR(S): Kishore, V.; Narain, N. K.; Kumar, S.; Parmar, S. S.

CORPORATE SOURCE: Dep. Chem., Univ. North Dakota, Grand Forks, ND, USA

SOURCE: Pharmacological Research Communications (1976


), 8(1), 43-51

CODEN: PLRCAT; ISSN: 0031-6989

DOCUMENT TYPE: Journal

LANGUAGE: English

GI



AB The six 2-substituted imino-3(3-diethylaminopropyl)-4-oxothiazol-5-ylacetic acids (I) (100 mg/kg, i.p.) tested provided 6.7-27.8% protection against carrageenin-induced edema in rats. The ref. **drugs**, hydrocortisone [50-23-7] (10 mg/kg, i.p.) and oxyphenbutazone [129-20-4] (40 mg/kg, i.p.), exhibited greater antiinflammatory activity, the degree of protection being 48.9 and 52.2%, resp. I (1 mM) possessed antiproteolytic activity which was reflected by 19.2-31.3% protection obsd. with these compds. against in vitro trypsin-induced hydrolysis of bovine serum albumin. With Na salicylate [54-21-7], 55.6% protection was obsd. Introduction of a methyl, methoxy, or chloro substituent in the phenyl nucleus decreased the antiinflammatory and antiproteolytic properties of substituted I. Thus, the antiproteolytic activity of I may contribute to the mechanism of action of the antiinflammatory properties of I.


IT **730-19-8P**

RL: SPN (Synthetic preparation); PREP (Preparation)

(prepn. of and reaction with maleic anhydride)

RN 730-19-8 CA

CN Thiourea, N-[3-(diethylamino)propyl]-N'-phenyl- (9CI) (CA INDEX NAME)



IT 730-19-8P 23061-70-3P 52607-67-7P

58860-24-5P 58860-25-6P 58860-26-7P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of and reaction with maleic anhydride)

L9 ANSWER 19 OF 20 CA COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 83:90995 CA

TITLE: Parachors in **drug** design

AUTHOR(S): Ahmad, Parvez; Fyfe, Colin A.; Mellors, Alan

CORPORATE SOURCE: Dep. Chem., Univ. Guelph, Guelph, ON, Can.

SOURCE: Biochemical Pharmacology (1975), 24(10),
1103-9

CODEN: BCPCA6; ISSN: 0006-2952

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Good correlation was found between parachor values and the thyromimetic activity of 3'-substituted thyroxine analogs, the blood-clotting-inhibitory activity of 5-substituted pentylamines, and the local anesthetic activity of paracaines. Correlations with parachor were comparable with those obtained with the Hansch hydrophobic const. .pi. for 6 more **drug** classes: antibiotic activity of penicillins, fibrinolytic activity of 2,4-substituted benzoic acids, parasympatholytic activity of 2-alkyl diphenhydramines, .beta.-receptor activity of sympathomimetics, fibrinolytic activity of 5-substituted salicylic acids, and isohemolytic conc. for n-alcs.


IT 56807-79-5

RL: PRP (Properties)

(parachor of, anticoagulant activity in relation to)

RN 56807-79-5 CA

CN Urea, N-(5-aminopentyl)-N'-(4-methylphenyl)- (9CI) (CA INDEX NAME)



IT 56807-79-5

RL: PRP (Properties)

(parachor of, anticoagulant activity in relation to)

L9 ANSWER 20 OF 20 CA COPYRIGHT 2003 ACS on STN


ACCESSION NUMBER: 74:141216 CA

TITLE: Chemotherapeutic agents against Mycobacterium tuberculosis. XXVI. Synthesis and antituberculous activity of phenylthiourea, p-ethoxyphenylthiourea, and 3-bromo-4-ethoxyphenylthiourea derivatives

AUTHOR(S): Fujikawa, Fukujiro; Hirai, Kunio; Hirayama, Teruhisa; Matsunashi, Teruki; Nakanishi, Yoshikuni; Kumoto, Kayoko; Shimizu, Tatsuzo; Sakaki, Chiichiro; Hamuro, Yoshitaro; et al.

10/019,652

CORPORATE SOURCE: Kyoto Coll. Pharm., Kyoto, Japan
SOURCE: Yakugaku Zasshi (1971), 91(2), 159-65
CODEN: YKKZAJ; ISSN: 0031-6903
DOCUMENT TYPE: Journal
LANGUAGE: Japanese
GI For diagram(s), see printed CA Issue.
AB Seventy-five thioureas, comprising 27 derivs. of phenylthiourea (I), 25 of p-ethoxyphenylthiourea (II), and 23 of 3-bromo-4-ethoxyphenylthiourea (III), were prepd. from corresponding phenyl isothiocyanates and tested for antibacterial activity against a strain of human-type, **drug**-sensitive Mycobacterium tuberculosis in vitro. Six of them were active, but their min. **inhibitory** concns. (MIC) were significantly higher than those of control agents, such as isoniazid and p-aminosalicylic acid. The MIC of 1-phenyl-3-[4-(dimethylamino)-phenyl]-2-thiourea and 1-(4-ethoxyphenyl)-3-(4-bromophenyl)-2-thiourea were 3.13 and 6.25 .degree.mg/ml, resp.
IT **24775-54-0**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antitubercular activity of)
RN 24775-54-0 CA
CN Thiourea, N,N''-1,2-ethanediyldis[N'-phenyl- (9CI) (CA INDEX NAME)



IT **24775-54-0 31864-68-3**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antitubercular activity of)

=> file uspatfull

=> d ibib abs fhitr 1-3

L14 ANSWER 1 OF 3 USPATFULL on STN

ACCESSION NUMBER: 2002:12633 USPATFULL
TITLE: Methods for making multivalent arrays
INVENTOR(S): Kiessling, Laura L., Madison, WI, UNITED STATES
Strong, Laura E., Madison, WI, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002007016	A1	20020117
	US 6538072	B2	20030325
APPLICATION INFO.:	US 2001-888098	A1	20010622 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1999-335430, filed on 17 Jun 1999, GRANTED, Pat. No. US 6271315		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	Greenlee, Winner and Sullivan, 5370 Manhattan Circle, Suite 201, Boulder, CO, 80303		
NUMBER OF CLAIMS:	43		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	6 Drawing Page(s)		

10/019,652

LINE COUNT: 1089

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method of preparing a multivalent array that includes: polymerizing at least one monomer comprising at least one polymerizable group and at least one latent reactive group in the presence of a metal carbene catalyst to form a polymer template comprising at least one latent reactive group; and combining the polymer template with at least one functionalizing reagent comprising at least one reactive group under conditions effective to react the latent reactive group of the polymer template with the reactive group of the functionalizing reagent to form a multivalent array.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 87328-05-0P

(telechelic polymer useful in multivalent arrays and combinatorial libraries)

RN 87328-05-0 USPATFULL

CN Thiourea, N-(5-aminopentyl)-N'-(3',6'-dihydroxy-3-oxospiro[isobenzofuran-1(3H),9'-[9H]xanthen]-5-yl)- (9CI) (CA INDEX NAME)



L14 ANSWER 2 OF 3 USPATFULL on STN

ACCESSION NUMBER: 2001:126077 USPATFULL

TITLE: Methods for making multivalent arrays

INVENTOR(S): Kiessling, Laura L., Madison, WI, United States

Strong, Laura E., Madison, WI, United States

PATENT ASSIGNEE(S): Wisconsin Alumni Research Foundation, Madison, WI, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6271315	B1	20010807
APPLICATION INFO.:	US 1999-335430		19990617 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Wu, David W.		
ASSISTANT EXAMINER:	Harlan, R.		
LEGAL REPRESENTATIVE:	Greenlee, Winner and Sullivan, P.C.		
NUMBER OF CLAIMS:	36		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	8 Drawing Figure(s); 6 Drawing Page(s)		
LINE COUNT:	1178		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method of preparing a multivalent array that includes: polymerizing at least one monomer comprising at least one polymerizable group and at least one latent reactive group in the presence of a metal carbene catalyst to form a polymer template comprising at least one latent reactive group; and combining the polymer template with at least one

functionalizing reagent comprising at least one reactive group under conditions effective to react the latent reactive group of the polymer template with the reactive group of the functionalizing reagent to form a multivalent array.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 87328-05-0P

(telechelic polymer useful in multivalent arrays and combinatorial libraries)

RN 87328-05-0 USPATFULL

CN Thiourea, N-(5-aminopentyl)-N'-(3',6'-dihydroxy-3-oxospiro[isobenzofuran-1(3H),9'-[9H]xanthen]-5-yl)- (9CI) (CA INDEX NAME)



L14 ANSWER 3 OF 3 USPATFULL on STN

ACCESSION NUMBER: 2001:63688 USPATFULL

TITLE: Acetylenic .alpha.-amino acid-based sulfonamide hydroxamic acid tase **inhibitors**

INVENTOR(S): Levin, Jeremy I., New City, NY, United States
Chen, James M., Bedminster, NJ, United States
Cole, Derek C., New City, NY, United States
Du, Mila T., Suffern, NY, United States
Laakso, Leif M., New City, NY, United States

PATENT ASSIGNEE(S): American Cyanamid Company, Madison, NJ, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6225311	B1	20010501
APPLICATION INFO.:	US 2000-492691		20000127 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-155249P	19990127 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Shah, Mukund J.	
ASSISTANT EXAMINER:	Patel, Sudhaker B.	
LEGAL REPRESENTATIVE:	Barrett, Rebecca R.	
NUMBER OF CLAIMS:	13	
EXEMPLARY CLAIM:	1	
LINE COUNT:	8429	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds of the formula: ##STR1##

are useful in treating disease conditions mediated by TNF-.alpha., such as rheumatoid arthritis, osteoarthritis, sepsis, AIDS, ulcerative colitis, multiple sclerosis, Crohn's disease and degenerative cartilage

10/019,652

loss.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 287406-64-8P

(prepn. of acetylenic .alpha.-amino acid-based sulfonamide hydroxamic acid TACE inhibitors)

RN 287406-64-8 USPATFULL

CN Pentanamide, 2-[[[4-(2-butynyloxy)phenyl]sulfonyl]amino]-N-hydroxy-5-
[[[(phenylamino)carbonyl]amino]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> d ibib abs fhitr 1-30

L17 ANSWER 1 OF 90 USPATFULL on STN

ACCESSION NUMBER: 2002:310955 USPATFULL

TITLE: 5-(2-imidazolinyllamino)-benzimidazole derivatives,
their preparation and their use as .alpha.-adrenoceptor
agonists with improved metabolic stability

INVENTOR(S): Cupps, Thomas Lee, Norwich, NY, United States
Bogdan, Sophie Eva, Maineville, OH, United States
Nikolaides, Nick, Mason, OH, United States
Gilbert, Sheri Ann, Cincinnati, OH, United States
Gazda, Michael, Mason, OH, United States
Dobson, Roy Lee, Hamilton, OH, United States
Cruze, Charles Andrew III, West Chester, OH, United States

PATENT ASSIGNEE(S): The Procter & Gamble Company, Cincinnati, OH, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6486190	B1	20021126	
	WO 9926942		19990603	<--
APPLICATION INFO.:	US 2000-554698		20000518	(9)
	WO 1998-US24694		19981120	
			20000518	PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-66767P	19971124 (60)
	US 1997-66700P	19971125 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Stockton, Laura L.	
LEGAL REPRESENTATIVE:	Upte, David V., Kellerman, James C.	
NUMBER OF CLAIMS:	19	

10/019,652

EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 1731
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Benzimidazole compounds having the generic structure: ##STR1##

are used to treat alpha-2 mediated disorders, including nasal congestion, glaucoma, asthma, migraine, and diarrhea.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 214688-04-7P

(prepn. and cyclization with Hg(OAc)₂; prepn. of 5-(2-imidazolinylamino)benzimidazoles as .alpha.-2 adrenoceptor agonists)

RN 214688-04-7 USPATFULL

CN Thiourea, N-(2-aminoethyl)-N'-(4,6-dimethyl-1H-benzimidazol-5-yl)- (9CI)
(CA INDEX NAME)



L17 ANSWER 2 OF 90 USPATFULL on STN

ACCESSION NUMBER: 2001:215054 USPATFULL

TITLE: Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives

INVENTOR(S): Burke, James A., Santa Ana, CA, United States
Garst, Michael E., Newport Beach, CA, United States
Wheeler, Larry A., Irvine, CA, United States

PATENT ASSIGNEE(S): Allergan, Waco, TX, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6323204	B1	20011127	<--
APPLICATION INFO.:	US 1998-222844		19981230	(9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1998-12517, filed on 23 Jan 1998, now abandoned Division of Ser. No. US 1996-636740, filed on 19 Apr 1996, now patented, Pat. No. US 5756503 Division of Ser. No. US 1995-458949, filed on 2 Jun 1995, now patented, Pat. No. US 5587376 Division of Ser. No. US 1995-390265, filed on 15 Feb 1995, now patented, Pat. No. US 5561132 Continuation of Ser. No. US 1993-135716, filed on 13 Oct 1993, now abandoned			
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	GRANTED			
PRIMARY EXAMINER:	Geist, Gary			
ASSISTANT EXAMINER:	White, Everett			
LEGAL REPRESENTATIVE:	Stout, Uxa, Buyan & Mullins, LLP, Uxa, Frank J.			
NUMBER OF CLAIMS:	17			
EXEMPLARY CLAIM:	1			
LINE COUNT:	696			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method of treating a mammal comprises administering to a mammal an

effective amount to provide a desired therapeutic effect in the mammal of a compound selected from the group consisting of those having the formula: ##STR1##

and **pharmaceutically** acceptable acid addition salts thereof and mixtures thereof, wherein R.sub.1 and R.sub.2 each is selected from the group consisting of alkyl radicals containing 1 to 4 carbon atoms and alkoxy radicals containing 1 to 4 carbon atoms, the 2-imidazolin-2-ylamino group may be in any of the 5-, 6-, 7- or 8-positions of the quinoxaline nucleus, and R.sub.3, R.sub.4 and R.sub.5 each is located in one of the remaining 5-, 6-, 7- or 8-positions of the quinoxaline nucleus and is independently selected from the group consisting of Cl, Br, H and alkyl radicals containing 1 to 3 carbon atoms. Such compounds, when administered to a mammal, provide desired therapeutic effects, such as reduction in peripheral pain.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **134892-47-0P**

(prepn. of (2-imidazolin-2-ylamino)quinoxalines for the treatment of pain)

RN 134892-47-0 USPATFULL

CN Thiourea, N-(2-aminoethyl)-N'-(5-bromo-6-quinoxaliny)- (9CI) (CA INDEX NAME)



L17 ANSWER 3 OF 90 USPATFULL on STN

ACCESSION NUMBER: 2001:191146 USPATFULL

TITLE: Substituted amino acids as erythropoietin mimetics

INVENTOR(S): Connolly, Peter J., New Providence, NJ, United States

Bandurco, Victor T., Bridgewater, NJ, United States

Wetter, Steven K., Flemington, NJ, United States

Johnson, Sigmond, Three Bridges, NJ, United States

Bussolari, Jacqueline, Skillman, NJ, United States

Murray, William V., Belle Mead, NJ, United States

PATENT ASSIGNEE(S): Ortho-McNeil Pharmaceutical, Inc., Raritan, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6310078	B1	20011030
APPLICATION INFO.:	US 2000-517976		20000303 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1999-294785, filed on 19 Apr 1999, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Richter, Johann		
ASSISTANT EXAMINER:	Davis, Brian J.		
LEGAL REPRESENTATIVE:	Wallen, III, John W.		
NUMBER OF CLAIMS:	4		
EXEMPLARY CLAIM:	1		

10/019,652

LINE COUNT: 2753

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to a series of substituted amino acids of Formula I ##STR1##

pharmaceutical compositions containing them and intermediates used in their manufacture. The compounds of the invention are small molecules which bind to the erythropoietin **receptor** and compete with the natural ligand for binding to this **receptor**.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 247205-06-7P


(prepn. of substituted amino acids as erythropoietin mimetics)

RN 247205-06-7 USPATFULL

CN Hexanamide, 2-[bis[(2E)-3-(3-phenoxyphenyl)-2-propenyl]amino]-N-[2-(4-methoxyphenyl)ethyl]-6-[[(phenylamino)carbonyl]amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



L17 ANSWER 4 OF 90 USPATFULL on STN

ACCESSION NUMBER: 2001:158434 USPATFULL

TITLE: Methods and reagents for capping ruthenium or osmium carbene-catalyzed ROMP products

INVENTOR(S): Kiessling, Laura L., Madison, WI, United States
Gordon, Eva J., Wheeling, IL, United States
Strong, Laura E., Madison, WI, United States

PATENT ASSIGNEE(S): Wisconsin Alumni Research Foundation, Madison, WI, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6291616	B1	20010918	<--
APPLICATION INFO.:	US 1999-336121		19990617 (9)	
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	GRANTED			

10/019,652

PRIMARY EXAMINER: Wu, David W.
ASSISTANT EXAMINER: Harlan, R.
LEGAL REPRESENTATIVE: Greenlee, Winner and Sullivan, P.C.
NUMBER OF CLAIMS: 48
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 10 Drawing Figure(s); 8 Drawing Page(s)
LINE COUNT: 1437

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods of preparing a telechelic polymer (mono- or bi-telechelic) that use a ruthenium or osmium carbene catalyst and a capping agent, at least one of which is functionalized.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **87328-05-0P**

(telechelic polymer useful in multivalent arrays and combinatorial libraries)

RN 87328-05-0 USPATFULL

CN Thiourea, N-(5-aminopentyl)-N'-(3',6'-dihydroxy-3-oxospiro[isobenzofuran-1(3H),9'-[9H]xanthen]-5-yl)- (9CI) (CA INDEX NAME)



L17 ANSWER 5 OF 90 USPATFULL on STN

ACCESSION NUMBER: 2001:55965 USPATFULL

TITLE: Acyclic metalloprotease **inhibitors**

INVENTOR(S): Almstead, Neil Gregory, Loveland, OH, United States
Bookland, Roger Gunnard, Cincinnati, OH, United States
Taiwo, Yetunde Olabisi, West Chester, OH, United States
Bradley, Rimma Sandler, Fairfield, OH, United States
Bush, Rodney Dean, Fairfield, OH, United States
De, Biswanath, Cincinnati, OH, United States
Natchus, Michael George, Glendale, OH, United States
Pikul, Stanislaw, Mason, OH, United States

PATENT ASSIGNEE(S): The Procter & Gamble Co., Cincinnati, OH, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6218389	B1	20010417	<--
APPLICATION INFO.:	US 1998-127678		19980731 (9)	

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-54348P	19970731 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Kight, John	
ASSISTANT EXAMINER:	Covington, Raymond	
LEGAL REPRESENTATIVE:	Kellerman, James C., Roof, Carl J.	

10/019,652

NUMBER OF CLAIMS: 29
EXEMPLARY CLAIM: 1
LINE COUNT: 2384

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides compounds of formula ##STR1##

as described in the claims, or an optical isomer, diastereomer or enantiomer thereof, or a **pharmaceutically**-acceptable salt, or biohydrolyzable amide, ester, or imide thereof are useful as **inhibitors** of metalloproteases.

Also disclosed are **pharmaceutical** compositions and methods of treating diseases, disorders and conditions characterized by metalloprotease activity using these compounds or the **pharmaceutical** compositions containing them.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 220390-41-0P

(prepn. of substituted amino acid N-hydroxyamides as metalloprotease inhibitors)

RN 220390-41-0 USPATFULL

CN Hexanamide, 6-amino-N-hydroxy-2-[[[(4-methylphenyl)amino]carbonyl]amino]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L17 ANSWER 6 OF 90 USPATFULL on STN

ACCESSION NUMBER: 2001:48114 USPATFULL

TITLE: Aryl sulfonamides and sulfamide derivatives and uses thereof

INVENTOR(S): Islam, Imadul, Hercules, CA, United States
Dhanoo, Daljit S., West Chester, PA, United States
Finn, John M., Andover, MA, United States
Du, Ping, Mahwah, NJ, United States
Gluchowski, Charles, Danville, CA, United States
Jeon, Yoon T., Ridgewood, NJ, United States
PATENT ASSIGNEE(S): Synaptic Pharmaceutical Corporation, Paramus, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6211241	B1	20010403	<--
APPLICATION INFO.:	US 1998-88450		19980601	(9)
RELATED APPLN. INFO.:	Continuation of Ser. No. WO 1996-US19085, filed on 27 Nov 1996 Continuation of Ser. No. US 1995-566104, filed on 1 Dec 1995, now abandoned			
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	Granted			
PRIMARY EXAMINER:	Radio, Barbara			
LEGAL REPRESENTATIVE:	White, John P.Cooper & Dunham LLP			

10/019,652

NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
LINE COUNT: 2513

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention is directed to novel aryl sulfonamide and sulfamide compounds which bind selectively to and **inhibit** the activity of the human Y5 **receptor**. This invention is also related to uses of these compounds for the treatment of feeding disorders such as obesity, anorexia nervosa, bulimia nervosa, and abnormal conditions such as sexual/reproductive disorders, depression, epileptic seizure, hypertension, cerebral hemorrhage, congestive heart failure or sleep disturbances and for the treatment of any disease in which antagonism of a Y5 **receptor** may be useful.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 191931-97-2P

(prepn. of aryl sulfonamide and sulfamide derivs. which bind selectively to the human Y5 receptor)

RN 191931-97-2 USPATFULL

CN 1-Naphthalenesulfonamide, N-[6-[[[(1-naphthalenylamino)carbonyl]amino]hexyl]- (9CI) (CA INDEX NAME)



L17 ANSWER 7 OF 90 USPATFULL on STN

ACCESSION NUMBER: 2001:4934 USPATFULL

TITLE: Polyamine analogues as therapeutic and diagnostic agents

INVENTOR(S): Vermeulin, Nicolaas M. J., Woodinville, WA, United States

O'Day, Christine L., Mountlake Terrace, WA, United States

Webb, Heather K., Seattle, WA, United States

Burns, Mark R., Shoreline, WA, United States

Bergstrom, Donald E., West Lafayette, IN, United States

PATENT ASSIGNEE(S): Oridigm Corporation, Seattle, WA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6172261	B1	20010109	<--
	WO 9903823		19990128	<--
APPLICATION INFO.:	US 1999-341400		19990903	(9)
	WO 1998-US14896		19980715	
			19990903	PCT 371 date
			19990903	PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-52586P	19970715 (60)
	US 1997-65728P	19971114 (60)
	US 1998-85538P	19980515 (60)
DOCUMENT TYPE:	Patent	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Henley, III, Raymond	
LEGAL REPRESENTATIVE:	Morrison & Foerster LLP	
NUMBER OF CLAIMS:	24	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	50 Drawing Figure(s); 38 Drawing Page(s)	
LINE COUNT:	3638	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel **inhibitors** of polyamine transport having **inhibition** constants two orders of magnitude lower than those of known compounds are disclosed. These polyamine analogues are useful **pharmaceutical** agents for treating diseases where it is desired to **inhibit** polyamine transport or other polyamine binding proteins, for example cancer and post-angioplasty injury. Novel chemical synthetic methods to obtain polyamine analogues are disclosed, including the production of a combinational polyamine library. These approaches yield analogues with desirable activities both for diagnostic and research assays and therapy. The assays of the invention are useful for high throughput screening of targets in the discovery of **drugs** that interact with the polyamine system.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 220221-10-3P

(prepn. of polyamines as therapeutic and diagnostic agents)

RN 220221-10-3 USPATFULL

CN Urea, N-[3-[[4-[(3-aminopropyl)amino]butyl]amino]propyl]-N'-1-anthracenyl-
(9CI) (CA INDEX NAME)



L17 ANSWER 8 OF 90 USPATFULL on STN

ACCESSION NUMBER: 2000:171042 USPATFULL

TITLE: 2-imidazolinylaminoindole compounds useful as alpha-2 adrenoceptor agonists

INVENTOR(S): Henry, Raymond Todd, Pleasant Plain, OH, United States
Sheldon, Russell James, Fairfield, OH, United States
Seibel, William Lee, Hamilton, OH, United States

PATENT ASSIGNEE(S): The Procter & Gamble Company, Cincinnati, OH, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6162818		20001219 <--

APPLICATION INFO.: US 1999-290731 19990413 (9)
 RELATED APPLN. INFO.: Continuation of Ser. No. WO 1997-US20801, filed on 21
 Nov 1997

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-31777P	19961111 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	McKane, Joseph K.	
ASSISTANT EXAMINER:	Oswiecki, Jane C.	
LEGAL REPRESENTATIVE:	Bott, Cynthia M., Kellerman, James C., Clark, Karen F.	
NUMBER OF CLAIMS:	42	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2524	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention involves compounds having the following structure:
 ##STR1## wherein: a) R.sub.1 is hydrogen; or alkyl; bond (a) is a single
 or a double bond;

b) R.sub.2 and R.sub.3 are each independently selected from hydrogen;
 unsubstituted C.sub.1 -C.sub.3 alkanyl, alkenyl or alkynyl;
 cycloalkanyl, cycloalkenyl; unsubstituted C.sub.1 -C.sub.3 alkylthio or
 alkoxy; hydroxy; thio; nitro; cyano; amino; C.sub.1 -C.sub.3 alkylamino
 or C.sub.1 -C.sub.3 dialkylamino and halo;

c) R.sub.4, R.sub.5 and R.sub.6 are each independently selected from
 hydrogen; unsubstituted C.sub.1 -C.sub.3 alkanyl, alkenyl or alkynyl;
 cycloalkanyl, cycloalkenyl; unsubstituted C.sub.1 -C.sub.3 alkylthio or
 alkoxy; hydroxy; thio; nitro; cyano; amino; C.sub.1 -C.sub.3 alkylamino
 or C.sub.1 -C.sub.3 dialkylamino; halo; and 2-imidazolinylamino; and
 wherein one and only one of R.sub.4, R.sub.5 and R.sub.6 is
 2-imidazolinylamino;

d) R.sub.7 is selected from hydrogen; unsubstituted C.sub.1 -C.sub.3
 alkanyl, alkenyl or alkynyl; cycloalkanyl, cycloalkenyl; unsubstituted
 C.sub.1 -C.sub.3 alkylthio or alkoxy; hydroxy; thio; nitro; cyano;
 amino; C.sub.1 -C.sub.3 alkylamino or C.sub.1 -C.sub.3 dialkylamino and
 halo;

e) the compound is not 4-(2-imidazolinylamino)indole;

enantiomers, optical isomers, stereoisomers, diastereomers, tautomers,
 addition salts, biohydrolyzable amides and esters thereof, and
pharmaceutical compositions comprising such novel compounds. The
 invention also relates to the use of such compounds for treating
 disorders modulated by alpha-2 adrenoceptors.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 208510-96-7P

(prepn. of 2-imidazolinylaminoindoles as alpha-2 adrenoceptor agonists)

RN 208510-96-7 USPATFULL

CN Thiourea, N-(2-aminoethyl)-N'-(2,3-dihydro-7-methyl-1H-indol-6-yl)- (9CI)
 (CA INDEX NAME)



L17 ANSWER 9 OF 90 USPATFULL on STN

ACCESSION NUMBER: 2000:121514 USPATFULL

TITLE: 6-(2-imidazolinylamino)quinoxaline compounds useful as alpha-2 adrenoceptor agonists

INVENTOR(S): Maurer, Peter J., Cincinnati, OH, United States
Henry, Raymond T., Pleasant Plain, OH, United States
Sheldon, Russell James, Fairfield, OH, United States

PATENT ASSIGNEE(S): The Procter & Gamble Company, Cincinnati, OH, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6117871		20000912 <--
APPLICATION INFO.:	US 1996-755941		19961125 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1995-496707, filed on 29 Jun 1995, now abandoned which is a continuation-in-part of Ser. No. US 1993-169785, filed on 17 Dec 1993, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Fay, Zohreh		
LEGAL REPRESENTATIVE:	Bott, Cynthia M., Kellerman, James C., Suter, David L.		
NUMBER OF CLAIMS:	18		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1432		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The subject invention relates to methods of treating alpha-2 adrenoceptor modulated disorders, comprising administration, to a mammal in need of such treatment, of a safe and effective amount of a compound having the following structure: ##STR1## wherein: (a) R is unsubstituted C.sub.1 -C.sub.3 alkanyl or alkenyl; and

(b) R' is selected from hydrogen; unsubstituted C.sub.1 -C.sub.3 alkanyl or alkenyl; unsubstituted C.sub.1 -C.sub.3 alkylthio or alkoxy; hydroxy; thiol; and halo.

The subject invention also relates compounds and compositions for preventing or treating of disorders modulated by alpha-2 adrenoceptors.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 183278-01-5P

(synthesis and formulations of 6-(2-imidazolinylamino)quinoxaline compds. useful as alpha-2 adrenoceptor agonists)

RN 183278-01-5 USPATFULL

CN Thiourea, N-(2-aminoethyl)-N'-(5-methyl-6-quinoxaliny)- (9CI) (CA INDEX NAME)



L17 ANSWER 10 OF 90 USPATFULL on STN

ACCESSION NUMBER: 2000:117771 USPATFULL

TITLE: Amino acid derivatives, **pharmaceutical**
compositions containing these compounds and processes
for preparing themINVENTOR(S): Engel, Wolfhard, Biberach, Germany, Federal Republic of
Eberlein, Wolfgang, Biberach, Germany, Federal Republic of
of
Rudolf, Klaus, Biberach, Germany, Federal Republic of
Doods, Henri, Warthausen, Germany, Federal Republic of
Wieland, Heike-Andrea, Biberach, Germany, Federal
Republic of
Willim, Klaus-Dieter, Hochdorf/Schweinhausen, Germany,
Federal Republic of
Entzeroth, Michael, Warthausen, Germany, Federal
Republic of
Wienen, Wolfgang, Biberach/Rissegg, Germany, Federal
Republic ofPATENT ASSIGNEE(S): Karl Thomae GmbH, Biberach, Germany, Federal Republic
of (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6114390		20000905 <--
APPLICATION INFO.:	US 1997-950113		19971014 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 945048.		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Raymond, Richard L.		
LEGAL REPRESENTATIVE:	Raymond, Robert P., Stempel, Alan R., Devlin, Mary-Ellen M.		
NUMBER OF CLAIMS:	10		
EXEMPLARY CLAIM:	1		
LINE COUNT:	6573		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB NPY-antagonistic compounds of the formula ##STR1## Exemplary are: (A)
(R)-N-[[4-(Aminocarbonylaminomethyl)phenyl]methyl]-N.sup.2
-bis(4-hydroxyphenyl)acetyl]-argininamide-trifluoroacetate;

(B) (R)-N-[[4-(Aminocarbonylaminomethyl)phenyl]methyl]-N.sup.2
-[bis(4-chlorophenyl)acetyl]-argininamide-trifluoroacetate;

(C) (R)-N-[[4-(Aminocarbonylaminomethyl)phenyl]methyl]-N.sup.2
-(diphenylacetyl)-argininamide-trifluoroacetate;

(D) (R)-N.sup.2 -(Diphenylacetyl)-N-[[4-(ethoxycarbonylmethylamino-
carbonylaminomethyl)phenyl]methyl]-argininamide-trifluoroacetate;

(E) (R,S)-N.sup.5 -(Aminoiminomethyl)-N.sup.2 -(diphenylacetyl)-N-[(4-hy-

droxyphenyl)methyl]-N.sup.5 -methyl-ornithinamide-hydrochloride;

(F) (R)-N-[[4-(Aminocarbonylmethyl)phenyl]methyl]-N.sup.2
-(diphenyl-acetyl)-argininamide-diacetate;

(G) (R)-N.sup.2 -(Diphenylacetyl)-N-[[4-(ethylaminocarbonylamino-methyl)-
phenyl]methyl]-argininamide-bis-(trifluoroacetate); and,

(H) (R)-N.sup.2 -(Diphenylacetyl)-N-[[4-(ethoxycarbonylamino-
carbonylaminomethyl)phenyl]methyl]-argininamide-trifluoroacetate.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 191870-71-0P

(prepn. of amino acid derivs. as neuropeptide Y antagonists)

RN 191870-71-0 USPATFULL

CN Pentanamide, N-[[4-[[[(aminocarbonyl)amino]methyl]phenyl]methyl]-5-
[(aminoiminomethyl)amino]-2-[[[(1-naphthalenylamino)carbonyl]amino]-,
(R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L17 ANSWER 11 OF 90 USPATFULL on STN

ACCESSION NUMBER: 2000:113979 USPATFULL

TITLE: 2-imidazolinylaminobenzoxazole compounds useful as
alpha-2 adrenoceptor agonists

INVENTOR(S): Henry, Raymond Todd, Pleasant Plain, OH, United States
Sheldon, Russell James, Fairfield, OH, United States
Seibel, William Lee, Hamilton, OH, United States

PATENT ASSIGNEE(S): The Procter & Gamble Company, Cincinnati, OH, United
States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6110952		20000829	<--
	WO 9823611		19980604	<--
APPLICATION INFO.:	US 1999-308792		19990809	(9)
	WO 1997-US20803		19971121	
			19990809	PCT 371 date
			19990809	PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-31787P	19961125 (60)
DOCUMENT TYPE:	Utility	

10/019,652

FILE SEGMENT: Granted
PRIMARY EXAMINER: McKane, Joseph
ASSISTANT EXAMINER: Wright, Sonya N
LEGAL REPRESENTATIVE: Kellerman, James C., Roof, Carl J.
NUMBER OF CLAIMS: 42
EXEMPLARY CLAIM: 1
LINE COUNT: 1879

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to compounds of formula I, (2-imidazolinylamino)benzoxazoles. The compounds have been found to be alpha-2 adrenocepto agonists and are useful for treatment of disorders modulated by alpha-2 adrenoceptors.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 208450-33-3P

(prepn. of 2-imidazolinylaminobenzoxazoles as alpha-2 adrenoceptor agonists)

RN 208450-33-3 USPATFULL

CN Thiourea, N-(2-aminoethyl)-N'-(4-methyl-5-benzoxazolyl)- (9CI) (CA INDEX NAME)



L17 ANSWER 12 OF 90 USPATFULL on STN

ACCESSION NUMBER: 1999:124931 USPATFULL

TITLE: 2-Imidazolinylamino heterocyclic compounds useful as alpha-2 adrenoceptor agonists

INVENTOR(S): Maurer, Peter J., Cincinnati, OH, United States
Ares, Jeffrey J., Hamilton, OH, United States
Seibel, William L., Hamilton, OH, United States
Walker, Daniel P., Bloomington, IN, United States
Sheldon, Russell James, Fairfield, OH, United States
Henry, Raymond T., Pleasant Plain, OH, United States

PATENT ASSIGNEE(S): The Procter & Gamble Company, Cincinnati, OH, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5965595		19991012 <--
APPLICATION INFO.:	US 1996-756085		19961125 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1995-478708, filed on 7 Jun 1995, now patented, Pat. No. US 5663189 which is a continuation-in-part of Ser. No. US 1993-86482, filed on 1 Jul 1993, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Goldberg, Jerome D.		
LEGAL REPRESENTATIVE:	Kellerman, James C., Roof, Carl J., Suter, David L.		
NUMBER OF CLAIMS:	19		
EXEMPLARY CLAIM:	2		
LINE COUNT:	1891		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			

AB The subject invention relates to compounds having the structure:
 ##STR1## wherein (a) n is an integer from 1 to about 3;

(b) X and Y are each independently selected from O, S and CH.sub.2, with at least one of X and Y being O or S;

(c) R is unsubstituted, straight or branched chain alkanyl or alkanoxy having from 1 to about 3 non-hydrogen atoms; and

(d) R' is selected from hydrogen, methyl, cyano, and halo;

pharmaceutical compositions containing such compounds; and the use of such compounds for preventing or treating of disorders modulated by alpha-2 adrenoceptors.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 196091-23-3P

(prepn. of 2-Imidazolinylamino heterocyclic compds. as
 .alpha.2-adrenoceptor agonists)

RN 196091-23-3 USPATFULL

CN Thiourea, N-(2-aminoethyl)-N'-(2,3-dihydro-5-methyl-1,4-benzodioxin-6-yl)-
 (9CI) (CA INDEX NAME)



L17 ANSWER 13 OF 90 USPATFULL on STN

ACCESSION NUMBER: 1999:72592 USPATFULL

TITLE: 7-(2-imidazolinylamino)quinoline compounds useful as
 alpha-2 adrenoceptor agonists

INVENTOR(S): Cupps, Thomas Lee, Oxford, OH, United States
 Bogdan, Sophie E., Maineville, OH, United States
 Henry, Raymond T., Pleasant Plain, OH, United States
 Sheldon, Russell James, Fairfield, OH, United States

PATENT ASSIGNEE(S): The Procter & Gamble Company, Cincinnati, OH, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5916900		19990629 <--
APPLICATION INFO.:	US 1996-758118		19961125 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1995-496796, filed on 29 Jun 1995, now patented, Pat. No. US 5716966		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Fay, Zohreh		
LEGAL REPRESENTATIVE:	Kellerman, James C., Graff, Milton B., Suter, David L.		
NUMBER OF CLAIMS:	8		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1627		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention involves the use of compounds having the following structure: ##STR1## wherein: (a) R is unsubstituted C.sub.1

10/019,652

-C.sub.3 alkanyl or alkenyl; and

(b) R' is selected from hydrogen; unsubstituted C.sub.1 -C.sub.3 alkanyl or alkenyl; unsubstituted C.sub.1 -C.sub.3 alkylthio or alkoxy; hydroxy; thiol; cyano; and halo;

for preventing or treating of disorders modulated by alpha-2 adrenoceptors.

The subject invention also involves novel compounds and compositions.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 168770-36-3P

(prepn. of (imidazolinylamino)quinolines as alpha-2 adrenoceptor agonists)

RN 168770-36-3 USPATFULL

CN Thiourea, N-(2-aminoethyl)-N'-(5-cyano-8-methyl-7-quinolinyl)- (9CI) (CA INDEX NAME)



L17 ANSWER 14 OF 90 USPATFULL on STN

ACCESSION NUMBER: 1999:69731 USPATFULL

TITLE: 2-imidazolinylamino heterocyclic compounds useful as alpha-2 adrenoceptor agonists

INVENTOR(S): Maurer, Peter J., Cincinnati, OH, United States
Ares, Jeffrey J., Hamilton, OH, United States
Seibel, William L., Hamilton, OH, United States
Walker, Daniel P., Bloomington, OH, United States
Sheldon, Russell James, Fairfield, OH, United States
Henry, Raymond T., Pleasant Plain, OH, United States
PATENT ASSIGNEE(S): The Procter & Gamble Company, Cincinnati, OH, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5914342		19990622 <--
APPLICATION INFO.:	US 1998-159698		19980924 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1996-756085, filed on 25 Nov 1996 which is a continuation-in-part of Ser. No. US 1995-478708, filed on 7 Jun 1995, now patented, Pat. No. US 5663189		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Goldberg, Jerome D.		
LEGAL REPRESENTATIVE:	Kellerman, James C., Roof, Carl J., Graff, Milton B.		
NUMBER OF CLAIMS:	20		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1872		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

10/019,652

AB The subject invention relates to compounds having the structure:
##STR1## wherein (a) n is an integer from 1 to about 3;

(b) X and Y are each independently selected from O, S and CH.sub.2, with at least one of X and Y being O or S;

(c) R is unsubstituted, straight or branched chain alkanyl or alkanoxy having from 1 to about 3 non-hydrogen atoms; and

(d) R' is selected from hydrogen, methyl, cyano, and halo;
pharmaceutical compositions containing such compounds; and the use of such compounds for preventing or treating of disorders modulated by alpha-2 adrenoceptors.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 196091-23-3P

(prepn. of (imidazolidinylideneamino)benzoheterocycles as .alpha.2 adrenoceptor agonists)

RN 196091-23-3 USPATFULL

CN Thiourea, N-(2-aminoethyl)-N'-(2,3-dihydro-5-methyl-1,4-benzodioxin-6-yl)-
(9CI) (CA INDEX NAME)



L17 ANSWER 15 OF 90 USPATFULL on STN

ACCESSION NUMBER: 1998:162551 USPATFULL

TITLE: Guanylhydrazones and their use to treat inflammatory conditions

INVENTOR(S): Bianchi, Marina, Milan, Italy
Cerami, Anthony, Shelter Island, NY, United States
Tracey, Kevin J., Old Greenwich, CT, United States
Ulrich, Peter, Old Tappan, NJ, United States

PATENT ASSIGNEE(S): The Picower Institute for Medical Research, Manhasset, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5854289		19981229 <--
APPLICATION INFO.:	US 1996-632305		19960415 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1995-463568, filed on 5 Jun 1995, now patented, Pat. No. US 5750573 which is a continuation-in-part of Ser. No. US 1994-315170, filed on 29 Sep 1994, now patented, Pat. No. US 5599984 which is a continuation-in-part of Ser. No. US 1994-184540, filed on 21 Jan 1994, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Kumar, Shailendra		
LEGAL REPRESENTATIVE:	Oster, Jeffrey B.		
NUMBER OF CLAIMS:	8		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	36 Drawing Figure(s); 29 Drawing Page(s)		

LINE COUNT: 2430

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention concerns new methods and compositions that are useful in preventing and ameliorating cachexia, the clinical syndrome of poor nutritional status and bodily wasting associated with cancer and other chronic diseases. More particularly, the invention relates to aromatic guanylhydrazone (more properly termed amidinohydrazone) compositions and their use to **inhibit** the uptake of arginine by macrophages and/or its conversion to urea. These compositions and methods are also useful in preventing the generation of nitric oxide (NO) by cells, and so to prevent NO-mediated inflammation and other responses in persons in need of same. In another embodiment, the compounds can be used to **inhibit** arginine uptake in arginine-dependent tumors and infections, and autoimmune or other diseases in which activated macrophages are involved, such as septic shock, heumatoid arthritis and multiple sclerosis.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 169764-76-5P

(guanylhydrazones and their prepn. for treating cachexia and inflammatory conditions)

RN 169764-76-5 USPATFULL

CN Urea, N,N''-(2-methyl-1,5-pentanediy1)bis[N'-(3,5-diacetylphenyl)- (9CI)
(CA INDEX NAME)



L17 ANSWER 16 OF 90 USPATFULL on STN

ACCESSION NUMBER: 1998:157334 USPATFULL

TITLE: Phenol compound having antioxidative activity and the process for preparing the same

INVENTOR(S): Suzuki, Toshikazu, Urawa, Japan
Ohmizu, Hiroshi, Kyoto, Japan
Hashimura, Yoshimasa, Urawa, Japan
Kubota, Hitoshi, Hyogo-ken, Japan
Tanaka, Keiko, Urawa, Japan

PATENT ASSIGNEE(S): Tanabe Seiyaku Co., Ltd., Osaka, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5849732		19981215	<--
APPLICATION INFO.:	US 1997-800680		19970214	(8)

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1996-28083	19960215
	JP 1996-300032	19961112
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Higel, Floyd D.	
LEGAL REPRESENTATIVE:	Birch, Stewart, Kolasch & Birch, LLP	

10/019,652

NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
LINE COUNT: 2841

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are a phenol compound represented by the formula (1): ##STR1## wherein R.sup.0 represents H, alkyl or alkyloxy; R.sup.1 represents alkyl; R.sup.2 represents alkyl or alkyloxy; OR.sup.3 represents OH; R.sup.4 represents H, lower alkyl or acyl, each of the above substituents may be substituted; W represents O, S or NR.sup.7 ; where R.sup.7 represents H, alkyl, aryl, OH or alkyloxy, a group of the formula (2): ##STR2## represents an amino which may be mono- or di-substituted or heterocyclic group containing N atom,

or a **pharmaceutically** acceptable salt thereof, and a process for preparing the same.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 195312-53-9P

(prepn. of ureidophenols as ACAT inhibitors and antioxidants)

RN 195312-53-9 USPATFULL

CN L-Lysine, N2-[[[3-(1,1-dimethylethyl)-2-hydroxy-5-methoxyphenyl]amino]carbonyl]-N6-[(phenylmethoxy)carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L17 ANSWER 17 OF 90 USPATFULL on STN

ACCESSION NUMBER: 1998:138903 USPATFULL

TITLE: 6-(2-imidazolinyllamino) quinoxaline compounds useful as .alpha.-2 adrenoreceptor agonists

INVENTOR(S): Maurer, Peter Julian, Cincinnati, OH, United States

PATENT ASSIGNEE(S): The Procter & Gamble Company, Cincinnati, OH, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5834470		19981110	<--
APPLICATION INFO.:	US 1997-911570		19970814	(8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1993-169785, filed on 17 Dec 1993, now abandoned			
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	Granted			
PRIMARY EXAMINER:	Fay, Zohreh			
LEGAL REPRESENTATIVE:	Hake, Richard A., McMahon, Mary Pat, Graff, IV, Milton B.			
NUMBER OF CLAIMS:	10			
EXEMPLARY CLAIM:	1			
LINE COUNT:	649			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The subject invention involves methods of treating nasal congestion comprising administration, to a human or lower animal in need of such treatment of a safe and effective amount of a compound having the following structure: ##STR1## wherein (a) R is unsubstituted C.sub.1 -C.sub.3 alkanyl or alkenyl; and

(b) R' is selected from hydrogen; unsubstituted C.sub.1 -C.sub.3 alkanyl or alkenyl, unsubstituted C.sub.1 -C.sub.3 alkylthio or alkoxy; hydroxy; thiol; and halo.

The subject invention also involves the use of such compounds for preventing or treating other respiratory, ocular and/or gastrointestinal disorders.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 183278-01-5P

(comps. for (imidazolinylamino)quinoxaline compds. as .alpha.2-adrenoceptor agonists for prevention and treatment of respiratory, ocular and/or gastrointestinal disorders)

RN 183278-01-5 USPATFULL

CN Thiourea, N-(2-aminoethyl)-N'-(5-methyl-6-quinoxaliny)- (9CI) (CA INDEX NAME)



L17 ANSWER 18 OF 90 USPATFULL on STN

ACCESSION NUMBER: 1998:108418 USPATFULL

TITLE: 6-(2-imidazolinylamino) quinolines useful as alpha-2 adrenoceptor agonists

INVENTOR(S): Cupps, Thomas Lee, Oxford, OH, United States
Maurer, Peter J., Cincinnati, OH, United States
Ares, Jeffrey J., Hamilton, OH, United States
Henry, Raymond T., Pleasant Plain, OH, United States
Sheldon, Russell James, Fairfield, OH, United States
Mielsing, Glen E., West Chester, OH, United States
Bogdan, Sophie E., Maineville, OH, United States

PATENT ASSIGNEE(S): The Procter & Gamble Company, Cincinnati, OH, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5804587		19980908 <--
APPLICATION INFO.:	US 1996-755936		19961125 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1995-496704, filed on 29 Jun 1995, now patented, Pat. No. US 5739148		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Ramsuer, Robert W.		
ASSISTANT EXAMINER:	Sackey, Ebenezer O.		
LEGAL REPRESENTATIVE:	Hake, Richard A., Graff, Milton B., Suter, David L.		

10/019,652

NUMBER OF CLAIMS: 36

EXEMPLARY CLAIM: 1

LINE COUNT: 1924

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The subject invention relates to compounds having the structure:
##STR1## as defined in the claims, and to **pharmaceutical**
compositions containing such compounds, and the use of such compounds
for preventing or treating of disorders modulated by alpha-2
adrenoceptors.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 170854-01-0P

(prepn. and formulation of 6-(2-imidazolidinylideneimino)quinolines as
.alpha.2-adrenoceptor agonists)

RN 170854-01-0 USPATFULL

CN Thiourea, N-(2-aminoethyl)-N'-(4,5,8-trimethyl-6-quinolinyl)- (9CI) (CA
INDEX NAME)



L17 ANSWER 19 OF 90 USPATFULL on STN

ACCESSION NUMBER: 1998:92028 USPATFULL

TITLE: Indeno[1,2-E]pyrazine-4-ones, their preparation and the
medicaments containing them

INVENTOR(S): Aloup, Jean-Claude, Villeneuve le Roi, France
Audiau, Fran.cedilla.ois, Charenton le Pont, France
Barreau, Michel, Montgeron, France
Damour, Dominique, Orly, France
Genevois-Borella, Arielle, Thiais, France
Jimonet, Patrick, Villepreux, France
Mignani, Serge, Chatenay-Malabry, France
Ribeill, Yves, Villemoisson Sur Orge, France
PATENT ASSIGNEE(S): Rhone-Poulenc Rorer S.A., Antony Cedex, France
(non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5789406		19980804	<--
	WO 9526349		19951005	<--
APPLICATION INFO.:	US 1996-714163		19960927	(8)
	WO 1995-FR357		19950323	
			19960927	PCT 371 date
			19960927	PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	FR 1994-3581	19940328
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Berch, Mark L.	

10/019,652

LEGAL REPRESENTATIVE: Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P.

NUMBER OF CLAIMS: 9

EXEMPLARY CLAIM: 1

LINE COUNT: 3931

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The compounds of formula (I) ##STR1## wherein R, R.sub.1 and R.sub.2 are defined in the disclosure, and salts thereof.

The compounds of formula (I) are non-competitive N-methyl-D-aspartate (NMDA) **receptor** antagonists, particularly NMDA **receptor** glycine modulation site ligands, and are alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) **receptor** antagonists, this **receptor** is also known as the quisqualate **receptor**.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 173252-30-7P

(prepn. of imidazoindenopyrazinones as AMPA and NMDA receptor antagonists)


RN 173252-30-7 USPATFULL

CN Thiourea, N-(2-aminoethyl)-N'-(5,10-dihydro-4-oxo-4H-imidazo[1,2-a]indeno[1,2-e]pyrazin-8-yl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 173252-29-4


CMF C16 H16 N6 O S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



L17 ANSWER 20 OF 90 USPATFULL on STN

ACCESSION NUMBER: 1998:75586 USPATFULL

TITLE: Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives

INVENTOR(S): Burke, James A., Tustin, CA, United States
Garst, Michael E., Newport Beach, CA, United States

PATENT ASSIGNEE(S): Wheeler, Larry A., Irvine, CA, United States
Allergan, Waco, TX, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5773440		19980630 <--
APPLICATION INFO.:	US 1997-880473		19970623 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1996-693745, filed on 7 Aug 1996, now patented, Pat. No. US 5703077 which is a division of Ser. No. US 1995-458949, filed on 2 Jun 1995, now patented, Pat. No. US 5587376 which is a division of Ser. No. US 1995-390265, filed on 15 Feb 1995, now patented, Pat. No. US 5561132 which is a continuation of Ser. No. US 1993-135716, filed on 13 Oct 1993		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Spivack, Phyllis G.		
LEGAL REPRESENTATIVE:	Uxa, Frank J.		
NUMBER OF CLAIMS:	18		
EXEMPLARY CLAIM:	1		
LINE COUNT:	708		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method of treating a mammal is disclosed comprises administering to a mammal an effective amount to provide a desired therapeutic effect in the mammal of a compound selected from the group consisting of those having the formula: ##STR1##, and **pharmaceutically** acceptable acid addition salts thereof and mixtures thereof, wherein R.sub.1 and R.sub.2 each is selected from the group consisting of alkyl radicals containing 1 to 4 carbon atoms and alkoxy radicals containing 1 to 4 carbon atoms, the 2-imidazolin-2-ylamino group may be in any of the 5-, 6-, 7- or 8-positions of the quinoxaline nucleus, and R.sub.3, R.sub.4 and R.sub.5 each is located in one of the remaining 5-, 6-, 7- or 8-positions of the quinoxaline nucleus and is independently selected from the group consisting of Cl, Br, H and alkyl radicals containing 1 to 3 carbon atoms wherein said desired therapeutic effect is a reduction of at least one effect of an inflammatory disorder.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 134892-47-0P

(imidazolinylamino quinoxaline deriv. prepn. and therapeutic use)

RN 134892-47-0 USPATFULL

CN Thiourea, N-(2-aminoethyl)-N'-(5-bromo-6-quinoxaliny)- (9CI) (CA INDEX NAME)



L17 ANSWER 21 OF 90 USPATFULL on STN

ACCESSION NUMBER: 1998:57927 USPATFULL

TITLE: Methods for using (2-imidazolin-2-ylamino) Quinoxaline derivatives

10/019,652

INVENTOR(S): Burke, James A., Tustin, CA, United States
Garst, Michael E., Newport Beach, CA, United States
Wheeler, Larry A., Irvine, CA, United States
PATENT ASSIGNEE(S): Allergan, Waco, TX, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5756503		19980526 <--
APPLICATION INFO.:	US 1996-636740		19960419 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1995-458949, filed on 2 Jun 1995, now patented, Pat. No. US 5587376 which is a division of Ser. No. US 1995-390265, filed on 15 Feb 1995, now patented, Pat. No. US 5561132 which is a continuation of Ser. No. US 1993-135716, filed on 13 Oct 1993, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Spivack, Phyllis G.		
LEGAL REPRESENTATIVE:	Uxa, Frank J.		
NUMBER OF CLAIMS:	17		
EXEMPLARY CLAIM:	1		
LINE COUNT:	733		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method of treating a mammal is disclosed comprising administering to a mammal an effective amount to provide a desired therapeutic effect in the mammal of a compound selected from the group consisting of those having the formula: ##STR1## and **pharmaceutically** acceptable acid addition salts thereof and mixtures thereof, wherein R.sub.1 and R.sub.2 each is selected from the group consisting of alkyl radicals containing 1 to 4 carbon atoms and alkoxy radicals containing 1 to 4 carbon atoms, the 2-imidazolin-2-ylamino group may be in any of the 5-, 6-, 7- or 8- positions of the quinoxaline nucleus, and R.sub.3, R.sub.4 and R.sub.5 each is located in one of the remaining 5-, 6-, 7- or 8- positions of the quinoxaline nucleus and is independently selected from the group consisting of Cl, Br, H and alkyl radicals containing 1 to 3 carbon atoms. Such compounds, when administered to a mammal, provide desired therapeutic effects, such as reduction in peripheral pain.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 134892-47-0P

(imidazolinylamino quinoxaline deriv. prepn. and therapeutic use)

RN 134892-47-0 USPATFULL

CN Thiourea, N-(2-aminoethyl)-N'-(5-bromo-6-quinoxaliny)- (9CI) (CA INDEX NAME)



L17 ANSWER 22 OF 90 USPATFULL on STN

ACCESSION NUMBER: 1998:39539 USPATFULL

TITLE: 6-(2-Imidazolinylamino) quinoxaline compounds useful as alpha-2 adrenoceptor agonists

10/019,652

INVENTOR(S): Cupps, Thomas Lee, Oxford, OH, United States
Maurer, Peter Julian, Cincinnati, OH, United States
Ares, Jeffrey Joseph, Hamilton, OH, United States
PATENT ASSIGNEE(S): The Procter & Gamble Company, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5739148		19980414 <--
APPLICATION INFO.:	US 1995-496704		19950629 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1994-326564, filed on 20 Oct 1994, now patented, Pat. No. US 5578607 which is a continuation-in-part of Ser. No. US 1993-169343, filed on 17 Dec 1993, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Richter, Johann		
ASSISTANT EXAMINER:	Oswecki, Jane C.		
LEGAL REPRESENTATIVE:	Hake, Richard A., Graff, M. B., Suter, D. L.		
NUMBER OF CLAIMS:	14		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1174		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The subject invention relates to compounds having the structure:
##STR1## wherein: (a) R is unsubstituted C.sub.1 -C.sub.3 alkanyl or alkenyl;

(b) R' is selected from unsubstituted C.sub.1 -C.sub.3 alkanyl or alkenyl; unsubstituted C.sub.1 -C.sub.3 alkylthio or alkoxy; hydroxy; thiol; and halo; and

(c) R" is selected from hydrogen; unsubstituted C.sub.1 -C.sub.3 alkanyl or alkenyl; methyl monosubstituted with hydroxy, thiol or amino; unsubstituted C.sub.1 -C.sub.3 alkylthio or alkoxy; amino; unsubstituted amide; unsubstituted or C.sub.1 -C.sub.3 substituted amido; halo; unsubstituted sulfoxide; unsubstituted sulfonyl; and cyano;
pharmaceutical compositions containing such compounds, and the use of such compounds for preventing or treating respiratory, ocular, and/or gastrointestinal disorders.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **170854-01-0P**

(6-(2-imidazolinylamino)quinolines useful as .alpha.-2 adrenoceptor agonists)

RN 170854-01-0 USPATFULL

CN Thiourea, N-(2-aminoethyl)-N'-(4,5,8-trimethyl-6-quinolinyl)- (9CI) (CA INDEX NAME)



L17 ANSWER 23 OF 90 USPATFULL on STN

ACCESSION NUMBER: 1998:14813 USPATFULL

TITLE: 7-(2-imidazolinylamino)quinoline compounds useful as
alpha-2 adrenoceptor agonistsINVENTOR(S): Cupps, Thomas Lee, Oxford, OH, United States
Bogdan, Sophie Eva, Mainville, OH, United StatesPATENT ASSIGNEE(S): The Procter & Gamble Company, Cincinnati, OH, United
States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5716966		19980210 <--
APPLICATION INFO.:	US 1995-496796		19950629 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1994-292672, filed on 18 Aug 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-169342, filed on 17 Dec 1993, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Fay, Zohreh		
LEGAL REPRESENTATIVE:	Hake, Richard A., Graff, Milton B.		
NUMBER OF CLAIMS:	23		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1251		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The subject invention involves methods of treating nasal congestion comprising administration, to a human or lower animal in need of such treatment of a safe and effective amount of a compound having the following structure: ##STR1## wherein: (a) R is unsubstituted C.sub.1 -C.sub.3 alkanyl or alkenyl; and

(b) R' is selected from hydrogen; unsubstituted C.sub.1 -C.sub.3 alkanyl or alkenyl; unsubstituted C.sub.1 -C.sub.3 alkylthio or alkoxy; hydroxy; thiol; cyano; and halo.

The subject invention also involves the use of such compounds for preventing or treating other respiratory, ocular and/or gastrointestinal disorders. The subject invention also involves novel compounds having the above structure wherein R' is hydrogen or fluoro or cyano.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 168770-36-3P

(prepn. of (imidazolinylamino)quinolines as .alpha.2 adrenoceptor agonists)

RN 168770-36-3 USPATFULL

CN Thiourea, N-(2-aminoethyl)-N'-(5-cyano-8-methyl-7-quinolinyl)- (9CI) (CA INDEX NAME)



10/019,652

L17 ANSWER 24 OF 90 USPATFULL on STN
ACCESSION NUMBER: 1998:12027 USPATFULL
TITLE: Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
INVENTOR(S): Burke, James A., Tustin, CA, United States
Garst, Michael E., Newport Beach, CA, United States
Wheeler, Larry A., Irvine, CA, United States
PATENT ASSIGNEE(S): Allergan, Naco, TX, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5714486		19980203	<--
APPLICATION INFO.:	US 1996-695103		19960807	(8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1995-458949, filed on 2 Jun 1995, now patented, Pat. No. US 5587376 which is a division of Ser. No. US 1995-390265, filed on 15 Feb 1995, now patented, Pat. No. US 5561132 which is a continuation of Ser. No. US 1993-135716, filed on 13 Oct 1993, now abandoned			
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	Granted			
PRIMARY EXAMINER:	Spivack, Phyllis G.			
LEGAL REPRESENTATIVE:	Uxa, Frank J.			
NUMBER OF CLAIMS:	18			
EXEMPLARY CLAIM:	1			
LINE COUNT:	705			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method of treating a mammal comprises administering to a mammal an effective amount to provide a desired therapeutic effect in the mammal of a compound selected from the group consisting of those having the formula: ##STR1## and **pharmaceutically** acceptable acid addition salts thereof and mixtures thereof, wherein R.sub.1 and R.sub.2 each is selected from the group consisting of alkyl radicals containing 1 to 4 carbon atoms and alkoxy radicals containing 1 to 4 carbon atoms, the 2-imidazolin-2-ylamino group may be in any of the 5-, 6-, 7- or 8-positions of the quinoxaline nucleus, and R.sub.3, R.sub.4 and R.sub.5 is each located in one of the remaining 5-, 6-, 7- or 8-positions of the quinoxaline nucleus and is independently selected from the group consisting of Cl, Br, H and alkyl radicals containing 1 to 3 carbon atoms. Such compounds, when administered to a mammal, provide anesthetization of the central nervous system.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 134892-47-0P

(imidazolinylamino quinoxaline deriv. prepn. and therapeutic use)

RN 134892-47-0 USPATFULL

CN Thiourea, N-(2-aminoethyl)-N'-(5-bromo-6-quinoxaliny)- (9CI) (CA INDEX NAME)



10/019,652

L17 ANSWER 25 OF 90 USPATFULL on STN

ACCESSION NUMBER: 97:123213 USPATFULL

TITLE: Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives

INVENTOR(S): Burke, James A., Tustin, CA, United States
Garst, Michael E., Newport Beach, CA, United States
Wheeler, Larry A., Irvine, CA, United States

PATENT ASSIGNEE(S): Allergan, Waco, TX, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5703077		19971230 <--
APPLICATION INFO.:	US 1996-693745		19960807 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1995-458949, filed on 2 Jun 1995, now patented, Pat. No. US 5587376 which is a division of Ser. No. US 1995-390265, filed on 15 Feb 1995, now patented, Pat. No. US 5561132 which is a continuation of Ser. No. US 1993-135716, filed on 13 Oct 1993, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Spivack, Phyllis G.		
LEGAL REPRESENTATIVE:	Uxa, Frank J.		
NUMBER OF CLAIMS:	19		
EXEMPLARY CLAIM:	1		
LINE COUNT:	726		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method of treating a mammal comprises administering to a mammal an effective amount to provide a desired therapeutic effect in the mammal of a compound selected from the group consisting of those having the formula: ##STR1## and **pharmaceutically** acceptable acid addition salts thereof and mixtures thereof, wherein R.sub.1 and R.sub.2 each is selected from the group consisting of alkyl radicals containing 1 to 4 carbon atoms and alkoxy radicals containing 1 to 4 carbon atoms, the 2-imidazolin-2-ylamino group may be in any of the 5-, 6-, 7- or 8-positions of the quinoxaline nucleus, and R.sub.3, R.sub.4 and R.sub.5 each is located in one of the remaining 5-, 6-, 7- or 8-positions of the quinoxaline nucleus and is independently selected from the group consisting of Cl, Br, H and alkyl radicals containing 1 to 3 carbon atoms wherein the desired therapeutic effect is an increase in renal fluid flow.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **134892-47-0P**

(imidazolinylamino quinoxaline deriv. prepn. and therapeutic use)

RN 134892-47-0 USPATFULL

CN Thiourea, N-(2-aminoethyl)-N'-(5-bromo-6-quinoxaliny)- (9CI) (CA INDEX NAME)



10/019,652

L17 ANSWER 26 OF 90 USPATFULL on STN
ACCESSION NUMBER: 97:109926 USPATFULL
TITLE: 5-(2-imidazolinylamino)benzimidazole compounds useful
as alpha-2-adrenoceptor agonists
INVENTOR(S): Cupps, Thomas Lee, Oxford, OH, United States
Bogdan, Sophie Eva, Maineville, OH, United States
PATENT ASSIGNEE(S): The Procter & Gamble Company, Cincinnati, OH, United
States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5691370		19971125 <--
APPLICATION INFO.:	US 1996-675745		19960703 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1995-496706, filed on 29 Jun 1995, now patented, Pat. No. US 5541210 which is a continuation-in-part of Ser. No. US 1994-349558, filed on 8 Dec 1994, now patented, Pat. No. US 5478858 which is a continuation-in-part of Ser. No. US 1993-169868, filed on 17 Dec 1993, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Jordan, Kimberly		
LEGAL REPRESENTATIVE:	Hake, Richard A., Graff, IV, Milton B., Suter, David L.		
NUMBER OF CLAIMS:	2		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1219		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			

AB The subject invention involves compounds having the following structure:
##STR1## wherein: (a) R is unsubstituted C.sub.1 -C.sub.3 alkanyl or
alkenyl;

(b) R' is selected from hydrogen; unsubstituted C.sub.1 -C.sub.3 alkanyl
or alkenyl; unsubstituted C.sub.1 -C.sub.3 alkylthio or alkoxy; hydroxy;
thiol; cyano; and halo; and

(c) R" is selected from hydrogen, methyl, ethyl and i-propyl.

The subject invention also involves **pharmaceutical**
compositions containing such novel compounds, compositions thereof and
the use of such compounds for preventing or treating respiratory, ocular
and/or gastrointestinal disorders.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 170918-16-8P

(prepn. of 5-(2-imidazolidinylideneamino)benzimidazoles as
.alpha.2-adrenergic agonists)

RN 170918-16-8 USPATFULL

CN 1H-Benzimidazole-1-carboxylic acid, 5-[[[(2-aminoethyl)amino]thioxomethyl]
amino]-4-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



L17 ANSWER 27 OF 90 USPATFULL on STN
 ACCESSION NUMBER: 97:78458 USPATFULL
 TITLE: 2-imidazolinyldiamino heterocyclic compounds useful as
 alpha-2 adrenoceptor agonists
 INVENTOR(S): Maurer, Peter Julian, Cincinnati, OH, United States
 Ares, Jeffrey Joseph, Fairfield, OH, United States
 Seibel, William Lee, Hamilton, OH, United States
 Walker, Daniel P., Bloomington, IN, United States
 PATENT ASSIGNEE(S): The Procter & Gamble Company, Cincinnati, OH, United
 States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5663189		19970902 <--
APPLICATION INFO.:	US 1995-478708		19950607 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1993-86482, filed on 1 Jul 1993, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Morris, Patricia L.		
LEGAL REPRESENTATIVE:	Graff, Milton B., McMahon, Mary Pat, Hake, Richard A.		
NUMBER OF CLAIMS:	22		
EXEMPLARY CLAIM:	1		
LINE COUNT:	989		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The subject invention relates to compounds having the structure:
 ##STR1## wherein (a) n is an integer from 1 to about 3;

(b) X and Y are each independently selected from O, S and CH.sub.2, with
 at least one of X and Y being O or S;

(c) R is unsubstituted, straight or branched chain alkanyl or alkanoxy
 having from 1 to about 3 non-hydrogen atoms; and

(d) R' is selected from hydrogen, methyl, cyano, and halo;
pharmaceutical compositions containing such compounds; and the
 use of such compounds for preventing or treating one or more of
 respiratory disorders, ocular disorders, and gastrointestinal disorders.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 196091-23-3P

(prepn. of (imidazolidinyldieneamino)benzoheterocycles as .alpha.2
 adrenoceptor agonists)

RN 196091-23-3 USPATFULL

CN Thiourea, N-(2-aminoethyl)-N'-(2,3-dihydro-5-methyl-1,4-benzodioxin-6-yl)-
 (9CI) (CA INDEX NAME)



L17 ANSWER 28 OF 90 USPATFULL on STN
 ACCESSION NUMBER: 96:118588 USPATFULL
 TITLE: Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
 INVENTOR(S): Burke, James A., Tustin, CA, United States
 Garst, Michael E., Newport Beach, CA, United States
 Wheeler, Larry A., Irvine, CA, United States
 PATENT ASSIGNEE(S): Allergan, Waco, TX, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5587376		19961224 <--
APPLICATION INFO.:	US 1995-458949		19950602 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1995-390265, filed on 15 Feb 1995 which is a continuation of Ser. No. US 1993-135716, filed on 13 Oct 1993, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Spivack, Phyllis G.		
LEGAL REPRESENTATIVE:	Uxa, Frank J.		
NUMBER OF CLAIMS:	18		
EXEMPLARY CLAIM:	1		
LINE COUNT:	720		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method of treating a mammal comprises administering to a mammal an effective amount to provide a desired therapeutic effect in the mammal of a compound selected from the group consisting of those having the formula: ##STR1## and **pharmaceutically** acceptable acid addition salts thereof and mixtures thereof, wherein R.sub.1 and R.sub.2 each is selected from the group consisting of alkyl radicals containing 1 to 4 carbon atoms and alkoxy radicals containing 1 to 4 carbon atoms, the 2-imidazolin-2-ylamino group may be in any of the 5-, 6-, 7- or 8-positions of the quinoxaline nucleus, and R.sub.3, R.sub.4 and R.sub.5 each is located in one of the remaining 5-, 6-, 7- or 8- positions of the quinoxaline nucleus and is independently selected from the group consisting of Cl, Br, H and alkyl radicals containing 1 to 3 carbon atoms. Such compounds, when administered to a mammal, provide desired therapeutic effects, such as constriction of one or more blood vessels and decongestion of one or more nasal passages.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **134892-47-0P**

(imidazolinylamino quinoxaline deriv. prepn. and therapeutic use)

RN 134892-47-0 USPATFULL

CN Thiourea, N-(2-aminoethyl)-N'-(5-bromo-6-quinoxaliny)- (9CI) (CA INDEX NAME)



L17 ANSWER 29 OF 90 USPATFULL on STN
 ACCESSION NUMBER: 96:116475 USPATFULL
 TITLE: Substituted thioureas as bifunctional chelators
 INVENTOR(S): Coughlin, Daniel J., Robbinsville, NJ, United States
 Belinka, Jr., Benjamin A., Kendall Park, NJ, United States
 PATENT ASSIGNEE(S): Cytogen Corporation, Princeton, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5585468		19961217	<--
	WO 9321151		19931028	<--
APPLICATION INFO.:	US 1994-204197		19940627	(8)
	WO 1993-US3208		19930408	
			19940627	PCT 371 date
			19940627	PCT 102(e) date
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1992-866375, filed on 9 Apr 1992, now patented, Pat. No. US 5326856, issued on 5 Jul 1994			
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	Granted			
PRIMARY EXAMINER:	Hollinden, Gary E.			
ASSISTANT EXAMINER:	Hartley, Michael G.			
LEGAL REPRESENTATIVE:	Lowe, Price, LeBlanc & Becker			
NUMBER OF CLAIMS:	8			
EXEMPLARY CLAIM:	1			
NUMBER OF DRAWINGS:	19 Drawing Figure(s); 11 Drawing Page(s)			
LINE COUNT:	1829			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to chelating agents useful for coupling metal ions to biologically active molecules. In particular, substantial thioureas for chelating metals such as technetium are provided that can be conjugated to a targeting molecule such as an antibody, a peptide or a protein.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 151890-17-4P

(substituted thioureas as bifunctional chelators, prepn., conjugates with peptides, proteins, and antibodies, and use in imaging of tumors and thrombi)

RN 151890-17-4 USPATFULL

CN Ethanaminium, 2,2'-[(5-carboxy-1,3-phenylene)bis(iminocarbonothioylimino)] bis[N,N,N-trimethyl-, dichloride (9CI) (CA INDEX NAME)



● 2 Cl⁻

L17 ANSWER 30 OF 90 USPATFULL on STN
 ACCESSION NUMBER: 96:108976 USPATFULL
 TITLE: 6-(2-imidazolinylamino)quinoline compounds useful as
 alpha-2 adrenoceptor agonists
 INVENTOR(S): Cupps, Thomas L., Oxford, OH, United States
 Maurer, Peter J., Cincinnati, OH, United States
 Ares, Jeffrey J., Hamilton, OH, United States
 PATENT ASSIGNEE(S): The Procter & Gamble Company, Cincinnati, OH, United
 States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5578607		19961126 <--
APPLICATION INFO.:	US 1994-326564		19941020 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1993-169343, filed on 17 Dec 1993, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Springer, David B.		
LEGAL REPRESENTATIVE:	Clark, Karen F., Hake, Richard A., McMahon, Mary Pat		
NUMBER OF CLAIMS:	17		
EXEMPLARY CLAIM:	1		
LINE COUNT:	982		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The subject invention relates to compounds having the structure:
 ##STR1## wherein: (a) R is unsubstituted C.sub.1 -C.sub.3 alkanyl or
 alkenyl;

(b) R' is selected from unsubstituted C.sub.1 -C.sub.3 alkanyl or
 alkenyl; unsubstituted C.sub.1 -C.sub.3 alkylthio or alkoxy; hydroxy;
 thiol; and halo; and

(c) R" is selected from hydrogen; unsubstituted C.sub.1 -C.sub.3 alkanyl
 or alkenyl; methyl monosubstituted with hydroxy, thiol or amino;
 unsubstituted C.sub.1 -C.sub.3 alkylthio or alkoxy; amino; unsubstituted
 amide; unsubstituted or C.sub.1 -C.sub.3 substituted amido; halo;
 unsubstituted sulfoxide; unsubstituted sulfonyl; and cyano;

pharmaceutical compositions containing such compounds, and the
 use of such compounds for preventing or treating respiratory, ocular,
 and/or gastrointestinal disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


10/019,652

IT 170854-03-2P

(prepn. of 6-(2-imidazolinylimino)quinolines useful as .alpha.2
adrenoceptor agonists)

RN 170854-03-2 USPATFULL

CN Thiourea, N-(2-aminoethyl)-N'-(5,8-dimethyl-6-quinolinyl)- (9CI) (CA
INDEX NAME)



=> d his

(FILE 'HOME' ENTERED AT 14:55:47 ON 09 DEC 2003)

FILE 'REGISTRY' ENTERED AT 14:55:52 ON 09 DEC 2003

L1 STRUCTURE UPLOADED
L2 STRUCTURE UPLOADED
L3 2587 S L1 FULL
L4 10046 S L2 FULL
L5 7459 S L4 NOT L3

FILE 'CA' ENTERED AT 15:01:03 ON 09 DEC 2003

L6 1093 S L5
L7 933 S L6 AND PY<2001
L8 143 S INHIBIT? AND L7
L9 20 S L8 AND DRUG?

FILE 'USPATFULL' ENTERED AT 15:02:22 ON 09 DEC 2003

L10 315 S L5
L11 220 S L10 AND (INHIBIT? OR DRUG?)
L12 186 S L11 AND PHARM?
L13 2198 S CCR AND .12
L14 3 S CCR AND L12
L15 183 S L12 NOT L14
L16 124 S L15 AND RECEPTOR?
L17 90 S L16 AND PY<2002

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

STN INTERNATIONAL LOGOFF AT 15:04:40 ON 09 DEC 2003

10/019,652

10/019,652

Welcome to STN International! Enter x:x

LOGINID:sssptal203mxm

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 SEP 09 CA/CAPLUS records now contain indexing from 1907 to the
present
NEWS 4 AUG 05 New pricing for EUROPATFULL and PCTFULL effective
August 1, 2003
NEWS 5 AUG 13 Field Availability (/FA) field enhanced in BEILSTEIN
NEWS 6 AUG 18 Data available for download as a PDF in RDISCLOSURE
NEWS 7 AUG 18 Simultaneous left and right truncation added to PASCAL
NEWS 8 AUG 18 FROSTI and KOSMET enhanced with Simultaneous Left and Right
Truncation
NEWS 9 AUG 18 Simultaneous left and right truncation added to ANABSTR
NEWS 10 SEP 22 DIPPR file reloaded
NEWS 11 SEP 25 INPADOC: Legal Status data to be reloaded
NEWS 12 SEP 29 DISSABS now available on STN
NEWS 13 OCT 10 PCTFULL: Two new display fields added
NEWS 14 OCT 21 BIOSIS file reloaded and enhanced
NEWS 15 OCT 28 BIOSIS file segment of TOXCENTER reloaded and enhanced

NEWS EXPRESS OCTOBER 01 CURRENT WINDOWS VERSION IS V6.01a, CURRENT
MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
AND CURRENT DISCOVER FILE IS DATED 23 SEPTEMBER 2003
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 14:43:53 ON 12 NOV 2003

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 14:44:01 ON 12 NOV 2003

10/019,652

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 11 NOV 2003 HIGHEST RN 615535-77-8
DICTIONARY FILE UPDATES: 11 NOV 2003 HIGHEST RN 615535-77-8

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2003

Please note that search-term pricing does apply when
conducting SmartSELECT searches.


Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP
PROPERTIES for more information. See STNote 27, Searching Properties
in the CAS Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=>
Uploading 10019652.str

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 O,S

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sam
SAMPLE SEARCH INITIATED 14:44:16 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 13654 TO ITERATE

7.3% PROCESSED 1000 ITERATIONS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

28 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**


10/019,652

PROJECTED ITERATIONS: 266086 TO 280074
PROJECTED ANSWERS: 6473 TO 8819

L2 28 SEA SSS SAM L1

=> d scan

L2 28 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN Urea, N-[3-[[[(4-methylphenyl)amino]carbonyl]amino]propyl]-N,N'-diphenyl-
(9CI)
MF C24 H26 N4 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):end

=> s ll full

FULL SEARCH INITIATED 14:44:25 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 274133 TO ITERATE

100.0% PROCESSED 274133 ITERATIONS 9693 ANSWERS
SEARCH TIME: 00.00.06

L3 9693 SEA SSS FUL L1

=> file ca

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	148.15	148.36

FILE 'CA' ENTERED AT 14:44:34 ON 12 NOV 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 6 Nov 2003 VOL 139 ISS 20
FILE LAST UPDATED: 6 Nov 2003 (20031106/ED)

This file contains CAS Registry Numbers for easy and accurate

10/019,652

substance identification.

=> s 13

L4 1587 L3

=> file uspatfull

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.40

148.76

FILE 'USPATFULL' ENTERED AT 14:44:45 ON 12 NOV 2003

CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 11 Nov 2003 (20031111/PD)

FILE LAST UPDATED: 11 Nov 2003 (20031111/ED)

HIGHEST GRANTED PATENT NUMBER: US6647548

HIGHEST APPLICATION PUBLICATION NUMBER: US2003208825

CA INDEXING IS CURRENT THROUGH 11 Nov 2003 (20031111/UPCA)

ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 11 Nov 2003 (20031111/PD)

REVISED CLASS FIELDS (/NCL) LAST RELOADED: Aug 2003

USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Aug 2003

>>> USPAT2 is now available. USPATFULL contains full text of the <<<
>>> original, i.e., the earliest published granted patents or <<<
>>> applications. USPAT2 contains full text of the latest US <<<
>>> publications, starting in 2001, for the inventions covered in <<<
>>> USPATFULL. A USPATFULL record contains not only the original <<<
>>> published document but also a list of any subsequent <<<
>>> publications. The publication number, patent kind code, and <<<
>>> publication date for all the US publications for an invention <<<
>>> are displayed in the PI (Patent Information) field of USPATFULL <<<
>>> records and may be searched in standard search fields, e.g., /PN, <<<
>>> /PK, etc. <<<

>>> USPATFULL and USPAT2' can be accessed and searched together <<<
>>> through the new cluster USPATALL. Type FILE USPATALL to <<<
>>> enter this cluster. <<<
>>> <<<
>>> Use USPATALL when searching terms such as patent assignees, <<<
>>> classifications, or claims, that may potentially change from <<<
>>> the earliest to the latest publication. <<<

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> s 13

L5 503 L3

=> s 15 and py<2001

2781385 PY<2001

L6 357 L5 AND PY<2001

=> d ibib abs fhitr 1-50

L6 ANSWER 1 OF 357 USPATFULL on STN

ACCESSION NUMBER: 2003:129820 USPATFULL

TITLE: FEN-1 endonucleases, mixtures and cleavage methods

INVENTOR(S): Kaiser, Michael W., Madison, WI, United States

Lyamichev, Victor I., Madison, WI, United States

10/019,652

PATENT ASSIGNEE(S): Lyamicheva, Natasha, Madison, WI, United States
Third Wave Technologies, Ins., Madison, WI, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6562611	B1	20030513
	WO 9823774		19980604 <--
APPLICATION INFO.:	US 1999-308825		19991008 (9)
	WO 1997-US21783		19971126
			19991008 PCT 371 date
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1996-757653, filed on 29 Nov 1996, now patented, Pat. No. US 5843669		
	Continuation of Ser. No. US 1996-758314, filed on 2 Dec 1996, now patented, Pat. No. US 6090606		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Patterson, Jr., Charles L.		
LEGAL REPRESENTATIVE:	Medlen & Carroll, LLP		
NUMBER OF CLAIMS:	47		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	198 Drawing Figure(s); 185 Drawing Page(s)		
LINE COUNT:	13398		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			

AB The present invention relates to means for the detection and characterization of nucleic acid sequences, as well as variations in nucleic acid sequences. The present invention also relates to improved cleavage means for the detection and characterization of nucleic acid sequences. Structure-specific nucleases derived from a variety of thermostable organisms are provided. These structure-specific nucleases are used to cleave target-dependent cleavage structures, thereby indicating the presence of specific nucleic acid sequences or specific variations thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 194286-48-1


(for charge-based nucleic acid sepn.; invasive cleavage of nucleic acids for detecting and characterizing target nucleic acids)

RN 194286-48-1 USPATFULL

CN Phenanthridinium, 3,8-diamino-5-[3-[[2-[[2-[[[(3',6'-dihydroxy-3-oxospiro[isobenzofuran-1(3H),9'-[9H]xanthen]-5-yl)amino]thioxomethyl]amino]ethyl]amino]ethyl]amino]propyl]-6-phenyl-, chloride, dihydrochloride (9CI) (CA INDEX NAME)


PAGE 1-A

HO—

● Cl⁻

● 2 HCl

PAGE 1-B



L6 ANSWER 2 OF 357 USPATFULL on STN

ACCESSION NUMBER: 2003:115601 USPATFULL

TITLE: Use of (meth)acrylic acid copolymers to increase the permeability of mucous membranes

INVENTOR(S): Kolter, Karl, Limburgerhof, GERMANY, FEDERAL REPUBLIC OF

Subkowski, Thomas, Mutterstadt, GERMANY, FEDERAL REPUBLIC OF

Raditsch, Martin, Eppelheim, GERMANY, FEDERAL REPUBLIC OF

Schehlmann, Volker, Romerberg, GERMANY, FEDERAL REPUBLIC OF

PATENT ASSIGNEE(S): BASF Aktiengesellschaft, Ludwigshafen, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6555124	B1	20030429
	WO 9805360		19980212

<--

APPLICATION INFO.: US 1999-230741 19990201 (9)
WO 1997-EP3899 19970721

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1996-19631084	19960801
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Page, Thurman K.	
ASSISTANT EXAMINER:	Pulliam, Amy E	
LEGAL REPRESENTATIVE:	Keil & Weinkauff	
NUMBER OF CLAIMS:	8	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	3 Drawing Figure(s); 3 Drawing Page(s)	
LINE COUNT:	394	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB (Meth)acrylic acid copolymers are used to increase mucosal permeability, comonomers present being (meth)acrylic esters and/or other monomers capable of free-radical polymerization, and the (meth)acrylic acid:comonomer molar ratio varying from 99:1 to 1:99.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **134759-22-1**

((meth)acrylic acid copolymers for increasing the permeability of mucous membranes)


RN 134759-22-1 USPATFULL


CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, N-[6-[[5-[[[(3',6'-dihydroxy-3-oxospiro[isobenzofuran-1(3H), 9'-[9H]xanthen]-5-yl)amino]thioxomethyl]amino]pentyl]amino]-6-oxohexyl]hexahydro-2-oxo-, (3aS,4S,6aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A

HO—





L6 ANSWER 3 OF 357 USPATFULL on STN
 ACCESSION NUMBER: 2003:13296 USPATFULL
 TITLE: 20(S) camptothecin glycoconjugates
 INVENTOR(S): Lerchen, Hans-Georg, Leverkusen, GERMANY, FEDERAL
 REPUBLIC OF
 von dem Bruch, Karsten, Leverkusen, GERMANY, FEDERAL
 REPUBLIC OF
 Baumgarten, Jorg, Wuppertal, GERMANY, FEDERAL REPUBLIC
 OF
 Sperzel, Michael, Wuppertal, GERMANY, FEDERAL REPUBLIC
 OF
 PATENT ASSIGNEE(S): Bayer Aktiengesellschaft, Leverkusen, GERMANY, FEDERAL
 REPUBLIC OF (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6506734	B1	20030114
	WO 9851703		19981119
APPLICATION INFO.:	US 1999-403872		19991027 (9)
	WO 1998-EP2620		19980504
			19991027 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1997-19720043	19970514
	DE 1997-19737477	19970828
	DE 1998-19801037	19980114
	DE 1998-19813137	19980325

DOCUMENT TYPE: Utility
 FILE SEGMENT: GRANTED
 PRIMARY EXAMINER: Fonda, Kathleen Kahler
 ASSISTANT EXAMINER: Maier, Leigh C.
 LEGAL REPRESENTATIVE: Chiu, Jerrie L.
 NUMBER OF CLAIMS: 12
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)
 LINE COUNT: 1038

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to glycoconjugates of 20(S)-camptothecin, in which a 3-O-methylated .beta.-L-fucose unit is linked to the 20-hydroxyl group of a camptothecin derivative via a thiourea-modified peptide spacer. The invention furthermore relates to processes for the preparation of the compounds according to the invention and to their use

10/019,652

as medicaments, in particular in connection with oncoses.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **215604-61-8P**


(prepn. and use of 20(S) camptothecin glycoconjugates as medicaments)

RN 215604-61-8 USPTAFULL


CN Leucine, N2-[[[4-[(6-deoxy-3-O-methyl-.beta.-L-galactopyranosyl)oxy]phenyl]amino]thioxomethyl]-N6-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-lysyl-, (4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl ester (9CI)
(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



L6 ANSWER 4 OF 357 USPATFULL on STN

ACCESSION NUMBER: 2002:325986 USPATFULL

TITLE: Glycoconjugates from modified camptothecin derivatives
(20-O-linkage)INVENTOR(S): Lerchen, Hans-Georg, Leverkusen, GERMANY, FEDERAL
REPUBLIC OF
von dem Bruch, Karsten, Leverkusen, GERMANY, FEDERAL
REPUBLIC OF
Buamgarten, Jorg, Wuppertal, GERMANY, FEDERAL REPUBLIC
OF
Sperzel, Michael, Wuppertal, GERMANY, FEDERAL REPUBLIC
OFPATENT ASSIGNEE(S): Bayer Aktiengesellschaft, Leverkusen, GERMANY, FEDERAL
REPUBLIC OF (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6492335	B1	20021210	
	WO 9814459		19980409	<--
APPLICATION INFO.:	US 1999-269317		19990324	(9)
	WO 1997-EP5088		19970917	
			19990324	PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1996-19640206	19960930
	DE 1996-19643764	19961023
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Wilson, James O.	
ASSISTANT EXAMINER:	Maier, Leigh C.	
LEGAL REPRESENTATIVE:	Norris McLaughlin & Marcus	
NUMBER OF CLAIMS:	11	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)	
LINE COUNT:	1324	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to glycoconjugates of camptothecin derivatives in which at least one carbohydrate component is linked via suitable spacers with the 20-hydroxyl group of a camptothecin derivative. The invention furthermore relates to processes for preparing the compounds according to the invention and to their use as medicaments, in particular in connection with cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 205178-95-6P

(prepn. and use of glycoconjugates of modified camptothecine derivs. in treatment of cancer)

RN 205178-95-6 USPATFULL

CN L-Alanine, N2,N6-bis[[[4-[(6-deoxy-3-O-methyl-.beta.-L-galactopyranosyl)oxy]phenyl]amino]thioxomethyl]-L-lysyl-, (4S)-4,11-diethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 5 OF 357 USPATFULL on STN
 ACCESSION NUMBER: 2002:310955 USPATFULL
 TITLE: 5-(2-imidazolinylamino)-benzimidazole derivatives,
 their preparation and their use as .alpha.-adrenoceptor
 agonists with improved metabolic stability
 INVENTOR(S): Cupps, Thomas Lee, Norwich, NY, United States
 Bogdan, Sophie Eva, Maineville, OH, United States
 Nikolaides, Nick, Mason, OH, United States
 Gilbert, Sheri Ann, Cincinnati, OH, United States
 Gazda, Michael, Mason, OH, United States
 Dobson, Roy Lee, Hamilton, OH, United States
 Cruze, Charles Andrew III, West Chester, OH, United
 States
 PATENT ASSIGNEE(S): The Procter & Gamble Company, Cincinnati, OH, United
 States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6486190	B1	20021126
	WO 9926942		19990603 <--
APPLICATION INFO.:	US 2000-554698		20000518 (9)
	WO 1998-US24694		19981120
			20000518 PCT 371 date


	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-66767P	19971124 (60)
	US 1997-66700P	19971125 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Stockton, Laura L.	
LEGAL REPRESENTATIVE:	Upite, David V., Kellerman, James C.	
NUMBER OF CLAIMS:	19	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)	
LINE COUNT:	1731	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB	Benzimidazole compounds having the generic structure: ##STR1##	

are used to treat alpha-2 mediated disorders, including nasal
 congestion, glaucoma, asthma, migraine, and diarrhea.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **214688-04-7P**(prepn. and cyclization with Hg(OAc)₂; prepn. of 5-(2-imidazolinylamino)benzimidazoles as .alpha.-2 adrenoceptor agonists)

RN 214688-04-7 USPATFULL

CN Thiourea, N-(2-aminoethyl)-N'-(4,6-dimethyl-1H-benzimidazol-5-yl)- (9CI)
(CA INDEX NAME)

L6 ANSWER 6 OF 357 USPATFULL on STN

ACCESSION NUMBER: 2002:88519 USPATFULL

TITLE: Cell adhesion inhibitors

INVENTOR(S): Adams, Steven P., Andover, MA, United States
 Lin, Ko-Chung, Lexington, MA, United States
 Lee, Wen-Cherng, Lexington, MA, United States
 Castro, Alfredo C., Woburn, MA, United States
 Zimmerman, Craig N., Somerville, MA, United States
 Hammond, Charles E., Burlington, MA, United States
 Liao, Yu-Sheng, Lexington, MA, United States
 Cuervo, Julio Hernan, Arlington, MA, United States
 Singh, Juswinder, Malden, MA, United States

PATENT ASSIGNEE(S): Biogen, Inc., Cambridge, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6376538	B1	20020423
	WO 9622966		19960801
APPLICATION INFO.:	US 1997-875321		19970919 (8)
	WO 1996-US1349		19960118
			19970919 PCT 371 date
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1995-376372, filed on 23 Jan 1995, now patented, Pat. No. US 6306840		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Aulakh, Charanjit S.		
LEGAL REPRESENTATIVE:	Fish & Richardson P.C.		
NUMBER OF CLAIMS:	56		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)		
LINE COUNT:	4655		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel compounds that are useful for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. This invention also relates to pharmaceutical formulations comprising these compounds and methods of using them for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. The compounds and pharmaceutical compositions of this invention can be used as therapeutic or prophylactic agents. They are particularly well-suited

for treatment of many inflammatory and autoimmune diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 181522-89-4P

(prepn. of .beta.-amino acid dipeptide derivs. as cell adhesion inhibitors)

RN 181522-89-4 USPATFULL

CN 1,3-Benzodioxole-5-propanoic acid, .beta.-[[(2S)-4-(dimethylamino)-1-oxo-2-[[(phenylamino)carbonyl]amino]butyl]amino]-, (.beta.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 7 OF 357 USPATFULL on STN

ACCESSION NUMBER: 2002:88205 USPATFULL

TITLE: Process for labeling a ribonucleic acid, and labeled RNA fragments which are obtained thereby

INVENTOR(S): Laayoun, Ali, Lyons, FRANCE

PATENT ASSIGNEE(S): Bio Merieux, Marcy l'Etoile, FRANCE (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6376179	B1	20020423	
	WO 9965926		19991223	<--
APPLICATION INFO.:	US 1999-446156		19991217	(9)
	WO 1999-FR1469		19990617	
			19991217	PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	FR 1998-7870	19980617
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Fredman, Jeffrey	
ASSISTANT EXAMINER:	Chakrabarti, Arun Kr.	
LEGAL REPRESENTATIVE:	Oliff & Berridge, PLC	
NUMBER OF CLAIMS:	36	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	8 Drawing Figure(s); 4 Drawing Page(s)	
LINE COUNT:	909	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a process for labeling a synthetic or natural ribonucleic acid (RNA). It also relates to RNA fragments, which have been labeled by fragmenting the RNA to free a terminal phosphate of each fragment for further reaction, and labeling each fragment at the freed terminal phosphate which is located at the 3' end and/or the 5'

end of each fragment of the RNA, and to the use of such RNA fragments, for example, in the field of medical diagnosis.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 87328-05-0

(reaction with phosphate of; method for marking RNA and resulting marked RNA fragments)

RN 87328-05-0 USPATFULL

CN Thiourea, N-(5-aminopentyl)-N'-(3',6'-dihydroxy-3-oxospiro[isobenzofuran-1(3H),9'-[9H]xanthen]-5-yl)- (9CI) (CA INDEX NAME)



L6 ANSWER 8 OF 357 USPATFULL on STN

ACCESSION NUMBER: 2001:163339 USPATFULL

TITLE: Dibenzofuran sulfonamide matrix metalloproteinase inhibitors

INVENTOR(S): Picard, Joseph Armand, Canton, MI, United States
Sliskovic, Drago Robert, Saline, MI, United States

PATENT ASSIGNEE(S): Warner-Lambert Company, Morris Plains, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6294674	B1	20010925	
	WO 9809957		19980312	<--
APPLICATION INFO.:	US 1999-254403		19990302	(9)
	WO 1997-US15444		19970902	
			19990302	PCT 371 date
			19990302	PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-25063P	19960904 (60)
	US 1997-55714P	19970807 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: GRANTED

PRIMARY EXAMINER: Stockton, Laura L.

LEGAL REPRESENTATIVE: Ashbrook, Charles W.

NUMBER OF CLAIMS: 1

EXEMPLARY CLAIM: 1

LINE COUNT: 1871

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to compounds of Formula I that inhibit matrix metalloproteinases and to a method of inhibiting matrix metalloproteinases using the compounds. ##STR1##

wherein Q is an un-natural amino acid. More particularly, the present invention relates to a method of treating diseases in which matrix

metalloproteinases are involved such as multiple sclerosis, atherosclerotic plaque rupture, restenosis, aortic aneurism, heart failure, periodontal disease, corneal ulceration, burns, decubital ulcers, chronic ulcers or wounds, cancer metastasis, tumor angiogenesis, arthritis, or other autoimmune or inflammatory diseases dependent upon tissue invasion by leukocytes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 204769-01-7P

(prepn. of dibenzofuransulfonyl and related amino acids for inhibition of matrix metalloproteinases)

RN 204769-01-7 USPATFULL

CN L-Lysine, N2-(2-dibenzofuranylsulfonyl)-N6-[[4-methoxyphenyl)amino]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 9 OF 357 USPATFULL on STN

ACCESSION NUMBER: 2001:126103 USPATFULL

TITLE: Sugar-modified cytostatics

INVENTOR(S): Lerchen, Hans-Georg, Leverkusen, Germany, Federal Republic of
von dem Bruch, Karsten, Leverkusen, Germany, Federal Republic of
Petersen, Uwe, Leverkusen, Germany, Federal Republic of
Baumgarten, Jorg, Wuppertal, Germany, Federal Republic of
Piel, Norbert, Erkrath, Germany, Federal Republic of
Antonicek, Horst-Peter, Bergisch Gladbach, Germany, Federal Republic of
Weichel, Walter, Odenthal, Germany, Federal Republic of
Sperzel, Michael, Wuppertal, Germany, Federal Republic of
Bremm, Klaus Dieter, Recklinghausen, Germany, Federal Republic of
PATENT ASSIGNEE(S): Bayer Aktiengesellschaft, Leverkusen, Germany, Federal Republic of (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6271342	B1	20010807	
	WO 9631532		19961010	<--
APPLICATION INFO.:	US 1997-930546		19970925	(8)
	WO 1996-EP1279		19960322	
			19970925	PCT 371 date
			19970925	PCT 102(e) date

10/019,652

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1995-19512484	19950404
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Low, Christopher S. F.	
ASSISTANT EXAMINER:	Lukton, David	
LEGAL REPRESENTATIVE:	Norris McLaughlin & Marcus	
NUMBER OF CLAIMS:	9	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	1 Drawing Figure(s); 1 Drawing Page(s)	
LINE COUNT:	5962	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to cytostatics which, by modification with sugar, are tumor-specific. Suitable spacers ensure serum stability and at the same time an intracellular action.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **183875-48-1P**


(prepn. of carbohydrate-modified cytostatic agents)

RN 183875-48-1 USPATFULL


CN D-Alaninamide, N6-[[[4-[(6-deoxy-.beta.-L-galactopyranosyl)oxy]phenyl]amino]thioxomethyl]-L-lysyl-N-(10,12-dihydro-12-oxoisindolo[1,2-b]quinazolin-8-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



L6 ANSWER 10 OF 357 USPATFULL on STN
ACCESSION NUMBER: 2001:97933 USPATFULL
TITLE: Pyrimidine derivatives and processes for the preparation thereof

10/019,652

INVENTOR(S): Bold, Guido, Gipf-Oberfrick, Switzerland
Frei, Jorg, Holstein, Switzerland
Lang, Marc, Mulhouse, France
Traxler, Peter, Schonenbuch, Switzerland
PATENT ASSIGNEE(S): Novartis AG, Basel, Switzerland (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6251911	B1	20010626
	WO 9814450		19980409
APPLICATION INFO.:	US 1999-269823		19990401 (9)
	WO 1997-EP5369		19970930
			19990401 PCT 371 date
			19990401 PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	CH 1996-2399	19961002
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Raymond, Richard L.	
ASSISTANT EXAMINER:	Liu, Hung	
LEGAL REPRESENTATIVE:	Borovian, Joseph J.	
NUMBER OF CLAIMS:	11	
EXEMPLARY CLAIM:	1	
LINE COUNT:	3384	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB 4-Amino-1H-pyrazolo[3,4-d]pyrimidine derivatives of formula I ##STR1##

wherein the substituents are as defined in claim 1, are described.

These compounds inhibit the tyrosine kinase activity of the receptor for epidermal growth factor (EGF) and c-erbB2 kinase and can be used as anti-tumor agents.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 205452-61-5P

(prepn. of pyrazolo[3,4-d]-3,4-diamines as epidermal growth factor receptor 2 antagonists)

RN 205452-61-5 USPATFULL

CN Urea, N-(3-chlorophenyl)-N'-[2-[[4-[(3-chlorophenyl)amino]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



10/019,652

L6 ANSWER 11 OF 357 USPATFULL on STN
ACCESSION NUMBER: 2001:48039 USPATFULL
TITLE: Methods and compositions for reducing ischemic injury
of the heart by administering adenosine receptor
agonists and antagonists
INVENTOR(S): Liang, Bruce T., Merion Station, PA, United States
Jacobson, Kenneth A., Silver Springs, MD, United States
PATENT ASSIGNEE(S): The Trustees of the University of Pennsylvania,
Philadelphia, PA, United States (U.S. corporation)
The United States of America as represented by the
Department of Health and Human Services, Washington,
DC, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6211165	B1	20010403
	WO 9850047		19981112
APPLICATION INFO.:	US 1999-423129		19991105 (9)
	WO 1998-US9031		19980508
			19991105 PCT 371 date
			19991105 PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-46030P	19970509 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Henley, III, Raymond	
LEGAL REPRESENTATIVE:	Dann, Dorman, Herrell and Skillman	
NUMBER OF CLAIMS:	60	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	41 Drawing Figure(s); 30 Drawing Page(s)	
LINE COUNT:	1364	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for reducing or preventing ischemic damage of the heart are disclosed. A preferred embodiment of the invention comprises the simultaneous administration of specific A3/A1 receptor agonists, to patients suffering from ischemic damage or at risk for the same. In yet another embodiment of the invention, a binary conjugate which acts as an agonist for the A3 receptor and an antagonist at the A2a receptor, is administered to reduce or prevent ischemic damage to the heart.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.



IT 215933-96-3P

(methods and compns. for reducing ischemic injury of heart by administering adenosine receptor agonists and antagonists)

RN 215933-96-3 USPATFULL

CN .beta.-D-Ribofuranuronamide, 1-deoxy-N-methyl-1-[6-[[[3-[3-[[[4-[[[2-[[[4-[[[4-[(9-.beta.-D-ribofuranosyl-9H-purin-6-yl)amino]phenyl]acetyl]amino]phenyl]acetyl]amino]ethoxy]thiomethyl]amino]phenyl]amino]thiomethyl]amino]-1-propynyl]phenyl]methyl]amino]-9H-purin-9-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



||
O

L6 ANSWER 12 OF 357 USPATFULL on STN
 ACCESSION NUMBER: 2001:4934 USPATFULL
 TITLE: Polyamine analogues as therapeutic and diagnostic agents
 INVENTOR(S): Vermeulin, Nicolaas M. J., Woodinville, WA, United States
 O'Day, Christine L., Mountlake Terrace, WA, United States
 Webb, Heather K., Seattle, WA, United States
 Burns, Mark R., Shoreline, WA, United States
 Bergstrom, Donald E., West Lafayette, IN, United States
 PATENT ASSIGNEE(S): Oridigm Corporation, Seattle, WA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6172261	B1	20010109	
	WO 9903823		19990128	<--
APPLICATION INFO.:	US 1999-341400		19990903	(9)
	WO 1998-US14896		19980715	
			19990903	PCT 371 date
			19990903	PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-52586P	19970715 (60)
	US 1997-65728P	19971114 (60)
	US 1998-85538P	19980515 (60)
DOCUMENT TYPE:	Patent	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Henley, III, Raymond	
LEGAL REPRESENTATIVE:	Morrison & Foerster LLP	
NUMBER OF CLAIMS:	24	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	50 Drawing Figure(s); 38 Drawing Page(s)	
LINE COUNT:	3638	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel inhibitors of polyamine transport having inhibition constants two orders of magnitude lower than those of known compounds are disclosed. These polyamine analogues are useful pharmaceutical agents for treating diseases where it is desired to inhibit polyamine transport or other polyamine binding proteins, for example cancer and post-angioplasty injury. Novel chemical synthetic methods to obtain polyamine analogues are disclosed, including the production of a combinational polyamine library. These approaches yield analogues with desirable activities both for diagnostic and research assays and therapy. The assays of the invention are useful for high throughput screening of targets in the discovery of drugs that interact with the polyamine system.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 220221-10-3P

(prepn. of polyamines as therapeutic and diagnostic agents)

RN 220221-10-3 USPATFULL

10/019,652

CN Urea, N-[3-[[4-[(3-aminopropyl)amino]butyl]amino]propyl]-N'-1-anthracenyl-
(9CI) (CA INDEX NAME)



L6 ANSWER 13 OF 357 USPATFULL on STN

ACCESSION NUMBER: 2000:174654 USPATFULL

TITLE: Diaminopuridine-containing thiourea inhibitors of herpes viruses

INVENTOR(S): Bloom, Jonathan, Nyack, NY, United States
DiGrandi, Martin, Congers, NY, United States
Dushin, Russell, Garrison, NY, United States
Lang, Stanley, Blauvent, NY, United States
O'Hara, Bryan, Norwood, NJ, United States

PATENT ASSIGNEE(S): American Home Products Corporation, Madison, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6166028		20001226	<--
APPLICATION INFO.:	US 1999-444782		19991122	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-150698P	19981209 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Rotman, Alan L.	
ASSISTANT EXAMINER:	Desai, Rita	
LEGAL REPRESENTATIVE:	Barrett, Rebecca R.	
NUMBER OF CLAIMS:	20	
EXEMPLARY CLAIM:	1	
LINE COUNT:	5148	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds of the formula ##STR1## are useful in the treatment of diseases associated with herpes viruses including human cytomegalovirus, herpes simplex viruses, Epstein-Barr virus, varicella-zoster virus, human herpesviruses-6 and -7, and Kaposi herpesvirus.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 273391-92-7P

(target compd.; prepn. of benzamide-contg. aryl thiourea derivs. as inhibitors of herpes viruses)

RN 273391-92-7 USPATFULL

CN 1,2,3-Thiadiazole-4-carboxamide, N-[4-[[[2-(phenylamino)ethyl]amino]thioxomethyl]amino]phenyl]- (9CI) (CA INDEX NAME)



L6 ANSWER 14 OF 357 USPATFULL on STN
 ACCESSION NUMBER: 2000:171042 USPATFULL
 TITLE: 2-imidazolinylaminoindole compounds useful as alpha-2
 adrenoceptor agonists
 INVENTOR(S): Henry, Raymond Todd, Pleasant Plain, OH, United States
 Sheldon, Russell James, Fairfield, OH, United States
 Seibel, William Lee, Hamilton, OH, United States
 PATENT ASSIGNEE(S): The Procter & Gamble Company, Cincinnati, OH, United
 States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6162818		20001219 <--
APPLICATION INFO.:	US 1999-290731		19990413 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. WO 1997-US20801, filed on 21 Nov 1997		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-31777P	19961111 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	McKane, Joseph K.	
ASSISTANT EXAMINER:	Oswecki, Jane C.	
LEGAL REPRESENTATIVE:	Bott, Cynthia M., Kellerman, James C., Clark, Karen F.	
NUMBER OF CLAIMS:	42	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2524	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention involves compounds having the following structure:
 ##STR1## wherein: a) R.sub.1 is hydrogen; or alkyl; bond (a) is a single
 or a double bond;

b) R.sub.2 and R.sub.3 are each independently selected from hydrogen;
 unsubstituted C.sub.1 -C.sub.3 alkanyl, alkenyl or alkynyl;
 cycloalkanyl, cycloalkenyl; unsubstituted C.sub.1 -C.sub.3 alkylthio or
 alkoxy; hydroxy; thio; nitro; cyano; amino; C.sub.1 -C.sub.3 alkylamino
 or C.sub.1 -C.sub.3 dialkylamino and halo;

c) R.sub.4, R.sub.5 and R.sub.6 are each independently selected from
 hydrogen; unsubstituted C.sub.1 -C.sub.3 alkanyl, alkenyl or alkynyl;
 cycloalkanyl, cycloalkenyl; unsubstituted C.sub.1 -C.sub.3 alkylthio or
 alkoxy; hydroxy; thio; nitro; cyano; amino; C.sub.1 -C.sub.3 alkylamino
 or C.sub.1 -C.sub.3 dialkylamino; halo; and 2-imidazolinylamino; and
 wherein one and only one of R.sub.4, R.sub.5 and R.sub.6 is
 2-imidazolinylamino;

d) R.sub.7 is selected from hydrogen; unsubstituted C.sub.1 -C.sub.3
 alkanyl, alkenyl or alkynyl; cycloalkanyl, cycloalkenyl; unsubstituted

C.sub.1 -C.sub.3 alkylthio or alkoxy; hydroxy; thio; nitro; cyano; amino; C.sub.1 -C.sub.3 alkylamino or C.sub.1 -C.sub.3 dialkylamino and halo;

e) the compound is not 4-(2-imidazolinylamino)indole;

enantiomers, optical isomers, stereoisomers, diastereomers, tautomers, addition salts, biohydrolyzable amides and esters thereof, and pharmaceutical compositions comprising such novel compounds. The invention also relates to the use of such compounds for treating disorders modulated by alpha-2 adrenoceptors.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 208510-96-7P

(prepn. of 2-imidazolinylaminoindoles as alpha-2 adrenoceptor agonists)

RN 208510-96-7 USPATFULL

CN Thiourea, N-(2-aminoethyl)-N'-(2,3-dihydro-7-methyl-1H-indol-6-yl)- (9CI)
(CA INDEX NAME)



L6 ANSWER 15 OF 357 USPATFULL on STN

ACCESSION NUMBER: 2000:168042 USPATFULL

TITLE: Substituted diaminocarboxylic acids

INVENTOR(S): Thorwart, Werner, Hochheim, Germany, Federal Republic of
Schwab, Wilfried, Wiesbaden, Germany, Federal Republic of
Schudok, Manfred, Eppstein/Ts, Germany, Federal Republic of
Haase, Burkhard, Hofheim, Germany, Federal Republic of
Neises, Bernhard, Offenburg, Germany, Federal Republic of
Billen, Gunter, Niedernhausen, Germany, Federal Republic of

PATENT ASSIGNEE(S): Aventis Pharma Deutschland GmbH, Frankfurt am Main, Germany, Federal Republic of (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6159995		20001212	<--
APPLICATION INFO.:	US 1998-74587		19980508	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1997-19719585	19970509
	DE 1997-19719428	19970512

DOCUMENT TYPE: Utility

FILE SEGMENT: Granted

PRIMARY EXAMINER: Raymond, Richard L.

ASSISTANT EXAMINER: Coleman, Brenda

LEGAL REPRESENTATIVE: Finnegan, Henderson, Farabow, Garrett and Dunner,

10/019,652

L.L.P.

NUMBER OF CLAIMS: 13
EXEMPLARY CLAIM: 1
LINE COUNT: 1333

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds of formula (I) ##STR1## are suitable for the production of pharmaceuticals for the prophylaxis and therapy of disorders in the course of which an increased activity of matrix-degrading metalloproteinases is involved.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 215164-88-8P

(prepn. and use of sulfonyldiaminocarboxylic acids as matrix-metalloproteinase inhibitors)

RN 215164-88-8 USPTAFULL

CN D-Ornithine, N2-[(4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]-N5-[(phenylamino)carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 16 OF 357 USPTAFULL on STN

ACCESSION NUMBER: 2000:164510 USPTAFULL

TITLE: Glycoconjugates of modified camptothecin derivatives (A-or B-ring linkage)

INVENTOR(S): Lerchen, Hans-Georg, Leverkusen, Germany, Federal Republic of
von dem Bruch, Karsten, Leverkusen, Germany, Federal Republic of
Baumgarten, Jorg, Wuppertal, Germany, Federal Republic of
Sperzel, Michael, Wuppertal, Germany, Federal Republic of

PATENT ASSIGNEE(S): Bayer Aktiengesellschaft, Leverkusen, Germany, Federal Republic of (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6156754		20001205	<--
	WO 9814468		19980409	<--
APPLICATION INFO.:	US 1999-269314		19990324	(9)
	WO 1997-EP5089		19970917	
			19990324	PCT 371 date
			19990324	PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1996-19640207	19960930

10/019,652

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Kight, John
ASSISTANT EXAMINER: Robinson, Binta
LEGAL REPRESENTATIVE: Norris, McLaughlin & Marcus, P.A.
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
LINE COUNT: 1019

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to glycoconjugates of camptothecin derivatives in which at least one carbohydrate component is linked via suitable spacers with the A or B ring of a camptothecin derivative. The invention furthermore relates to processes for preparing the compounds according to the invention and to their use as medicaments, in particular in connection with cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 205189-88-4P


(prepn. and use of glycoconjugates of camptothecine derivs. in treatment of cancer)



RN 205189-88-4 USPATFULL

CN L-Alanine, N2,N6-bis[[[4-[(6-deoxy-3-O-methyl-.beta.-L-galactopyranosyl)oxy]phenyl]amino]thioxomethyl]-L-lysyl-, [(4S)-4-ethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-11-yl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





L6 ANSWER 17 OF 357 USPATFULL on STN
 ACCESSION NUMBER: 2000:160769 USPATFULL
 TITLE: Photothermographic element
 INVENTOR(S): Arai, Tsutomu, Kanagawa, Japan
 Suzuki, Ryo, Kanagawa, Japan
 Goto, Takahiro, Kanagawa, Japan
 PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Kanagawa, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6153372		20001128	<--
APPLICATION INFO.:	US 1998-165347		19981002	(9)
	NUMBER		DATE	
PRIORITY INFORMATION:	JP 1997-287891		19971003	

JP 1998-78168 19980325
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Chea, Thorl
LEGAL REPRESENTATIVE: Birch, Stewart, Kolasch & Birch, LLP
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1
LINE COUNT: 3286

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A photothermographic element contains a non-photosensitive organic silver salt, a photosensitive silver halide which has been formed independent of the non-photosensitive organic silver salt, and a binder. An image forming layer contains the photosensitive silver halide, a latex of a polymer having a Tg of -30.degree. C. to 40.degree. C. as a main binder, and a compound of formula (I): ##STR1## wherein X is --N.dbd., --N(R)--, --O--, or --S--, wherein R is hydrogen, hydroxyl, aliphatic hydrocarbon, aryl or heterocyclic group, Z is a single bond or a group of atoms necessary to form a 5- to 7-membered ring with X, and Q.sub.1 and Q.sub.2 each are a group of atoms necessary to form an aromatic hydrocarbon or heterocyclic ring fused to the ring completed by Z.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 205367-44-8P

(heat-developable photog. material contg. polymer latex with low glass-transition temp. for scanner film)

RN 205367-44-8 USPATFULL

CN Urea, N,N''-1,2-ethanediylbis[N'-(9-ethyl-9H-carbazol-3-yl)- (9CI) (CA INDEX NAME)



L6 ANSWER 18 OF 357 USPATFULL on STN

ACCESSION NUMBER: 2000:153721 USPATFULL

TITLE: Antagonists of gonadotropin releasing hormone

INVENTOR(S): Goulet, Mark, Westfield, NJ, United States

Allen, Eric E, Somerset, NJ, United States

Wyvratt, Jr., Matthew J., Mountainside, NJ, United States

Jiang, Jinlong, Woodbridge, NJ, United States

Smith, Roy G., Westfield, NJ, United States

Walsh, Thomas F, Watchung, NJ, United States

Yang, Yi Tien, Neshanic Station, NJ, United States

Young, Jonathan R, Dayton, NJ, United States

Devita, Robert J., Westfield, NJ, United States

PATENT ASSIGNEE(S): Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6147088		20001114	<--
	WO 9744321		19971127	<--

APPLICATION INFO.: US 1998-180645 19981112 (9)
 WO 1997-US8479 19970516
 19981112 PCT 371 date
 19981112 PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-17150P	19960520 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Huang, Evelyn Mei	
LEGAL REPRESENTATIVE:	Korsen, Elliott, Daniel, Mark R.	
NUMBER OF CLAIMS:	26	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2405	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB There are disclosed compounds of formula (I) and pharmaceutical acceptable salts thereof which are useful as antagonists of GnRH and as such may be useful for the treatment of a variety of sex-hormone related conditions. ##STR1##


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 199939-99-6P

(prepn. of quinolinone derivs. as antagonists of gonadotropin releasing hormone)

RN 199939-99-6 USPATFULL

CN 6-Thia-2,5-diaza-9-siladecanamide, N-[7-chloro-3-(3,5-dimethylphenyl)-1,2-dihydro-2-oxo-4-[2-(2-piperidinyl)ethoxy]-6-quinolinyl]-9,9-dimethyl-, 6,6-dioxide (9CI) (CA INDEX NAME)



L6 ANSWER 19 OF 357 USPATFULL on STN
 ACCESSION NUMBER: 2000:124761 USPATFULL
 TITLE: Photothermographic material, novel 2,3-dihydrothiazole derivative, and photographic silver halide photosensitive material
 INVENTOR(S): Okada, Hisashi, Kanagawa, Japan
 Suzuki, Ryo, Kanagawa, Japan
 Asanuma, Naoki, Kanagawa, Japan
 Ikeda, Tadashi, Kanagawa, Japan
 Hirano, Shigeo, Kanagawa, Japan

10/019,652

PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd, Kanagawa, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6120983		20000919	<--
APPLICATION INFO.:	US 1997-956134		19971022	(8)

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1996-298154	19961022
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Chea, Thorl	
LEGAL REPRESENTATIVE:	Birch, Stewart Kolasch & Birch, LLP	
NUMBER OF CLAIMS:	11	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1881	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A photothermographic material contains an organic silver salt, a photosensitive silver halide, a reducing agent, a binder, and a compound of the formula: X--L.sub.1 --D wherein D is an electron donative group of atoms, X is an adsorption promoting group to silver halide, and L.sub.1 is a valence bond or a linking group. It has high sensitivity in the red to infrared region and experiences a minimal change of photographic properties under different developing conditions.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 122642-00-6

(IR-sensitive photothermog. materials contg. dihydrothiazole compds., org. silver salts, silver halides and)

RN 122642-00-6 USPTAFULL

CN Urea, N-[3-(2,5-dihydro-5-thioxo-1H-tetrazol-1-yl)phenyl]-N'-[3-(dimethylamino)propyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L6 ANSWER 20 OF 357 USPTAFULL on STN

ACCESSION NUMBER: 2000:121514 USPTAFULL

TITLE: 6-(2-imidazolinylamino)quinoxaline compounds useful as alpha-2 adrenoceptor agonists

INVENTOR(S): Maurer, Peter J., Cincinnati, OH, United States
Henry, Raymond T., Pleasant Plain, OH, United States
Sheldon, Russell James, Fairfield, OH, United States

PATENT ASSIGNEE(S): The Procter & Gamble Company, Cincinnati, OH, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6117871		20000912 <--
APPLICATION INFO.:	US 1996-755941		19961125 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1995-496707, filed on 29 Jun 1995, now abandoned which is a continuation-in-part of Ser. No. US 1993-169785, filed on 17 Dec 1993, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Fay, Zohreh		
LEGAL REPRESENTATIVE:	Bott, Cynthia M., Kellerman, James C., Suter, David L.		
NUMBER OF CLAIMS:	18		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1432		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The subject invention relates to methods of treating alpha-2 adenoreceptor modulated disorders, comprising administration, to a mammal in need of such treatment, of a safe and effective amount of a compound having the following structure: ##STR1## wherein: (a) R is unsubstituted C.sub.1 -C.sub.3 alkanyl or alkenyl; and

(b) R' is selected from hydrogen; unsubstituted C.sub.1 -C.sub.3 alkanyl or alkenyl; unsubstituted C.sub.1 -C.sub.3 alkylthio or alkoxy; hydroxy; thiol; and halo.

The subject invention also relates compounds and compositions for preventing or treating of disorders modulated by alpha-2 adrenoreceptors.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 183278-01-5P

(synthesis and formulations of 6-(2-imidazolinylamino)quinoxaline compds. useful as alpha-2 adrenoreceptor agonists)

RN 183278-01-5 USPATFULL

CN Thiourea, N-(2-aminoethyl)-N'-(5-methyl-6-quinoxaliny)- (9CI) (CA INDEX NAME)



L6 ANSWER 21 OF 357 USPATFULL on STN

ACCESSION NUMBER: 2000:117771 USPATFULL

TITLE: Amino acid derivatives, pharmaceutical compositions containing these compounds and processes for preparing them

INVENTOR(S): Engel, Wolfhard, Biberach, Germany, Federal Republic of
Eberlein, Wolfgang, Biberach, Germany, Federal Republic of
Rudolf, Klaus, Biberach, Germany, Federal Republic of
Doods, Henri, Warthausen, Germany, Federal Republic of
Wieland, Heike-Andrea, Biberach, Germany, Federal

Republic of
 Willim, Klaus-Dieter, Hochdorf/Schweinhausen, Germany,
 Federal Republic of
 Entzeroth, Michael, Warthausen, Germany, Federal
 Republic of
 Wienen, Wolfgang, Biberach/Risseegg, Germany, Federal
 Republic of
 PATENT ASSIGNEE(S): Karl Thomae GmbH, Biberach, Germany, Federal Republic
 of (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6114390		20000905	<--
APPLICATION INFO.:	US 1997-950113		19971014	(8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 945048			
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	Granted			
PRIMARY EXAMINER:	Raymond, Richard L.			
LEGAL REPRESENTATIVE:	Raymond, Robert P., Stempel, Alan R., Devlin, Mary-Ellen M.			
NUMBER OF CLAIMS:	10			
EXEMPLARY CLAIM:	1			
LINE COUNT:	6573			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB NPY-antagonistic compounds of the formula ##STR1## Exemplary are: (A)
 (R)-N-[[4-(Aminocarbonylaminoethyl)phenyl]methyl]-N.sup.2
 -bis(4-hydroxyphenyl)acetyl]-argininamide-trifluoroacetate;

 (B) (R)-N-[[4-(Aminocarbonylaminoethyl)phenyl]methyl]-N.sup.2
 -[bis(4-chlorophenyl)acetyl]-argininamide-trifluoroacetate;

 (C) (R)-N-[[4-(Aminocarbonylaminoethyl)phenyl]methyl]-N.sup.2
 -(diphenylacetyl)-argininamide-trifluoroacetate;

 (D) (R)-N.sup.2 -(Diphenylacetyl)-N-[[4-(ethoxycarbonylmethylamino-
 carbonylaminoethyl)phenyl]methyl]-argininamide-trifluoroacetate;

 (E) (R,S)-N.sup.5 -(Aminoiminomethyl)-N.sup.2 -(diphenylacetyl)-N-[(4-hy-
 droxyphenyl)methyl]-N.sup.5 -methyl-ornithinamide-hydrochloride;

 (F) (R)-N-[[4-(Aminocarbonylmethyl)phenyl]methyl]-N.sup.2
 -(diphenyl-acetyl)-argininamide-diacetate;

 (G) (R)-N.sup.2 -(Diphenylacetyl)-N-[[4-(ethylaminocarbonylamino-methyl)-
 phenyl]methyl]-argininamide-bis-(trifluoroacetate); and,

 (H) (R)-N.sup.2 -(Diphenylacetyl)-N-[[4-(ethoxycarbonylamino-
 carbonylaminoethyl)phenyl]methyl]-argininamide-trifluoroacetate.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 191870-71-0P

(prepn. of amino acid derivs. as neuropeptide Y antagonists)

RN 191870-71-0 USPTATFULL

CN Pentanamide, N-[[4-[[[(aminocarbonyl)amino]methyl]phenyl]methyl]-5-
 [(aminoiminomethyl)amino]-2-[[[(1-naphthalenylamino)carbonyl]amino]-,
 (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 22 OF 357 USPATFULL on STN
 ACCESSION NUMBER: 2000:117709 USPATFULL
 TITLE: Isoxazoline and isoxazole fibrogen receptor antagonists
 INVENTOR(S): Wityak, John, West Grove, PA, United States
 Xue, Chu-Biao, Hockessin, DE, United States
 Sielecki-Dzurdz, Thais Motria, Newark, DE, United States
 Olson, Richard Eric, Wilmington, DE, United States
 Degrado, William Frank, Moylan, PA, United States
 Cain, Gary Avonn, Wilmington, DE, United States
 Batt, Douglas Guy, Wilmington, DE, United States
 Pinto, Donald, Newark, DE, United States
 Hussain, Munir Alwan, Wilmington, DE, United States
 Mousa, Shaker Ahmed, Lincoln University, PA, United States
 PATENT ASSIGNEE(S): Dupont Pharmaceuticals Company, Wilmington, DE, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6114328		20000905 <--
APPLICATION INFO.:	US 1997-978295		19971125 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1995-455436, filed on 31 May 1995, now patented, Pat. No. US 5849736 which is a continuation-in-part of Ser. No. US 1994-337929, filed on 10 Nov 1994 which is a continuation-in-part of Ser. No. US 1994-232961, filed on 22 Apr 1994 which is a continuation-in-part of Ser. No. US 1993-157598, filed on 24 Nov 1993		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Kight, John		
ASSISTANT EXAMINER:	Covington, Raymond		
LEGAL REPRESENTATIVE:	Reinert, Norbert F.		
NUMBER OF CLAIMS:	49		
EXEMPLARY CLAIM:	1		
LINE COUNT:	12644		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to novel isoxazolines and isoxazoles which are useful as antagonists of the platelet glycoprotein IIb/IIIa fibrinogen receptor complex or the vitronectin receptor, to pharmaceutical compositions containing such compounds, processes for preparing such compounds, and to methods of using these compounds, alone or in

10/019,652

combination with other therapeutic agents, for the inhibition of platelet aggregation, as thrombolytics, and/or for the treatment of thromboembolic disorders.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 170724-36-4P

(prepn. of isoxazolinealkanoates and analogs as fibrinogen receptor antagonists)

RN 170724-36-4 USPATFULL

CN Alanine, 3-[[[3-[4-(aminoiminomethyl)phenyl]-4,5-dihydro-5-isoxazolyl]acetyl]amino]-N-[(phenylamino)carbonyl]-, methyl ester (9CI)
(CA INDEX NAME)



L6 ANSWER 23 OF 357 USPATFULL on STN
ACCESSION NUMBER: 2000:113979 USPATFULL
TITLE: 2-imidazolinyllaminobenzoxazole compounds useful as alpha-2 adrenoceptor agonists
INVENTOR(S): Henry, Raymond Todd, Pleasant Plain, OH, United States
Sheldon, Russell James, Fairfield, OH, United States
Seibel, William Lee, Hamilton, OH, United States
PATENT ASSIGNEE(S): The Procter & Gamble Company, Cincinnati, OH, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6110952		20000829	<--
	WO 9823611		19980604	<--
APPLICATION INFO.:	US 1999-308792		19990809	(9)
	WO 1997-US20803		19971121	
			19990809	PCT 371 date
			19990809	PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-31787P	19961125 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	McKane, Joseph	
ASSISTANT EXAMINER:	Wright, Sonya N	
LEGAL REPRESENTATIVE:	Kellerman, James C., Roof, Carl J.	
NUMBER OF CLAIMS:	42	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1879	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to compounds of formula I, (2-imidazolinyllamino)benzoxazoles. The compounds have been found to be alpha-2 adrenocepto agonists and are useful for treatment of disorders

modulated by alpha-2 adrenoceptors.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **208450-33-3P**

(prepn. of 2-imidazolinyllaminobenzoxazoles as alpha-2 adrenoceptor agonists)

RN 208450-33-3 USPATFULL

CN Thiourea, N-(2-aminoethyl)-N'-(4-methyl-5-benzoxazolyl)- (9CI) (CA INDEX NAME)



L6 ANSWER 24 OF 357 USPATFULL on STN

ACCESSION NUMBER: 2000:102317 USPATFULL

TITLE: Heterocyclic compounds as bradykinin antagonists

INVENTOR(S): Oku, Teruo, Tsukuba, Japan

Kayakiri, Hiroshi, Tsukuba, Japan

Abe, Yoshito, Inashiki-gun, Japan

Sawada, Yuki, Tsukuba, Japan

Mizutani, Tsuyoshi, Tsukuba, Japan

PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Osaka, Japan
(non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6100284		20000808	<--
APPLICATION INFO.:	US 1999-419684		19991015	(9)
RELATED APPLN. INFO.:	Division of Ser. No. US 29852			

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1995-19077	19950918
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Seaman, D. Margaret	
LEGAL REPRESENTATIVE:	Oblon, Spivak, McClelland, Maier & Neustadt, P.C.	
NUMBER OF CLAIMS:	8	
EXEMPLARY CLAIM:	1	
LINE COUNT:	3619	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to a compound of the formula: ##STR1## wherein
A.sup.1 is lower alkylene,

R.sup.1 is substituted quinolyl, etc.,

R.sup.2 is hydrogen, halogen or lower alkyl,

R.sup.3 is halogen or lower alkyl, and

R.sup.4 is a group of the formula:

--Q--A.sup.2 --R.sup.5, etc.,

in which

R.sup.5 is amino, acylamino, etc.,

A.sup.2 is lower alkylene or a single bond, and

Q is a group of the formula: ##STR2## etc., and pharmaceutically acceptable salts thereof, to processes for preparation thereof, to a pharmaceutical composition comprising the same, and to methods of using the same therapeutically in the prevention and/or the treatment of bradykinin or its analogues mediated diseases in human being or animals.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 189267-79-6P

(prepn. of N-[(heteroaryloxy)alkylphenyl]-2-(acylaminoalkyl)pyrroles and analogs as bradykinin antagonists)

RN 189267-79-6 USPATFULL

CN Benzamide, 2,4-dichloro-N-methyl-N-[2-[[[4-[(methylamino)carbonyl]phenyl]amino]carbonyl]amino]ethyl]-3-[[2-methyl-8-quinolinyl]oxy]methyl]-
(9CI) (CA INDEX NAME)



L6 ANSWER 25 OF 357 USPATFULL on STN
 ACCESSION NUMBER: 2000:91406 USPATFULL
 TITLE: Chiral surfactants and methods for their use in chiral separations
 INVENTOR(S): Mazzeo, Jeffrey R., Chelmsford, MA, United States
 Grover, Edward R., Randolph, MA, United States
 Swartz, Michael E., Uxbridge, MA, United States
 Merion, Michael, Los Gatos, CA, United States
 Petersen, John S., Acton, MA, United States
 PATENT ASSIGNEE(S): Waters Investments Limited, Wilmington, DE, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6090250		20000718	<--
	WO 9508529		19950330	<--
APPLICATION INFO.:	US 1996-617916		19960320	(8)
	WO 1994-US10655		19940920	

10/019,652

19960320 PCT 371 date
19960320 PCT 102(e) date

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1993-124681, filed
on 20 Sep 1993
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Beisner, William H.
ASSISTANT EXAMINER: Starsiak, Jr., John S.
LEGAL REPRESENTATIVE: Hamilton, Brook, Smith & Reynolds, P.C.
NUMBER OF CLAIMS: 52
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 120 Drawing Figure(s); 46 Drawing Page(s)
LINE COUNT: 1908


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Chiral surfactants, methods for their synthesis and use, and apparatus designed to facilitate chiral separations using nucellar capillary electrophoresis is disclosed. A chiral surfactant having the general formula: ##STR1## is described, R1 is the hydrophobic tail, Y-A-X is the linker, the brackets define a chiral center, and the hydrophilic head group is Z. All the various components may potentiate the enantioselectivity of the chiral surfactant. The capillary electrophoresis (CE) system includes a narrow diameter capillary, a high voltage power supply, an electrolyte reservoir at each end of the capillary, a means for injecting a sample, and a detector. Chiral surfactants are dissolved in the electrolyte above their critical micelle concentration (cmc), resulting in the formation of chiral micelles. The electrolyte reservoirs and capillary tube are filled with the electrolyte. A sample containing a mixture of enantiomers is then injected into the capillary, and a high voltage potential is applied across the capillary. The sample components migrate through the capillary due to the influence of the applied electric field. An example separation of the four sereoisomers of aspartame is shown.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 150331-57-0
(enantiomer resohn. by micellar electrokinetic capillary chromatog.
using chiral surfactants)
RN 150331-57-0 USPATFULL
CN L-Arginine, N2-[(6-quinolinylamino)carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 26 OF 357 USPATFULL on STN
ACCESSION NUMBER: 2000:84299 USPATFULL
TITLE: Constrained somatostatin agonists and antagonists
INVENTOR(S): Ankersen, Michael, Frederiksberg, Denmark
Dorwald, Florenzio Zaragoza, Herlev, Denmark
Stidsen, Carsten Enggaard, Soborg, Denmark
Crider, Albert Michael, Monroe, LA, United States
PATENT ASSIGNEE(S): Novo Nordisk A/S, Bagsvaerd, Denmark (non-U.S.)

corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6083960		20000704 <--
APPLICATION INFO.:	US 1999-397355		19990916 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1997-962098, filed on 31 Oct 1997, now patented, Pat. No. US 6020349		

	NUMBER	DATE
PRIORITY INFORMATION:	DK 1996-1216	19961031
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Kumar, Shailendra	
LEGAL REPRESENTATIVE:	Zelson, Esq., Steve T., Lambiris, Esq., Elias J.	
NUMBER OF CLAIMS:	11	
EXEMPLARY CLAIM:	1	
LINE COUNT:	937	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a compound of general formula I
 ##STR1## for treating medical disorders related to binding to human
 somatostatin receptor subtypes.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 207276-72-0P

(prepn. of thiourea derivs. and related compds. as constrained
 somatostatin agonists and antagonists)

RN 207276-72-0 USPATFULL

CN Thiourea, N-1H-benzotriazol-5-yl-N'-[2-[(5-bromo-2-pyridinyl)](3,4-
 dichlorophenyl)methyl]amino]ethyl]- (9CI) (CA INDEX NAME)



L6 ANSWER 27 OF 357 USPATFULL on STN

ACCESSION NUMBER: 2000:84283 USPATFULL

TITLE: Quinoline-containing .alpha.-ketoamide cysteine and
 serine protease inhibitors

INVENTOR(S): Chatterjee, Sankar, Wynnewood, PA, United States
 Mallamo, John P., Glenmoore, PA, United States
 Dunn, Derek Douglas, Thorndale, PA, United States
 Josef, Kurt Allen, Wilmington, DE, United States
 Gu, Zi-Qiang, Reston, VA, United States
 Daines, Robert A., Lansdale, PA, United States
 Kingsbury, William Dennis, Phoenixville, PA, United States
 Pendrak, Israel, Ambler, PA, United States
 Sham, Kelvin C., King of Prussia, PA, United States

PATENT ASSIGNEE(S): Cephalon, Inc., West Chester, PA, United States (U.S. corporation)
Smithkline Beecham Corp., Philadelphia, PA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6083944		20000704	<--
APPLICATION INFO.:	US 1998-167193		19981006	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-61267P	19971007 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Shah, Mukund J.	
ASSISTANT EXAMINER:	Rao, Deepak R.	
LEGAL REPRESENTATIVE:	Woodcock Washburn Kurtz Mackiewicz & Norris LLP	
NUMBER OF CLAIMS:	21	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1482	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to quinoline-containing .alpha.-ketoamide inhibitors of cysteine and serine proteases are disclosed. Methods for making these compounds, and methods for using the same are also disclosed.



CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **222959-30-0P**

(prepn. of quinoline-contg. .alpha.-ketoamide cysteine and serine protease inhibitors)

RN 222959-30-0 USPATFULL


CN 4-Quinolinecarboxamide, N-[3-[[2-[[[(4-bromophenyl)amino]carbonyl]amino]ethyl]amino]-2,3-dioxo-1-(phenylmethyl)propyl]-2-(phenylethynyl)- (9CI)
(CA INDEX NAME)




L6 ANSWER 28 OF 357 USPATFULL on STN
 ACCESSION NUMBER: 2000:76603 USPATFULL
 TITLE: Technology assisted learning
 INVENTOR(S): Parry, Kent, Orem, UT, United States
 Elzinga, C. Bret, American Fork, UT, United States
 PATENT ASSIGNEE(S): Intellectual Reserve, Inc., Salt Lake City, UT, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6077085		20000620	<--
APPLICATION INFO.:	US 1998-81706		19980519	(9)
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	Granted			

PAGE 1-A




PAGE 1-B



CM 2

CRN 64-19-7
CMF C2 H4 O2



L6 ANSWER 29 OF 357 USPATFULL on STN
 ACCESSION NUMBER: 2000:67843 USPATFULL
 TITLE: Carboxamide derivatives of piperidine for the treatment of thrombosis disorders
 INVENTOR(S): Costanzo, Michael J., Ivyland, PA, United States
 Hoekstra, William J., Villanova, PA, United States
 Maryanoff, Bruce E., Forest Grove, PA, United States
 PATENT ASSIGNEE(S): Ortho Pharmaceutical Corp., Raritan, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6069254		20000530	<--
APPLICATION INFO.:	US 1997-841016		19970429 (8)	

NUMBER	DATE
--------	------

10/019,652

PRIORITY INFORMATION: US 1996-16675P 19960501 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Rotman, Alan L.
LEGAL REPRESENTATIVE: Palo, Ralph R.
NUMBER OF CLAIMS: 2
EXEMPLARY CLAIM: 1
LINE COUNT: 1205

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Carboxamide derivatives of pyrrolidine, piperidine, and hexahydroazepine of formula (I): ##STR1## are disclosed as useful in treating platelet-mediated thrombotic disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 198958-90-6P

(prepn. of pyrrolidine, piperidine and hexahydroazepine carboxamide derivs. for treatment of thrombosis disorders)

RN 198958-90-6 USPATFULL

CN L-Alanine, N-[[[(3-methoxyphenyl)amino]carbonyl]-3-[[[(3R)-1-[1-oxo-3-(4-piperidinyl)propyl]-3-piperidinyl]carbonyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

L6 ANSWER 30 OF 357 USPATFULL on STN
ACCESSION NUMBER: 2000:54234 USPATFULL
TITLE: Anti-herpesvirus compounds and methods for identifying, making and using same
INVENTOR(S): Crute, James J., Danbury, CT, United States
Faucher, Anne-Marie, Oka, Canada
Grygon, Christine A., New Milford, CT, United States
Hargrave, Karl D., Brookfield, CT, United States
Simoneau, Bruno, Laval, Canada
Thavonekham, Bounkham, Longeuil, Canada
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6057451		20000502	<--
APPLICATION INFO.:	US 1996-759201		19961204	(8)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-23209P	19960802 (60)
	US 1995-9433P	19951229 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Dees, Jose' G.	
ASSISTANT EXAMINER:	Qazi, Sabiha N.	
LEGAL REPRESENTATIVE:	Raymond, Robert P., Bottino, Anthony P., Devlin, Mary-Ellen	
NUMBER OF CLAIMS:	15	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	5 Drawing Figure(s); 5 Drawing Page(s)	
LINE COUNT:	5087	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to methods for inhibiting herpes replication and for treating herpes infection in a mammal by inhibiting the herpes helicase-primase enzyme complex. This invention also relates to thiazolylphenyl derivatives that inhibit the herpes helicase-primase and to pharmaceutical compositions comprising the thiazolylphenyl derivatives, to methods of using and methods of producing the thiazolylphenyl derivatives.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 193348-90-2P

(prepn. of 4-(aminothiazolyl)acetanilides and analogs as antiherpes agents)

RN 193348-90-2 USPATFULL

CN Urea, N-[4-(2-amino-4-thiazolyl)phenyl]-N'-[2-bis(phenylmethyl)amino]ethyl]- (9CI) (CA INDEX NAME)



L6 ANSWER 31 OF 357 USPATFULL on STN

ACCESSION NUMBER: 2000:53723 USPATFULL

TITLE: Self-assembling heteropolymetallic chelates as imaging agents and radiopharmaceuticals

INVENTOR(S): Desreux, Jean F., 11 Allee des Rouges-gorges, B-4031, Angleur, Belgium
 Jacques, Vincent, 46/1 Rue Principale, B-4347, Fexhe-Le-Haut-Clocher, Belgium
 Humblet, Valerie, 8 Clos des Mesanges, B-4300, Waremmes, Belgium
 Hermann, Martine, 68 Rue abbe Toussaint, B-4980 Ovifat, Belgium
 Comblin-Tholet, Vinciane, 78 Rue des Hineux, B-4040 Herstal, Belgium
 Tweedle, Michael F., 72 Library Pl., Princeton, NJ, United States 08540

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6056939		20000502 <--
APPLICATION INFO.:	US 1998-141710		19980828 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Dees, Jose' G.		
ASSISTANT EXAMINER:	Jones, Dameron		
LEGAL REPRESENTATIVE:	Balogh, Imre		
NUMBER OF CLAIMS:	33		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	9 Drawing Figure(s); 8 Drawing Page(s)		
LINE COUNT:	1319		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Metal complexes of new ligands of the formula ##STR1## are useful as agents for medical imaging, particularly MRI, for in vitro or in vivo diagnostic or as radiopharmaceuticals. In these compounds, X--R.sup.1 --Y is a coordinating group able to form a highly stable complex with metal ions. Suitable units are for example derivatives of ortho-phenanthroline or of an hydroxamic acid. R.sup.2 and R.sup.3 are reactive functions such as amines or carboxylic groups. R.sup.4 and R.sup.5 are ligands, for instance diethylenetriaminepentaacetic acid 1,4,7,10-tetraacetic acid (DTPA), 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) or 1,4,8,11-tetraazacyclotetradecane-N, N', N''-tetraacetic acid (TETA), of a different type than the X--R.sup.1 --Y units and able to strongly encapsulate metal ions with which the X--R.sup.1 --Y moieties form less stable chelates. Stable high molecular weight multimetallic entities are spontaneously formed by these ligands that spontaneously associate around metal ions through the X--R.sup.1 --Y units. Higher relaxivities thus are achieved. Mixed-complexes containing two different radionuclides are also obtained thus allowing imaging and therapy with one single chelate.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 265655-41-2P

(prepn. as imaging agent when complexed with transition metal)


RN 265655-41-2 USPATFULL

CN Gadolate(2-), [.mu.-[.alpha.-[2-[4-[[[3-[2-[[[4-[3-(carboxy-.kappa.O)-3-[4,7,10-tris[(carboxy-.kappa.O)methyl]-1,4,7,10-tetraazacyclododec-1-yl-.kappa.N1,.kappa.N4,.kappa.N7,.kappa.N10]propyl]phenyl]amino]thioxomethyl]amino]ethyl]hydroxyamino]-3-oxopropyl]amino]thioxomethyl]amino]phenyl]ethyl]-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetato(8-)-.kappa.N1,.kappa.N4,.kappa.N7,.kappa.N10,.kappa.O1,.kappa.O4,.kappa.O7,.kappa.O10]]di-, dihydrogen (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



PAGE 2-A

● 2 H⁺

L6 ANSWER 32 OF 357 USPATFULL on STN
 ACCESSION NUMBER: 2000:26707 USPATFULL
 TITLE: Apparatus for reducing the axle load of a multi-axle
 movable telescopic crane
 INVENTOR(S): Irsch, Michael, Lebach, Germany, Federal Republic of
 PATENT ASSIGNEE(S): Mannesmann AG, Dusseldorf, Germany, Federal Republic of

(non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6032809		20000307	<--
APPLICATION INFO.:	US 1998-79732		19980515	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1997-19721865	19970516
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Brahan, Thomas J.	
LEGAL REPRESENTATIVE:	Cohen, Pontani, Lieberman & Pavane	
NUMBER OF CLAIMS:	12	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	13 Drawing Figure(s); 4 Drawing Page(s)	
LINE COUNT:	353	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An apparatus for reducing the axle load of a multi-axle movable crane which includes a truck; a superstructure rotatably mounted on the truck; a main jib including a basic jib and at least one telescopic section, the basic jib having a plurality of rollers fastened in operative connection, the main jib being releasably fastened to the superstructure; and a semitrailer having a front end and a back end with a loading area, a first ramp-like beam and a second ramp-like beam arranged in a longitudinal direction of the semitrailer in the loading area so as to be parallel to and at a distance from one another, each ramp-like beam having a top edge and a contoured runway disposed along the top edge, the rollers being configured to the contour of the runway and operable to transport the main jib from the superstructure to the semitrailer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 245462-74-2P

(peptidomimetic antagonists for treatment of CD11/CD18 adhesion receptor-mediated disorders)

RN 245462-74-2 USPTAFULL

CN L-Alanine, N-[2-chloro-4-[[[(3-hydroxyphenyl)methyl]amino]carbonyl]benzoyl]-3-[[[2-(1-methylethyl)phenyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 33 OF 357 USPTAFULL on STN
 ACCESSION NUMBER: 2000:24515 USPTAFULL
 TITLE: Liver function test

10/019,652

INVENTOR(S): Mills, Charles Oswald, Birmingham, United Kingdom
PATENT ASSIGNEE(S): Norgine Limited, United Kingdom (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6030841		20000229	<--
APPLICATION INFO.:	US 1998-32325		19980227	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1997-16962	19970812
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Snay, Jeffrey	
LEGAL REPRESENTATIVE:	Cantor Colburn LLP	
NUMBER OF CLAIMS:	13	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Figure(s); 1 Drawing Page(s)	
LINE COUNT:	373	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method for the determination of liver function, comprises the steps of:

(i)introducing an effective amount of a coloured or fluorescent bile acid derivative intravenously into a patient,

(ii)collecting samples of blood which has passed through the liver of the patient at timed intervals after step (i), and

(iii)assessing the colour or fluorescence of bile acid derivative in each sample.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 140616-46-2

(liver function test using colored or fluorescent derivs. of bile acids)


RN 140616-46-2 USPATFULL

CN L-Lysine, N6-[[[(3',6'-dihydroxy-3-oxospiro[isobenzofuran-1(3H),9'-[9H]xanthen]-5-yl)amino]thioxomethyl]-N2-[(3.alpha.,5.beta.,7.alpha.,12.alpha.)-3,7,12-trihydroxy-24-oxocholan-24-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A

HO—



PAGE 1-B



L6 ANSWER 34 OF 357 USPATFULL on STN
ACCESSION NUMBER: 2000:21575 USPATFULL
TITLE: Substituted quinolone derivatives and pharmaceuticals
containing the same
INVENTOR(S): Sada, Yoshihisa, Narita, Japan
Adegawa, Shigeru, Narita, Japan
Mogi, Kinichi, Narita, Japan
Honda, Haruyoshi, Tomisato-machi, Japan
Eto, Hiromichi, Narita, Japan
Morimoto, Shinichi, Sakura, Japan
Okawa, Junji, Tomisato-machi, Japan
Umehara, Norimitsu, Tokorozawa, Japan
Sato, Susumu, Narita, Japan
PATENT ASSIGNEE(S): SSP Co., Ltd., Tokyo, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE	
	-----	-----	-----	
PATENT INFORMATION:	US 6028081		20000222	<--

APPLICATION INFO.: US 1998-141374 19980827 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1997-234547	19970829
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Seaman, D. Margaret	
LEGAL REPRESENTATIVE:	Oblon, Spivak, McClelland, Maier & Neustadt, P.C.	
NUMBER OF CLAIMS:	5	
EXEMPLARY CLAIM:	1	
LINE COUNT:	878	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Substituted quinolone derivatives represented by the following formula:
 ##STR1## wherein R.sup.1 represents a substituted or unsubstituted
 (hetero)aryl group, R.sup.2 represents H or an alkoxycarbonyl,
 substituted aminocarbonyl, cyano or like group, and R.sup.3 and R.sup.4
 each independently represent H or a substituted alkyl, aryl, amino or
 like group, and salts thereof; pharmaceuticals containing the same.
 These derivatives and salts have excellent anti-ulcer activities.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 220866-27-3P

(prepn. and anti-ulcer activity of substituted quinolone derivs.)

RN 220866-27-3 USPATFULL

CN 3-Quinolonecarboxylic acid, 1,2-dihydro-2-oxo-1-phenyl-4-[[2-
 [(phenylamino)carbonyl]amino]ethyl]amino]-, ethyl ester (9CI) (CA
 INDEX NAME)



L6 ANSWER 35 OF 357 USPATFULL on STN
 ACCESSION NUMBER: 2000:21524 USPATFULL
 TITLE: Thermal sensitive recording medium
 INVENTOR(S): Nakano, Tomoyuki, Kita-ku, Japan
 Yanai, Koichi, Kita-ku, Japan
 Seki, Junko, Kita-ku, Japan
 Ohashi, Reiji, Kita-ku, Japan
 Yoshioka, Hidetoshi, Kita-ku, Japan
 PATENT ASSIGNEE(S): Nippon Paper Industrie Co., Ltd., Tokyo, Japan
 (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6028030		20000222 <--
APPLICATION INFO.:	US 1998-34402		19980304 (9)

NUMBER	DATE

10/019,652

PRIORITY INFORMATION: JP 1997-52133 19970306
JP 1997-220530 19970815

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Hess, Bruce
NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 1
LINE COUNT: 1308

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A thermal sensitive recording medium which further contains poly urea compound in the thermal color developing layer containing dye precursor and color developer, which displays an excellent image preservative stability. Said poly urea compound contains units of a structure represented by general formula (1), and further contains a repeating unit represented by general formulae (2).about.(7). ##STR1## In these formulae A.sup.1 .about.A.sup.7 are a divalent group, R.sup.1 .about.R.sup.5 are an alkyl group, an alkoxy group or an electron accepting group, o, p, and q are an integer from 0 to 4, r is an integer from 2 to 12 and s and t are an integer from 0 to 8.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **24936-18-3**

(heat-sensitive color-developing materials for thermal printing contg.)

RN 24936-18-3 USPATFULL

CN Poly(iminocarbonylimino-1,5-naphthalenediyliminocarbonylimino-1,6-hexanediyl) (9CI) (CA INDEX NAME)



L6 ANSWER 36 OF 357 USPATFULL on STN

ACCESSION NUMBER: 2000:15676 USPATFULL

TITLE: Guanylhydrazones and their use to treat inflammatory conditions

INVENTOR(S): Bianchi, Marina, Milan, Italy
Cerami, Anthony, Shelter Island, NY, United States
Tracey, Kevin J., Old Greenwich, CT, United States
Ulrich, Peter, Old Tappan, NJ, United States

PATENT ASSIGNEE(S): The Picower Institute for Medical Research, Manhasset, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6022900		20000208	<--
APPLICATION INFO.:	US 1995-471919		19950606	(8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1995-463568, filed on 5 Jun			

1995 which is a continuation-in-part of Ser. No. US 1994-315170, filed on 29 Sep 1994, now patented, Pat. No. US 5599984 which is a continuation-in-part of Ser. No. US 1994-184540, filed on 21 Jan 1994, now abandoned

DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Kumar, Shailendra
 LEGAL REPRESENTATIVE: Oster, Jeffrey B.
 NUMBER OF CLAIMS: 3
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 31 Drawing Figure(s); 23 Drawing Page(s)
 LINE COUNT: 2140

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention concerns new methods and compositions that are useful in preventing and ameliorating cachexia, the clinical syndrome of poor nutritional status and bodily wasting associated with cancer and other chronic diseases. More particularly, the invention relates to aromatic guanylhydrazone (more properly termed amidinohydrazone) compositions and their use to inhibit the uptake of arginine by macrophages and/or its conversion to urea. These compositions and methods are also useful in preventing the generation of nitric oxide (NO) by cells, and so to prevent NO-mediated inflammation and other responses in persons in need of same. In another embodiment, the compounds can be used to inhibit arginine uptake in arginine-dependent tumors and infections.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 169764-76-5P

(guanylhydrazones and their prepn. for treating cachexia and inflammatory conditions)

RN 169764-76-5 USPATFULL

CN Urea, N,N'-(2-methyl-1,5-pentanediy)bis[N'-(3,5-diacetylphenyl)- (9CI)
 (CA INDEX NAME)



L6 ANSWER 37 OF 357 USPATFULL on STN
 ACCESSION NUMBER: 2000:12812 USPATFULL
 TITLE: Constrained somatostatin agonists and antagonists
 INVENTOR(S): Ankersen, Michael, Frederiksberg, Denmark
 Dorwald, Florenzio Zaragoza, Herlev, Denmark
 Stidsen, Carsten Enggaard, Soborg, Denmark
 Crider, Albert Michael, Monroe, LA, United States
 PATENT ASSIGNEE(S): Novo Nordisk A/S, Bagsvaerd, Denmark (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6020349		20000201	<--
APPLICATION INFO.:	US 1997-962098		19971031	(8)

NUMBER	DATE
-----	-----

PRIORITY INFORMATION: DK 1996-1216 19961031
 DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Kumar, Shailendra
 LEGAL REPRESENTATIVE: Zelson, Steve T., Lambiris, Elias J.
 NUMBER OF CLAIMS: 20
 EXEMPLARY CLAIM: 1
 LINE COUNT: 959

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a compound of general formula I
 ##STR1## for treating medical disorders related to binding to human
 somatostatin receptor subtypes.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 207276-72-0P

(prepn. of thiourea derivs. and related compds. as constrained
 somatostatin agonists and antagonists)

RN 207276-72-0 USPATFULL

CN Thiourea, N-1H-benzotriazol-5-yl-N'-[2-[(5-bromo-2-pyridinyl)[(3,4-
 dichlorophenyl)methyl]amino]ethyl]- (9CI) (CA INDEX NAME)



L6 ANSWER 38 OF 357 USPATFULL on STN
 ACCESSION NUMBER: 1999:170647 USPATFULL
 TITLE: Guanylhydrazones and their use to treat inflammatory
 conditions
 INVENTOR(S): Bianchi, Marina, Milan, Italy
 Cerami, Anthony, Shelter Island, NY, United States
 Tracey, Kevin J., Old Greenwich, CT, United States
 Ulrich, Peter, Old Tappan, NJ, United States
 PATENT ASSIGNEE(S): The Picower Institute for Medical Research, Manhasset,
 NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6008255		19991228 <--
APPLICATION INFO.:	US 1995-471305		19950606 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1995-463568, filed on 5 Jun 1995 which is a continuation-in-part of Ser. No. US 1994-315170, filed on 29 Sep 1994, now patented, Pat. No. US 5599984 which is a continuation-in-part of Ser. No. US 1994-184540, filed on 21 Jan 1994, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Kumar, Shailendra		
LEGAL REPRESENTATIVE:	Oster, Jeffrey B.		
NUMBER OF CLAIMS:	6		

EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 31 Drawing Figure(s); 23 Drawing Page(s)
 LINE COUNT: 2096
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention concerns new methods and compositions that are useful in preventing and ameliorating cachexia, the clinical syndrome of poor nutritional status and bodily wasting associated with cancer and other chronic diseases. More particularly, the invention relates to aromatic guanylhyazone (more properly termed amidinohyazone) compositions and their use to inhibit the uptake of arginine by macrophages and/or its conversion to urea. These compositions and methods are also useful in preventing the generation of nitric oxide (NO) by cells, and so to prevent NO-mediated inflammation and other responses in persons in need of same. In another embodiment, the compounds can be used to inhibit arginine uptake in arginine-dependent tumors and infections.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 169764-76-5P

(guanylhyazones and their prepn. for treating cachexia and inflammatory conditions)

RN 169764-76-5 USPATFULL

CN Urea, N,N'-(2-methyl-1,5-pentanediy)bis[N'-(3,5-diacetylphenyl)- (9CI)
 (CA INDEX NAME)



L6 ANSWER 39 OF 357 USPATFULL on STN
 ACCESSION NUMBER: 1999:170621 USPATFULL
 TITLE: Heterocyclic compounds as bradykinin antagonists
 INVENTOR(S): Oku, Teruo, Tsukuba, Japan
 Kayakiri, Hiroshi, Tsukuba, Japan
 Abe, Yoshito, Ibaraki, Japan
 Sawada, Yuki, Tsukuba, Japan
 Mizutani, Tsuyoshi, Tsukuba, Japan
 PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Osaka, Japan
 (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6008229		19991228 <--
	WO 9711069		19970327 <--
	US 1998-29852		19980313 (9)
APPLICATION INFO.:	WO 1996-JP2669		19960918
			19980313 PCT 371 date
			19980313 PCT 102(e) date
PRIORITY INFORMATION:	GB 1995-19077		19950918
	DOCUMENT TYPE:		Utility
	FILE SEGMENT:		Granted
	PRIMARY EXAMINER:		Mach, D. Margaret

10/019,652

LEGAL REPRESENTATIVE: Oblon, Spivak, McClelland, Maier & Neustadt, P.C.

NUMBER OF CLAIMS: 8

EXEMPLARY CLAIM: 1

LINE COUNT: 3619

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to a compound of formula (I) wherein A^{sup.1} is lower alkylene, R^{sup.1} is substituted quinolyl, etc., R^{sup.2} is hydrogen, halogen or lower alkyl, R^{sup.3} is halogen or lower alkyl, and R^{sup.4} is a group of the formula: -Q-A^{sup.2}-R^{sup.5}, etc., in which R^{sup.5} is amino, acylamino, etc., A^{sup.2} is lower alkylene or a single bond, and Q is a group of formula (a), and pharmaceutically acceptable salts thereof, to processes for preparation thereof, to a pharmaceutical composition comprising the same, and to methods of using the same therapeutically in the prevention and/or the treatment of bradykinin or its analogues mediated diseases in human being or animals. ##STR1##


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 189267-79-6P

(prepn. of N-[(heteroaryloxy)alkylphenyl]-2-(acylaminoalkyl)pyrroles and analogs as bradykinin antagonists)

RN 189267-79-6 USPATFULL

CN Benzamide, 2,4-dichloro-N-methyl-N-[2-[[[4-[(methylamino)carbonyl]phenyl]amino]carbonyl]amino]ethyl]-3-[[2-methyl-8-quinolinyloxy]methyl]- (9CI) (CA INDEX NAME)



L6 ANSWER 40 OF 357 USPATFULL on STN

ACCESSION NUMBER: 1999:146773 USPATFULL

TITLE: Metal chelates as pharmaceutical imaging agents, processes of making such and uses thereof

INVENTOR(S): Marzilli, Luigi G., Atlanta, GA, United States
Lipowska, Malgorzata, Decatur, GA, United States
Hansen, Lory, Atlanta, GA, United States
Taylor, Jr., Andrew, Atlanta, GA, United States

PATENT ASSIGNEE(S): Emory University, Atlanta, GA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5986074		19991116	<--
APPLICATION INFO.:	US 1997-993219		19971218	(8)

10/019,652

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1996-643413, filed
on 6 May 1996, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Gonzalez, Porfirio Nazario
LEGAL REPRESENTATIVE: Greenlee, Winner and Sullivan, P.C.
NUMBER OF CLAIMS: 14
EXEMPLARY CLAIM: 1,9,12
NUMBER OF DRAWINGS: 14 Drawing Figure(s); 14 Drawing Page(s)
LINE COUNT: 1504
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel metal chelates, exemplified as
technetium-99m or rhenium chelates, and to the process of preparing such
metal chelates from corresponding ligands. These ligands and their
corresponding metal chelates are synthesized to have a cysteinylethylene
(EC) structure, a monothiourea (MTU) structure, or a dithiourea (DTU)
structure. The present invention further relates to a pharmaceutical
composition comprising a metal chelate, for example, a .sup.99m
Tc-chelate, to the use of the composition for renal imaging and
examination of renal function, and to a kit for preparing such a
composition prior to use.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 52420-78-7P

(prepn. and chelation with 99mTc, Re or other metals to give potential
pharmaceutical imaging agents)

RN 52420-78-7 USPATFULL

CN Thiourea, N,N''-1,3-propanediylbis[N'-phenyl- (9CI) (CA INDEX NAME)



L6 ANSWER 41 OF 357 USPATFULL on STN

ACCESSION NUMBER: 1999:141971 USPATFULL

TITLE: Water-soluble derivatives of paclitaxel, method for
producing same and uses thereof

INVENTOR(S): Page, Michel, Quebec, Canada
Paradis, Renee, Quebec, Canada
Bicamumpaka, Cyrille, Quebec, Canada

PATENT ASSIGNEE(S): Universite Laval, Quebec, Canada (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5981564		19991109	<--
APPLICATION INFO.:	US 1998-108585		19980701	(9)
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	Granted			
PRIMARY EXAMINER:	Richter, Johann			
ASSISTANT EXAMINER:	Solola, Taofiq A.			
LEGAL REPRESENTATIVE:	Klauber & Jackson			
NUMBER OF CLAIMS:	19			
EXEMPLARY CLAIM:	1			
NUMBER OF DRAWINGS:	14 Drawing Figure(s); 12 Drawing Page(s)			
LINE COUNT:	974			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to new paclitaxel derivatives showing an increased

solubility in water. More particularly, the invention relates to glutarylpaclitaxel, glutarylpaclitaxel 6-aminohexanol glucuronide and to different amino acid derivatives of the glutarylpaclitaxel, all of which possess the cytotoxicity activity of the parent compound, paclitaxel. Also disclosed are fluorescent derivatives of paclitaxel for determining a concentration of paclitaxel in a medium or for detecting apoptotic cancer cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **219474-45-0P**


(synthesis and cytotoxicity of water-sol. derivs. of paclitaxel)


RN 219474-45-0 USPTAFULL

CN Benzenepropanoic acid, .beta.-(benzoylamino)-.alpha.-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-4-[[5-[[6-[[[(3',6'-dihydroxy-3-oxospiro[isobenzofuran-1(3H),9'-[9H]xanthen]-5-yl)amino]thioxomethyl]amino]hexyl]amino]-1,5-dioxopentyl]oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-11-hydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (.alpha.R,.beta.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





L6 ANSWER 42 OF 357 USPATFULL on STN
 ACCESSION NUMBER: 1999:137447 USPATFULL
 TITLE: Activated peptides and conjugates
 INVENTOR(S): Annunziato, Michael E., Mansfield, MA, United States
 Palumbo, Paul S., West Newton, MA, United States
 PATENT ASSIGNEE(S): Dade Behring Marburg GmbH, Marburg, Germany, Federal
 Republic of (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5977299		19991102	<--
APPLICATION INFO.:	US 1997-833546		19970407	(8)
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	Granted			
PRIMARY EXAMINER:	MacMillan, Keith D.			
ASSISTANT EXAMINER:	Wessendorf, T. D.			
LEGAL REPRESENTATIVE:	Buchanan, Robert L			
NUMBER OF CLAIMS:	23			
EXEMPLARY CLAIM:	1			
LINE COUNT:	483			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel activated peptides and conjugates thereof, useful in diagnostic assays and therapeutics, and processes for the preparation thereof are disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **214467-78-4P**


(prepn. of activated peptides and conjugates)

RN 214467-78-4 USPATFULL


CN L-Arginine, N2-[[[4-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)phenyl]amino]carbonyl]-L-lysyl-L-isoleucyl-L-.alpha.-glutamyl-L-prolyl-L-leucylglycyl-L-valyl-L-alanyl-L-prolyl-L-threonyl-L-lysyl-L-alanyl-L-lysyl-L-arginyl-L-arginyl-L-valyl-L-valyl-L-glutamyl-L-arginyl-L-.alpha.-glutamyl-L-lysyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B



PAGE 1-C




PAGE 2-A



PAGE 2-B

—NH₂

PAGE 3-A



L6 ANSWER 43 OF 357 USPATFULL on STN
 ACCESSION NUMBER: 1999:124931 USPATFULL
 TITLE: 2-Imidazolinylamino heterocyclic compounds useful as

10/019,652

INVENTOR(S): alpha-2 adrenoceptor agonists
Maurer, Peter J., Cincinnati, OH, United States
Ares, Jeffrey J., Hamilton, OH, United States
Seibel, William L., Hamilton, OH, United States
Walker, Daniel P., Bloomington, IN, United States
Sheldon, Russell James, Fairfield, OH, United States
Henry, Raymond T., Pleasant Plain, OH, United States
PATENT ASSIGNEE(S): The Procter & Gamble Company, Cincinnati, OH, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5965595		19991012 <--
APPLICATION INFO.:	US 1996-756085		19961125 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1995-478708, filed on 7 Jun 1995, now patented, Pat. No. US 5663189 which is a continuation-in-part of Ser. No. US 1993-86482, filed on 1 Jul 1993, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Goldberg, Jerome D.		
LEGAL REPRESENTATIVE:	Kellerman, James C., Roof, Carl J., Suter, David L.		
NUMBER OF CLAIMS:	19		
EXEMPLARY CLAIM:	2		
LINE COUNT:	1891		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The subject invention relates to compounds having the structure:
##STR1## wherein (a) n is an integer from 1 to about 3;

(b) X and Y are each independently selected from O, S and CH.sub.2, with at least one of X and Y being O or S;

(c) R is unsubstituted, straight or branched chain alkanyl or alkanoxy having from 1 to about 3 non-hydrogen atoms; and

(d) R' is selected from hydrogen, methyl, cyano, and halo;

pharmaceutical compositions containing such compounds; and the use of such compounds for preventing or treating of disorders modulated by alpha-2 adrenoceptors.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 196091-23-3P

(prepn. of 2-Imidazolinylamino heterocyclic compds. as
.alpha.2-adrenoceptor agonists)

RN 196091-23-3 USPATFULL

CN Thiourea, N-(2-aminoethyl)-N'-(2,3-dihydro-5-methyl-1,4-benzodioxin-6-yl)-
(9CI) (CA INDEX NAME)



L6 ANSWER 44 OF 357 USPATFULL on STN

10/019,652

ACCESSION NUMBER: 1999:124895 USPATFULL
TITLE: Aminoheterocyclic derivatives as antithrombotic or
anticoagulant
INVENTOR(S): Faull, Alan Wellington, MacClesfield, United Kingdom
Stocker, Andrew, MacClesfield, United Kingdom
Mayo, Colette Marie, MacClesfield, United Kingdom
Preston, John, Knutsford, United Kingdom
PATENT ASSIGNEE(S): Zeneca Limited, London, United Kingdom (non-U.S.
corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5965559		19991012	<--
	WO 9610022		19960404	<--
APPLICATION INFO.:	US 1997-817031		19970326	(8)
	WO 1995-GB2285		19950925	
			19970326	PCT 371 date
			19970326	PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1994-19341	19940926
	GB 1994-25789	19941221
	GB 1995-11051	19950601
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Shah, Mukund J.	
ASSISTANT EXAMINER:	Coleman, Brenda	
LEGAL REPRESENTATIVE:	Cushman Darby & Cushman Intellectual Property Group of Pillsbury Madison & Sutro, LLP	
NUMBER OF CLAIMS:	23	
EXEMPLARY CLAIM:	1	
LINE COUNT:	5087	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention concerns compounds of formula (I), wherein each of
G.sup.1, G.sup.2 and G.sup.6 is CH or n; m is 1 or 2; R.sup.1 includes
hydrogen, halogeno and (1-4C)alkyl; M.sup.1 is a group of formula:
NR.sup.2 -L.sup.1 -T.sup.1 R.sup.3, in which R.sup.2 and R.sup.3
together form a (1-4C)alkylene group, L.sup.1 includes (1-4C)alkylene,
and T.sup.1 is CH or N; A may be a direct link; M.sup.2 is a group of
the formula: (T.sup.2 R.sup.4).sub.r -L.sup.2 T.sup.3 R.sup.5 in which R
is 0 or 1, each of T.sup.2 and T.sup.3 is CH or N, each of R.sup.4 and
R.sup.5 is hydrogen or (1-4C)alkyl, or R.sup.4 and R.sup.5 together form
a (1-4C)alkylene group, and L.sup.2 includes (1-4C)alkylene; M.sup.3 may
be a direct link to X; X includes sulphonyl; and Q includes naphthyl and
a heterocycle moiety; or a pharmaceutically-acceptable salt thereof;
processes for their preparation, pharmaceutical compositions containing
them and their use as antithrombotic or anticoagulant agents.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 179049-75-3P

(prepn. of aminoheterocyclic derivs. as antithrombotic or anticoagulant
agents)

RN 179049-75-3 USPATFULL

CN 4-Piperidinecarboxamide, N-[2-[[[(4-methylphenyl)amino]carbonyl]amino]-3-
oxo-3-(1-piperidinyl)propyl]-1-(4-pyridinyl)- (9CI) (CA INDEX NAME)



L6 ANSWER 45 OF 357 USPATFULL on STN
 ACCESSION NUMBER: 1999:124468 USPATFULL
 TITLE: Delivery of diagnostic and therapeutic agents to a target site
 INVENTOR(S): Griffiths, Gary L., Morristown, NJ, United States
 Hansen, Hans J., Mystic Island, NJ, United States
 Govindan, Serengulam V., Summit, NJ, United States
 Karacay, Habibe, Clifton, NJ, United States
 PATENT ASSIGNEE(S): Immunomedics, Inc., Morris Plains, NJ, United States
 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5965131		19991012 <--
APPLICATION INFO.:	US 1996-731107		19961009 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1995-486166, filed on 7 Jun 1995, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Hutzell, Paula K.		
ASSISTANT EXAMINER:	Worrall, Timothy A.		
LEGAL REPRESENTATIVE:	Foley & Lardner		
NUMBER OF CLAIMS:	26		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1379		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An improvement in in vivo pretargeting methods for delivering diagnostic or therapeutic agents to a target site in a mammal uses a clearing agent that binds to the target-binding site of the targeting species, whereby non-bound primary targeting species is cleared from circulation but the clearing agent does not remove the bound primary targeting species. Anti-idiotypic antibodies and antibody fragments are preferred clearing agents. Fast clearance is achieved by glycosylating the clearing agent with sugar residues that bind to the hepatic asialoglycoprotein receptor.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 245758-35-4P

(delivery of diagnostic and therapeutic agents to a target site)


RN 245758-35-4 USPATFULL

10/019,652

CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, N-[5-[[[4-[2-[acetyl[2-(diacetylamino)ethyl]amino]-3-(diacetylamino)propyl]phenyl]amino]thioxomethyl]amino]pentyl]hexahydro-2-oxo-, (3aS,4S,6aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—NAc2

—NAc2

L6 ANSWER 46 OF 357 USPATFULL on STN
ACCESSION NUMBER: 1999:113341 USPATFULL
TITLE: Metal chelates as pharmaceutical imaging agents, processes of making such and uses thereof
INVENTOR(S): Marzilli, Luigi Gaetano, Atlanta, GA, United States
Lipowska, Malgorzata, Decatur, GA, United States
Hansen, Lory, Atlanta, GA, United States
Taylor, Jr., Andrew, Atlanta, GA, United States
PATENT ASSIGNEE(S): Emory University, Atlanta, GA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5955053		19990921	<--
APPLICATION INFO.:	US 1996-643413		19960506	(8)
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	Granted			
PRIMARY EXAMINER:	Nazario-Gonzalez, Porfirio			
LEGAL REPRESENTATIVE:	Greenlee, Winner and Sullivan, P.C.			
NUMBER OF CLAIMS:	16			
EXEMPLARY CLAIM:	1,9,12			
LINE COUNT:	1371			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel metal chelates, exemplified as technetium-99m or rhenium chelates, and to the process of preparing such metal chelates from corresponding ligands. These ligands and their corresponding metal chelates are synthesized to have a cysteinylethylene (EC) structure, a thioacetamidethiourea (TATU) structure, or a dithiourea (DTU) structure. The present invention further relates to a pharmaceutical composition comprising a metal chelate, for example, a

.sup.99m Tc-chelate, to the use of the composition for renal imaging and examination of renal function, and to a kit for preparing such a composition prior to use.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **52420-78-7P**

(prepn. and chelation with rhenium oxo complex)

RN 52420-78-7 USPATFULL

CN Thiourea, N,N''-1,3-propanediylbis[N'-phenyl- (9CI) (CA INDEX NAME)



L6 ANSWER 47 OF 357 USPATFULL on STN

ACCESSION NUMBER: 1999:110177 USPATFULL

TITLE: Topiramate immunoassay

INVENTOR(S): Stenglein, Kenneth J., Portland, OR, United States

Cawley, Daniel B., Beaverton, OR, United States

Maryanoff, Bruce E., New Hope, PA, United States

Sorgi, Kirk L., Blue Bell, PA, United States

PATENT ASSIGNEE(S): Oxis International, Inc., Portland, OR, United States
(U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5952187		19990914	<--
APPLICATION INFO.:	US 1995-565143		19951201	(8)
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	Granted			
PRIMARY EXAMINER:	Ceperley, Mary E.			
LEGAL REPRESENTATIVE:	Klauber & Jackson			
NUMBER OF CLAIMS:	37			
EXEMPLARY CLAIM:	18			
LINE COUNT:	1584			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a topiramate immunoassay and reagents for use in the immunoassay. In particular, topiramate is derivatized at the sulfamate moiety or the 9-carbon or 10-carbon methyl group of topiramate to add a label bound directly or through a linking group for use as a tracer (competitive analyte analog) or to add a linking group bound to a carrier for use as an immunogen to induce anti-topiramate antibodies. Immunoassay methods and kits are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **192135-65-2P**

(analog and antibodies for topiramate immunoassay in body fluids)


RN 192135-65-2 USPATFULL

CN .beta.-D-Fructopyranose, 2,3:4,5-bis-O-(1-methylethylidene)-,
[2-[[2-[[[(3',6'-dihydroxy-3-oxospiro[isobenzofuran-1(3H),9'-
[9H]xanthen]-5-yl)amino]thioxomethyl]amino]ethyl]amino]-2-
oxoethyl]sulfamate (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A

HO



PAGE 1-B



L6 ANSWER 48 OF 357 USPATFULL on STN
 ACCESSION NUMBER: 1999:92643 USPATFULL
 TITLE: Compositions and methods for stimulating amyloid removal in amyloidogenic diseases using advanced glycosylation endproducts
 INVENTOR(S): Vitek, Michael P., East Norwich, NY, United States
 Cerami, Anthony, Shelter Island, NY, United States
 Bucala, Richard J., New York, NY, United States
 Ulrich, Peter C., Old Tappan, NJ, United States
 Vlassara, Helen, Shelter Island, NJ, United States
 Zhang, Xini, Jericho, NJ, United States
 PATENT ASSIGNEE(S): The Picower Institute For Medical Research, Manhasset, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5935927		19990810	<--
	WO 9520979		19950810	<--
APPLICATION INFO.:	US 1996-501127		19960810	(8)
	WO 1995-US1380		19950202	

19960810 PCT 371 date
19960810 PCT 102(e) date

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1994-311768, filed on 23 Sep 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-191579, filed on 3 Feb 1994, now abandoned

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Duffy, Patricia A.
LEGAL REPRESENTATIVE: Klauber & Jackson
NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 12 Drawing Figure(s); 8 Drawing Page(s)
LINE COUNT: 2154

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates generally to methods and compositions for treating amyloidogenic diseases such as Alzheimer's disease and the development of type II diabetes, in which deposition of amyloid in organs such as the brain and pancreas interfere with neurological function and insulin release, respectively. The methods and compositions are directed toward increasing the activity of scavenger cells within the body at recognizing and removing amyloid deposits from affected tissues and organs. Scavenger cells may be targeted to amyloid deposits by means of spontaneously-occurring chemical modifications called advanced glycosylation endproducts (AGEs). Compositions are described which increase scavenger cell activity towards AGE-modified amyloid. Amyloid removal may also be enhanced by increasing AGE levels in amyloid deposits within the body by administering AGE-modified amyloid targeting agents, which after becoming situated at sites containing amyloid, subsequently attract scavenger cells to degrade attendant amyloid. These methods and associated compositions result in a decrease in the extent of amyloid deposits in tissues, reducing the attendant pathology.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **169553-13-3P**

(prepn. and reaction; advanced glycosylation end-products for amyloid removal stimulation in amyloidogenic diseases)

RN 169553-13-3 USPATFULL

CN Urea, N-(6-aminohexyl)-N'-[4-(6-methyl-2-benzothiazolyl)phenyl]- (9CI)
(CA INDEX NAME)



L6 ANSWER 49 OF 357 USPATFULL on STN

ACCESSION NUMBER: 1999:72592 USPATFULL

TITLE: 7-(2-imidazolinylamino)quinoline compounds useful as alpha-2 adrenoceptor agonists

INVENTOR(S): Cupps, Thomas Lee, Oxford, OH, United States
Bogdan, Sophie E., Maineville, OH, United States
Henry, Raymond T., Pleasant Plain, OH, United States
Sheldon, Russell James, Fairfield, OH, United States

PATENT ASSIGNEE(S): The Procter & Gamble Company, Cincinnati, OH, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5916900		19990629 <--
APPLICATION INFO.:	US 1996-758118		19961125 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1995-496796, filed on 29 Jun 1995, now patented, Pat. No. US 5716966		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Fay, Zohreh		
LEGAL REPRESENTATIVE:	Kellerman, James C., Graff, Milton B., Suter, David L.		
NUMBER OF CLAIMS:	8		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1627		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention involves the use of compounds having the following structure: ##STR1## wherein: (a) R is unsubstituted C.sub.1 -C.sub.3 alkanyl or alkenyl; and

(b) R' is selected from hydrogen; unsubstituted C.sub.1 -C.sub.3 alkanyl or alkenyl; unsubstituted C.sub.1 -C.sub.3 alkylthio or alkoxy; hydroxy; thiol; cyano; and halo;

for preventing or treating of disorders modulated by alpha-2 adrenoceptors.

The subject invention also involves novel compounds and compositions.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **168770-36-3P**

(prepn. of (imidazolinylamino)quinolines as alpha-2 adrenoceptor agonists)

RN 168770-36-3 USPATFULL

CN Thiourea, N-(2-aminoethyl)-N'-(5-cyano-8-methyl-7-quinolinyl)- (9CI) (CA INDEX NAME)



L6 ANSWER 50 OF 357 USPATFULL on STN

ACCESSION NUMBER: 1999:69731 USPATFULL

TITLE: 2-imidazolinylamino heterocyclic compounds useful as alpha-2 adrenoceptor agonists

INVENTOR(S): Maurer, Peter J., Cincinnati, OH, United States
Ares, Jeffrey J., Hamilton, OH, United States
Seibel, William L., Hamilton, OH, United States
Walker, Daniel P., Bloomington, OH, United States
Sheldon, Russell James, Fairfield, OH, United States
Henry, Raymond T., Pleasant Plain, OH, United States

10/019,652

PATENT ASSIGNEE(S): The Procter & Gamble Company, Cincinnati, OH, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5914342		19990622 <--
APPLICATION INFO.:	US 1998-159698		19980924 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1996-756085, filed on 25 Nov 1996 which is a continuation-in-part of Ser. No. US 1995-478708, filed on 7 Jun 1995, now patented, Pat. No. US 5663189		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Goldberg, Jerome D.		
LEGAL REPRESENTATIVE:	Kellerman, James C., Roof, Carl J., Graff, Milton B.		
NUMBER OF CLAIMS:	20		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1872		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The subject invention relates to compounds having the structure:
##STR1## wherein (a) n is an integer from 1 to about 3;

(b) X and Y are each independently selected from O, S and CH.sub.2, with at least one of X and Y being O or S;

(c) R is unsubstituted, straight or branched chain alkanyl or alkanoxy having from 1 to about 3 non-hydrogen atoms; and

(d) R' is selected from hydrogen, methyl, cyano, and halo;
pharmaceutical compositions containing such compounds; and the use of such compounds for preventing or treating of disorders modulated by alpha-2 adrenoceptors.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 196091-23-3P

(prepn. of (imidazolidinylideneamino)benzoheterocycles as .alpha.2 adrenoceptor agonists)

RN 196091-23-3 USPATFULL

CN Thiourea, N-(2-aminoethyl)-N'-(2,3-dihydro-5-methyl-1,4-benzodioxin-6-yl)-(9CI) (CA INDEX NAME)



=>

---Logging off of STN---

=>

Executing the logoff script...

10/019,652

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	455.21	603.97

STN INTERNATIONAL LOGOFF AT 14:47:38 ON 12 NOV 2003



Creation date: 08-03-2004
Indexing Officer: SMOHAMMED - SUAD MOHAMMED
Team: 1600PrintWorkingFolder
Dossier: 10380628

Legal Date: 06-17-2004

No.	Doccode	Number of pages
1	SRNT	24

Total number of pages: 24

Remarks:

Order of re-scan issued on